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Radiotherapy is one of the gold standard treatments for non-metastatic prostate 
cancer (PCa), although development of radioresistance limits its effectiveness. 
Mounting evidence supports the ability of microRNAs to interfere with different 
radioresistance-associated pathways, suggesting their potential as 
radiosensitizers.  
To identify miRNAs likely to be involved in influencing PCa radiation 
response, we first performed miRNA-profiling analysis of PCa cell lines exposed 
to photon irradiation. Based on their modulation upon radiation exposure, and 
their role in regulating pathways associated with radiation response we singled-
out and characterized miR-23a-3p and miR-24-3p as potential radiosensitizer 
molecules in PCa, unrevealing a central role of miR-23a-3p-IL-6 axis. 
In the framework of miRNAs downregulated in PCa and known to 
regulate genes relevant to radiation, miR-875-5p and miR-205 were identified.  
Reconstitution of miR-875-5p, the expression of which directly correlates with 
that of E-cadherin, was able to enhance radiation response in PCa cell lines 
and xenografts through EGFR direct targeting. Consistent with the established 
role of EGFR in sustaining epithelial-to-mesenchymal transition (EMT) and 
promoting DNA repair following radiation, we found that miR-875-5p 
reconstitution in PCa cells counteracted EMT and impaired DNA lesion 
clearance, mainly via impairment of EGFR-ZEB1 axis. 
Restoration of miR-205 was able to significantly enhance PCa sensitivity to 
radiation, in both cell and animal models. Specifically, we found that miR-205 
radiosensitizing effect was imputable to the downregulation of PKC-ε. 
Consistent with PKC-ε well-established role in DNA damage repair, we found 
that pEGFR and, consequently, pDNA-PK levels were significantly reduced by 
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miR-205 reconstitution, thus suggesting that miR-205 enhances PCa radiation 
response via disruption of PKC-ε−EGFR−DNA-PK axis.  
Overall, the results of this project support the clinical interest in 
developing novel therapeutic approaches based on miRNA reconstitution (miR-
23a-3p, miR-875-5p and miR-205) to enhance PCa response to radiotherapy. 
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1. INTRODUCTION 
1.1 PROSTATE CANCER 
 
1.1.1 Epidemiology 
 
The prostate (from Ancient Greek prostates (aden), literally "one who stands 
before, leader, guardian”) is an exocrine gland of the male reproductive system. 
The size of a healthy prostate gland is about that of a chestnut and its weight 
ranges from 7 to 16 grams. The prostate is located directly below the bladder 
and above the muscles of the pelvic floor. Its location with respect to the 
bladder, if seen from below, justifies the etymology of its name, as it “stands 
before” the bladder (Fig. 1.1) [1].  
 
Figure 1.1 Location of the prostate gland 
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The main function of the prostate is to secrete an alkaline fluid that constitutes 
approximately 30% of the semen volume, along with sperm cells from the 
testicles and seminal vesicle fluid. The alkalinity of semen helps neutralize the 
acidity of the vaginal tract, prolonging the lifespan of sperm. The prostatic fluid 
is expelled in the first ejaculate fractions, together with most of the 
spermatozoa. The muscles of the prostate also ensure that the semen is 
forcefully pressed into the urethra and then expelled outwards during 
ejaculation [1]. 
Among the components of the prostatic fluid there is a particular protein called 
Prostate Specific Antigen (PSA), which is a biomarker used for the detection of 
prostate cancer [2]. 
Prostate cancer (PCa) is the first cancer for incidence and second for mortality, 
according to the data provided from Cancer Statistics 2018 (Fig.1.2)  [3].   
 
Figure 1.2  Ten Leading Cancer Types for the Estimated New Cancer Cases and 
Deaths by Sex, United States, 2018 (Adapted from Siegel et al. Cancer Statistics, 
2018). 
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Figure 1.3 Schematic summary of PCa epidemiology 
 
Prostate cancer diagnosis is very common in industrialized countries for two 
main reasons: i) the great development of techniques that allow an early 
diagnosis and ii) the increased aging of population. Nowadays, the factors that 
determine the risk of developing prostate cancer are not totally understood 
although there is increasing evidence for a possible link between nutrition and 
prostate cancer development [4]. For example, in a recent case–control study 
from Italy it was observed that a diet rich in animal products such as red meat, 
dairy products and refined cereals and sugars appears to have an unfavourable 
role on prostate cancer [5]. Another main risk factor for prostate cancer is age. 
The probability of developing the tumour increases from 0.005% in men 
younger than 39 years to 13.7% in men between 60 and 79 years [6]. Prostate 
cancer appears to be linked to hereditary factors in a minority of cases (<15%). 
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The risk of developing the tumour is twice as high for those with a relative 
(father, brother, etc.) affected by the disease compared to those not having any 
tumour case in their family. Moreover, the presence of mutations in specific 
genes such as BRCA1 and BRCA2, already involved in promoting the onset of 
breast and ovarian cancers, may increase the risk of developing prostate 
cancer [7]. 
Lastly, studies that establish a correlation between the prostate cancer and 
chronic or recurrent prostate inflammation are constantly increasing, yet only 
few epidemiological studies have confirmed this data. Although the cause of 
this inflammatory reaction is still unknown, some studies have shown that 
viruses, bacteria or toxic substances introduced into the body can play a 
decisive role. However, although microorganisms are thought to cause 
prostatitis or sexually transmitted infections, their role in the development of 
prostate cancer is still unknown [8].  
 
 
1.1.2 Diagnosis 
 
Over the years, many markers have been used for the diagnosis and follow-up 
of prostate cancer. Until recently, prostate-specific antigen (PSA) was 
considered the most reliable marker for prostate cancer detection.  
PSA, a kallikrein-like serine protease, is a glycoprotein produced by the 
prostate gland. As long as the prostate grows, blood levels of PSA get higher. 
In 1994, the FDA approved the use of PSA test in conjunction with a digital 
rectal exam (DRE) for asymptomatic prostate cancer diagnosis. Specifically, 
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blood PSA levels higher than 4.0 ng/mL are considered an indication of prostate 
cancer [9]. However, yet being organ-specific, PSA is not a cancer specific 
marker. Indeed, other conditions within the prostate have an elevation of serum 
PSA levels as a consequence, such as benign prostate hyperplasia (BPH), 
prostatitis and urinary tract infection. For this reason, PSA screening has fallen 
under controversy. Indeed, out of the men that display elevated PSA levels in 
the blood, only 25% are associated with prostate cancer [10].  
At present, diagnosis of PCa is based on examination of histopathological 
specimens from the organ, usually obtained by transrectal or transperineal 
ultrasound guided core biopsies.  
Prostate adenocarcinoma is graded according to the Gleason Pattern Score. 
This histopathologic grading system was developed by Donald F. Gleason in 
the 1960s and 1970s.  
The system is based on the architectural patterns of the tumour where the 
Gleason score is the sum of two scores, each varying from 1 (well-
differentiated) to 5 (undifferentiated), representative of the most prevalent and 
the second most prevalent differentiation grade within the tumour, respectively 
(Fig. 1.4). To be counted, a pattern needs to occupy more than 5% of the 
biopsy specimen [11].  
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Figure 1.4 Architectural patterns of the Gleason System 
 
The original Gleason grading system was modified in 2005 during a consensus 
conference of the International Society of Urological Pathology (ISUP) [12]. The 
ISUP 2005 modifications included changes to the morphologic criteria to include 
poorly formed glands as Gleason pattern 4 and restricted criteria to distinguish 
cribriform pattern 4 vs. cribriform pattern 3, as well as recommendations on how 
to grade the different variants of prostate cancer and on how to report the 
Gleason grading in needle biopsies and radical prostatectomies. However, after 
the 2005 modifications, several aspects of the grading system continued to be 
unresolved [11]. Another consensus of 2014 generated several further 
modifications to the original scheme proposed by Gleason, resulting in a current 
grading system that is dramatically different from the original one. According to 
the new grading system, certain patterns of Gleason score 6 are now 
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considered pattern 7, and therefore, the contemporary Gleason score 6-cancer 
has a better prognosis than the historic one. Moreover, scores 2–5 are no 
longer in use, therefore a scale from 2–10 is no longer applicable. The last 
updated grading system consists of five groups: grade group 1 (Gleason score 
≤6), grade group 2 (Gleason score 3 + 4 = 7), grade group 3 (Gleason score 
4 + 3 = 7), grade group 4 (Gleason score 4 + 4 = 8), and grade group 5 (Gleason 
score 9–10) (Table 1.1). With the current grading system, Epstein has 
addressed the deficiencies of the previous application of the Gleason system, 
mainly by differentiating the different subgroups associated woth Gleason score 
7. For instance, a Gleason score 7 can represent mostly well-differentiated 
cancer with a lesser component of more poorly differentiated cancer (Gleason 3 
+ 4 = 7) or mostly poorly differentiated cancer with a smaller component of well-
differentiated cancer (4 + 3 = 7). Treatment decisions using a simplified single 
Gleason score of 7 fail to recognize that 3 + 4 = 7 and 4 + 3 = 7 are very 
different from a prognostic point of view. The introduction of the new grading 
system, distinguishes between these two groups separating them into grade 
group 3 and 4, respectively [13,14]. 
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Figure 1.5 New PCa grading system (adapted from Epstein et al, Eurol 2015) 
 
Prostate cancer, as with all other types of cancer, is also classified by TNM 
system. The TNM classification system was developed as a tool to stage 
different types of cancer based on certain, standardized criteria: T refers to the 
size and extent of the main tumour; N refers to the number of nearby lymph 
nodes that present cancer; M refers to whether the cancer has metastasized, 
meaning that the cancer has spread from the primary tumour to other parts of 
the body. For example, patients with a tumour localized to the prostate are 
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characterized by the absence of extensions to the prostatic capsule (T1/T2), 
without lymphatic invasion (N0) and without metastasis (M0). Whereas, patients 
with disseminated prostate cancer are characterized by the extension of the 
tumour beyond seminal vesicles (T4), lymphatic invasion (N1) and/or 
metastasis (M1). 
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1.1.3 Therapy 
 
The treatment of prostate cancer proposes different goals, depending on 
various factors such as the anatomy extension and the aggressiveness of the 
disease, but also the life expectancy of the patient and the presence of 
comorbidities that may present a higher mortality than that associated with the 
prostatic neoplasia itself. 
Indeed, it is necessary to remember that a considerable portion (about 40%) of 
patients diagnosed with prostate cancer is destined to die “with” and not “for” 
their tumour. 
After this essential premise, today many options of prostate cancer treatment 
are available, each with specific benefits and side effects: active surveillance, 
surgery, radical prostatectomy, radiotherapy, hormone therapy and 
chemotherapy. 
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1.1.3.1	Active	surveillance	
 
For many men, prostate cancer treatment are likely to produce effects far worse 
than their cancer ever would.  In some cases the patient, under medical advice, 
can decide not to undergo immediate surgery or radiation therapy and monitor 
the course of the disease, with the possibility of intervening in case of tumour 
progression.  
This particular approach is called "active surveillance" (AS) and is proposed to 
patients with a low risk or limited life expectation. AS is a way of monitoring 
slow-growing prostate cancer, rather than treating it straight away. The aim is to 
avoid unnecessary treatment, or delay treatment and the possible side effects. 
Treatment objective is to observe the course of tumour in patients who will 
probably never develop cancer related symptoms [15].  
If there is evidence of increased risk of disease progression from the results of 
periodic monitoring, it will be proposed to reconsider a treatment with a radical 
intent to cure the tumour. AS is based on the assumption that the clinical 
development of low-risk cancer progression is so slow that, while postponing 
treatment at the time of the first signs of a major risk, it is possible to maintain 
high chances of healing. It is important to keep in mind that the patient can still 
decide, for whatever reason and at any time, to stop AS and undergo treatment 
without any difficulties or delays. 
This option might be a good choice for elder men (>75 years old) with limited 
life expectancy that are in no state to tolerate side effects of the traditional 
cancer therapy. 
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The main challenge for AS is the definition of the inclusion criteria. The basic 
concept underlying AS is that Gleason 6 prostate cancer is a pseudo-disease, 
part of the ageing process, a condition that develops normally in men and does 
not pose a significant threat to their lives. However, a minority of such patients 
harbour higher grade cancer that does pose a significant threat. Therefore, the 
definition of suitability for AS depends on the identification of “insignificant 
tumour”. The ideal active surveillance programme should identify patients at a 
very low risk of prostate cancer progression, as well as those who harbour more 
aggressive disease early after diagnosis. A commonly used stratification is the 
‘Epstein criteria’. According to Epstein criteria, characteristics of indolent tumors 
include: Gleason 6 or less on biopsy, no more than two positive cores, no 
involvement of more than 50% of a core and PSA density less than 0.15. 
Around 75% of such patients had a ‘clinically insignificant’ disease, and 25% 
had intermediate risk disease and about 90% can be expected to have organ-
confined disease [16].  
Once a patient is selected for AS, the schedule of clinical examinations and 
monitoring visits includes: 
• every 3 months: dosage of PSA (possibly always performed from the 
same laboratory); 
• at least every 6 months: urological visit with rectal exploration to evaluate 
the prostate (shape, size, texture); 
• after 1 year (and then after 4 and 7 years): a prostate biopsy. 
In case of positivity to the examinations, indicating tumour upgrading or 
upstaging, patients are redirected to treatment.  
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1.1.3.2	Surgery	
 
In prostate cancer patients, surgery represents, together with radiotherapy, the 
therapeutic option that provides the highest efficacy in terms of healing from the 
disease. The surgery intervention is called radical prostatectomy and consists of 
the complete removal of prostate, seminal vesicles and lymph nodes present in 
the regions surrounding the prostate and the pelvis. Until a few years ago, 
radical prostatectomy was performed "open-air", through an incision between 
navel and pubis. Today, this practice has been supplemented by the mini 
invasive radical prostatectomy that allows operating by 4-5 small incisions on 
the abdomen, minimizing invasiveness. 
Afterwards, robotic surgery, and in particular the use of Robot da Vinci, has led 
the practice of mini-invasive radical prostatectomy to a higher level and today it 
is considered a valid and well established alternative [17].  
Because the nerves that regulate erection run very close to the gland and part 
of the urethra passes inside, two possible consequences of prostatectomy may 
be the deficiency of erection and urinary incontinence. However, in recent 
years, “nerve sparing” techniques have been developed to help maintain 
erectile function. As for urinary incontinence, it is a disorder that manifests itself 
in the vast majority of patients immediately after surgery, but often regresses 
within three months. 
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1.1.3.3	Radiotherapy	
 
Together with prostatectomy, radiotherapy (RT) is a gold standard treatment for 
organ confined prostate cancer. Radiotherapy used in first line ensures 
comparable therapeutic success with respect to prostatectomy, displaying a 
different toxicity that can result beneficial based on patient conditions. For this 
reason, the choice between prostatectomy and radiotherapy is concerted 
between the patient and the physician. As in almost all tumours, radiotherapy 
can be also used as adjuvant treatment after prostatectomy. In these cases RT 
is delivered immediately post-operation in patients with adverse pathological 
features, when the tumour extends beyond the prostatic capsule thus 
increasing the risk of local relapse. 
Radiotherapy is delivered through the generation of high-energy beams of 
ionizing radiation produced by linear accelerators (external beam radiotherapy) 
or emitted by radioactive substances (brachytherapy).  
The main goal of external beam RT is to reach the maximum radiation dose at 
the target organ with less adjacent tissue damage. Because the prostate is 
influenced by both bowel and bladder filling, and thus mobile within the pelvis, 
the conventional RT had larger planning margin that results in underdosing of 
the target and overdosing of surrounding normal tissues. Consequently, three-
dimensional conformal radiotherapy (3D-CRT) and intensity modulated 
external-beam radiotherapy (IMRT) technics were developed for the high-dose 
treatment of PCa [18]. These high-precision radiotherapy techniques have 
improved the treatment of many types of cancer, including prostate cancer [19]. 
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Brachytherapy is a type of radiotherapy where tiny radioactive seeds are put 
into the prostate. It is a treatment option highly recommended for patients with 
an early-stage localised disease, being a minimally invasive treatment that is 
performed in day-surgery, characterized by a low rate of complications and 
guarantees a high preservation of life quality [20]. 
Most curative radiotherapy regimens consist of daily fractions in the range of 
1.8 to 3 Gy per day over a period of 5 to 8 weeks. Using modern planning 
techniques, doses up to about 75 Gy to the tumour can usually be achieved 
without causing severe side effects.   
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1.1.3.4	Hormone	therapy	
 
Hormones are part of the endocrine system and are our body’s chemical 
messengers.  Testosterone and dihydrotestosterone (DHT) have an important 
role in the proliferation, development, maintenance, differentiation and 
physiology of the prostate [21]. Hormone therapy, also called “androgen 
deprivation therapy” (ADT), seeks to counteract this action by slowing or 
blocking the synthesis of these hormones. Although most tumour cells respond 
to the deprivation, some proliferate independently of hormonal stimulation and 
do not respond to the treatment. The amount of these resistant cells can 
increase over time, making the disease "resistant to castration". 
The level of testosterone can be surgically reduced by orchiectomy or by 
administration of drug similar to the hormones produced by the body, which 
control the growth and activity of the cells. Hormone therapy may be used 
before, during or after surgery or radiotherapy. Unlike surgical removal, the 
effects of this therapy can be reversible. 
The main drugs used for hormone prostate therapy are: 
• super agonists of LHRH (or GnRH): They are analogs of the natural 
LH-RH. These drugs act more upstream than other hormone drugs 
because they block the production of luteinizing hormone (LH), produced 
by the pituitary gland and able to stimulate the activity of the testes. They 
suppress the function of the testicles, thus ceasing to produce hormones. 
The main drugs of this category are Triptorelina, Leuprorelina, Buserelin 
e Goserelin. 
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• Antiandrogen: Testosterone stimulates the replication of prostate 
cancer cells by binding to specific receptors on the surface of the tumour 
cells. Antiandrogens are drugs that block the interaction between male 
sexual hormone and these receptors, thus inhibiting tumour growth. They 
cause less erectile dysfunction but more pain in the breast than LHRH 
agonists. The main drugs of this category are: ciproterone acetate, 
cicalutamide, futamide and enzalutamide. 
Among antiandrogens is abiraterone acetate, an androgen biosynthesis 
inhibitor used in the management of CRPC. Abiraterone is an oral, well-
tolerated drug that targets a newly elucidated paradigm of continued AR 
activation in CRPC. It is approved in CRPC patients who have received 
docetaxel (chemotherapy), and recent data suggest that the drug will 
also be effective and utilized in the pre-chemotherapy setting [22]. 
 
 
The most common side effects of this therapy are hot flashes, muscle mass 
reduction, anemia, osteoporosis, libido loss and erectile dysfunction.   
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1.1.3.5	Chemotherapy	
 
Although ADT is one of the first line treatment for prostate cancer, some 
patients develop resistance to treatment and the tumour is called "castration-
resistant prostate cancer (CRPC)". In these cases, the tumour is still able to 
grow and progress ever in the presence of low doses of circulating 
testosterone. 
Currently, the first line drug used in these conditions is docetaxel, general 
associated with prednisone, which has been shown to contribute with increased 
survival of several months in treated patients. It is administered intravenously 
with cycles to be performed every three weeks in the hospital. Docetaxel is able 
to bind the tubulins that constitute the microtubules, stabilizing them and 
preventing their disassembly. Through this treatment, morphological changes 
lead the tumour cell into apoptosis. 
Recent studies have shown that cabazitaxel, a semi-synthetic derivative of 
taxol, is able to increase the survival of patients with CRPC who do not respond 
to chemotherapy with docetaxel [23]. 
Bone is the predominant prostate cancer metastasis site. Bone tissue 
treatments use drugs such as bisphosphonates, among which the most 
powerful currently available on the market is zometa. 
The most common side effects of chemotherapy include fatigue, hair loss, 
diarrhea, nausea and vomiting. These effects can be more or less controlled by 
drugs such as antiemetics. 
The new frontier for the treatment of tumour is based on the use of anti-tumour 
vaccines or immunomodulatory antibodies, such as anti PD1-PDL1, able to 
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stimulate the immune system. This method of treatment is called 
"immunotherapy" and aims to improve the immune response by making it able 
to selectively destroy cancer cells. Immune checkpoint inhibitors act by blocking 
the inhibition of T cells, also attacking patient's own cells, thus possibly giving 
rise to autoimmune reactions. The main side effects associated to autommunity 
can manifest as moderate systemic side effects such as fatigue, decreased 
appetite, fever, but also as serious effects affecting gastrointestinal and 
respiratory system. 
Although this therapy is still at an early stage, "Sipuleucel-T" is the first vaccine 
approved in the United States in 2010, so it is expected that these treatments 
can be recognized also in Italy [24]. 
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1.2 RADIOTHERAPY 
1.2.1 Photon Radiotherapy 
1.2.1.1	Ionizing	Radiation	
 
Ionizing radiations are emitted in the decay process of unstable nuclei or by de-
excitation of atoms and their nuclei in nuclear reactors, X-ray machines, 
cyclotrons and other devices. Ionizing radiation may be divided into directly and 
indirectly ionizing for the understanding of biological effects. When ionizing 
radiations traverse through matter, they lose energy gradually through various 
interaction processes along the length of their path. The density of energy 
deposition in a material such as tissue is called the Linear Energy Transfer 
(LET) of the radiation. LET essentially indicates the quality of different types of 
radiation and is important because the biological effect of a type of radiation (its 
relative biological effectiveness, RBE) depends on its average LET [25]. 
The biochemical changes produced by ionizing radiations are the fundamental 
events leading to radiation damage in tissues. Radiation is measured either as 
exposure or as absorbed dose. The absorbed dose is the amount of energy 
absorbed in a system and generally regarded as the best way to quantify the 
irradiation absorption. The amount of energy absorbed per mass is known as 
radiation dose. Specifically, radiation dose is the energy (Joules) absorbed per 
unit mass of tissue and has the (S.I.) units of Gray (1 Gy = 1 J/ kg). In the past 
the rad (radiation absorbed dose) was used, where 100 rad = 1 Gy (1 rad = 1 
cGy) [26]. 
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Most of the particulate types of radiation are directly ionizing i.e. individual 
particles with adequate kinetic energy can directly disrupt the atomic structure 
of the absorbing medium through which they pass producing chemical and 
biological damage to the molecules. In contrast, electromagnetic radiations, 
namely, X and γ rays, are indirectly ionizing because they do not produce 
chemical and biological damage themselves but produce secondary electrons 
(charged particles) after energy absorption in the material. Ionization is the 
process of removing one or more electrons from atoms by the incident radiation 
leaving behind electrically charged particles (an electron and a positively 
charged ion), which may subsequently produce significant biological effects in 
the irradiated material (Figure 1.5) [25].  
Figure 1.6 Direct and indirect effects of ionizing radiation on DNA  
 
The ionized or excited atom or molecule may either fragment producing free 
radicals. Free radicals are fragments of molecules having unpaired electrons, 
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which have high reactivity with cellular molecules. These radicals react with 
neighbouring molecules and produce secondary DNA or lipid radicals by 
reaction with another neighbouring molecule. Chain reactions may also occur, 
particularly in lipids, and may play a role in damage to cell membranes. Free 
radicals are known to play a major role in radiation effects on biological tissues 
and organisms. 
 
1.2.1.2	Radiation	induced	DNA	damage	
 
Radiation causes a wide range of lesions in DNA such as single strand breaks 
in the phosphodiester linkage, double strand breaks on opposing sites or 
displaced, base damage, protein-DNA crosslinks and protein-protein crosslinks 
involving nuclear proteins such as histones and non-histone proteins. The 
numbers of lesions induced in the DNA of a cell by a dose of 1-2 Gy are 
approximately: base damages > 1000; single strand breaks (SSBs) ~1000; 
double strand breaks (DSBs) ~40 [27]. DSBs play a critical role in cell killing, 
since they are the most difficult damages to repair, and are the major 
responsible for radiation-induced cell death. There are experimental data 
showing initially-produced DSBs to correlate with radiosensitivity and survival at 
low dose, and unrepaired or mis-repaired DSBs to correlate with survival after 
higher doses [27].  
It is possible to observe and measure the damage caused by the DSB by 
different methods including comet assay or immunostaining of specific 
protein. For example, DSB can be observed by immunostaining of the protein 
γH2AX, the phosphorylated form of the H2AX histone, that is considered one of 
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the earliest markers of the DSB signalling. H2AX is phosphorylated within 1 to 3 
minutes after DSB and the number of H2AX molecules phosphorylated 
increases linearly with the severity of the damage [28]. Phosphorylated H2AX 
(γH2AX) is rapidly concentrated in chromatin domains around DSBs after the 
action of ionizing radiation or chemical agents and at stalled replication forks 
during replication stress. γH2AX foci could be easily detected in cell nuclei 
using immunofluorescence microscopy that allows to use γH2AX as a 
quantitative marker of DSBs in various applications [29]. To assess DNA 
damage at single cell level, the most common method is comet assay. The 
assay depends on the relaxation of supercoiled DNA in agarose-embedded 
nucleoids, which allows the DNA to be drawn out towards the anode under 
electrophoresis, forming comet-like images as seen under fluorescence 
microscopy. The relative amount of DNA in the comet tail indicates DNA break 
frequency [30]. 
 
1.2.1.3	DNA	damage	repair	
 
Since cells cannot tolerate DNA damage, the evolution has selected the best 
systems to restore the lost information depending to the type of damage 
inflicted to the genome. There are multiple enzymatic mechanisms of DNA 
repair in cells that act on different types of lesions. For double strand breaks 
there are two primary repair pathways, non-homologous end joining (NHEJ) and 
homologous recombination (HR). NHEJ repair operates on blunt ended DNA 
fragments resulting from broken phosphodiester linkages. There is a 
requirement for Ku70/Ku80 repair proteins to recognize the lesion termini, 
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binding of the Ku-heterodimer to DNA-PK (protein kinase), and activation of the 
XRCC4 ligase enzyme by this complex for final religation of the fragments after 
enzymatic “cleaning up” of the broken ends of the DNA molecule, by a variety of 
other recruited proteins, so that ligation can occur [31]. Repair by NHEJ 
operates throughout the cell cycle but dominates in G1/S-phases. The process 
is error prone because it does not rely on sequence homology. DSB repair by 
homologous recombination (HR) utilizes sequence homology with an 
undamaged copy of the broken region and hence can only operate in late S- or 
G2- phases of the cell cycle. It starts by nucleolytic resection of blunt ends, 
binding of NBS/MRE11/rad50 protein complex to the DNA termini, followed by 
strand exchange facilitated by attachment of rad51/XRCC2 protein [32]. Then 
there is DNA synthesis of the missing nucleotides on the undamaged templates 
and ligation. This creates a complex strand crossover between the damaged 
and undamaged strands known as a Holliday junction, which is finally resolved 
before the repair process is complete. Other DNA repair mechanisms such as 
base excision repair (BER), mismatch repair (MR) and nucleotide excision 
repair (NER) respond to damage such a base oxidation, alkylation, and strand 
intercalation [32].  
Cells are generally regarded as having been “killed” by radiation if they have 
lost reproductive integrity. Loss of reproductive integrity can occur by apoptosis, 
necrosis, mitotic catastrophe or proliferative senescence. The accepted gold 
standard for measuring the radiosensitivity of a cell population is the retention of 
reproductive integrity or mitotic intactness i.e. the ability of a cell to undergo 
more than 5-6 cell divisions (and produce a viable colony containing at least 50 
cells). This is referred to as cell survival and survival fraction after irradiation is 
calculated by correcting for the ‘plating efficiency’ of not-irradiated cells.  
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There are many molecules that have been found to increase the radiosensitivity 
of cells, including molecules that enhance the persistence of DNA damage, 
such as inhibitors of DNA repair, modifiers of cell cycle checkpoints and 
microRNAs [33,34].  
 
Figure 1.7 Mammalian double-strand break (DSB) repair. Schematic representation 
of non-homologous end-joining (NHEJ) and homologous recombination (HR). (Adapted 
from ATP-dependent chromatin remodeling in the DNA-damage response. Hannes 
Lans et all. [30])  
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1.2.2 Hadrontherapy  
 
In radiotherapy the key problem is to deliver the dose in such a way that ideally 
the intended target volume (covering the tumour region) receives 100% of the 
planned dose needed to kill all cancer cells in the tumour, while the surrounding 
normal tissue does not receive any dose. This can not be achieved in practice 
because of the unavoidable dose deposited in the entrance channel of the 
irradiation, but in the past 60 years significant progress has been made to better 
understand the biological effectiveness of radiation and to improve the dose 
deposition towards the ideal and to increase thereby the tumour control rate for 
potentially curable cases. 
Charged particles (protons, heavy ions) have a physical advantage because 
they can give improved depth-dose distributions for deep-seated tumours. Much 
of their energy is deposited in tissue at the end of particle tracks (i.e., in the 
region of the Bragg peak). Bragg peak is the major physical advantage of heavy 
charged particles. Whereas the photon dose decreases exponentially with 
penetration depth according to the absorption law for electromagnetic radiation, 
the depth-dose profile of heavy charged particles exhibits a flat plateau region 
with low dose and a distinct peak near to the end of range of the particles, the 
so-called ‘Bragg peak’.  This characteristic allows the delivery of a high radiation 
dose to the target, yet significantly spearing surrounding normal tissues, which 
is the major challenge in radiotherapy [25]. 
Another important aspect of the use of heavy charged particles is the possibility 
of nuclear fragmentation. For instance, 12C may break up into three α-particles 
in nuclear reactions, thus producing lighter fragments at high energies. The 
projectile-fragments continue travelling with nearly the same velocity and 
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direction. As a consequence of nuclear fragmentation a rather complex 
radiation field is produced and leads to significant alterations.  
Another important advantage of ion beams is their elevated biological 
effectiveness  (RBE). The factor RBE was introduced to measure the relative 
effectiveness of ion beams with respect to X-ray. Specifically, the RBE is 
defined as ratio between X-ray dose and ion dose that are required to produce 
the same effect:  
RBE= DxDion  Isoeffect 
The elevated biological effectiveness of ion beams is of greatest importance for 
therapy applications and has to be correctly implemented into the treatment 
planning procedures [25]. 
 
Proton and carbon ion beam therapy require powerful accelerators in order to 
reach clinically relevant particle ranges in tissue up to 30 cm. Today most 
therapy facilities offering exclusively protons are operated with cyclotrons, while 
all facilities with 12C ions are using synchrotron accelerators. Cyclotrons are 
considered as easy to operate, highly reliable, and compact machines. They 
offer continuous beam (ideal for beam scanning) and extremely stable and 
regulable intensities, but no energy variation, i.e. only by means of passive 
degraders in the beam line. Synchrotrons, on the other hand, offer fast energy 
variation (from pulse to pulse), but need an injector and a delicate extraction 
system and are more complex in operation. Particle beams provided by 
cyclotron or synchrotron accelerators are typically narrow, pencil-like beams 
centred at the axis of the beam tube. Since the beams, and consequently the 
Bragg peaks, are relatively narrow, the irradiation of extended target volumes 
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requires the superposition of a number of Bragg curves in order to move the 
position of the Bragg peak in depth over the whole target volume (Fig 1.7).  
 
 
Figure 1.8 Dose distribution curves of heavy ion beams compared to x-rays 
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1.3 microRNAs 
microRNAs (miRNAs) are a class of small non-coding RNAs, naturally occurring 
small (~22 nucleotide long) non-coding RNA molecules involved in the 
regulation of gene expression. Through the binding of complementary 
sequences mostly situated in the 3’-untranslated region (3’-UTR) of target 
mRNAs, they negatively regulate protein expression mainly by inducing mRNA 
cleavage or translational repression [35]. Each miRNA is predicted to target 
hundreds of transcripts, and each transcript, in turn, can be subjected to the 
regulation of several miRNAs [36]. The ability of miRNAs to simultaneously 
regulate multiple genes, make them key regulators of various fundamental 
biological processes, including pathways responsible of tumour initiation and 
progression. The other way around, increasing evidence shows that the 
expression of miRNAs is markedly deregulated in cancer [36]. Due to their 
implication in regulating several cancer hallmarks, including tumour response to 
conventional treatments, miRNAs are promising candidates to be exploited as 
sensitizer molecules able to enhance cancer response to radiotherapy.  
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1.3.1 Biogenesis of miRNAs 
 
miRNAs are generally expressed by genes located in non-coding regions of the 
genome [35] and are often embedded in fragile chromosomal regions that are 
susceptible to translocations, microdeletions and amplifications [37]. Most 
miRNAs are encoded in independent transcription units. However, 
approximately one quarter of human miRNAs, including mirtrons, are within 
introns of mRNAs with the same orientation, suggesting that they are not 
transcribed from their own promoters but processed from introns by the splicing 
machinery. Other miRNAs are clustered in the genome and transcribed as 
polycistronic primary transcripts, suggestive of their functional relationships [35]. 
 RNA polymerase II contributes to the synthesis of a 5’-capped and 3’-
polyadenylated primary miRNA transcript (pri-miRNA) (Figure 1.8). This is then 
cleaved in the nucleus by an RNase III enzyme Drosha in association with its 
cofactor DGCR8 in humans, to generate a 70–90 nt long precursor miRNA (pre-
miRNA) that folds into an imperfect stem–loop hairpin structure. Pre-miRNA is 
then exported into the cytosol through the complex exportin-5/Ran-GTP [38]. 
RNase III Dicer is involved in the further remodelling of pre-miRNA in the 
cytoplasm, converting it into a mature double-stranded RNA, with two 
nucleotide-long 3’ overhangs at both ends. The miRNA is then separated into 
two single stranded molecules: the antisense strand is incorporated in the 
multiproteic RNA-induced silencing complex (RISC) through its interaction with 
Argonaute proteins, whereas the other strand, usually referred to as star miRNA 
(miRNA*), is degraded (Figure 1.8). 
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Figure 1.9 Schematic representation of miRNA Biogenesis 
 
Conserved base-pairing between the 3’-UTR of a mRNA and the “seed 
sequence” located in the 5’ end of the miRNA seems to have a major role in the 
selection of target mRNAs by miRNAs. Through evaluation of the minimal 
requirements for miRNA:mRNA interactions, Brennecke et al. [39] identified two 
broad categories of target sites: 5' dominant and 3’ compensatory sites. The 
first have sufficient complementarity to the miRNA 5' end to function with little or 
no support from pairing to the miRNA 3' end. They can be further classified in 
two subtypes: “canonical” sites, which pair well at both the 5’ and 3’ ends, and 
the “seed” sites, which require little or no 3’ pairing support. Targets in the 
second category, in contrast, have insufficient 5' pairing and require strong 3’ 
pairing for function. Specifically, these authors showed that i) complementarity 
of seven or more bases to the 5’ end miRNA is sufficient to confer regulation, 
even if the target 3’-UTR contains only a single site; ii) sites with weaker 5’ 
complementarity require compensatory pairing to the 3’ end of the miRNA in 
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order to confer regulation; and iii) extensive pairing to the 3’ end of the miRNA 
is not sufficient to confer regulation on its own without a minimal element of 5’ 
complementarity. Moreover, they demonstrated that, although all site types are 
used to mediate regulation by miRNAs, canonical sites are likely to be more 
effective than other site types because of their higher pairing energy, and may 
function when only one copy is present. In general, however, multiple sites in 
the 3’-UTR of the targeted mRNA confer better regulation than a single site. 
Cooperation and spacing between these sites are also important factors that 
determine the effectiveness of miRNA binding.  
The number of base pair mismatches between the miRNA and its target is 
fundamental in dictating the end result. If perfect complementarity exists, then 
generally the target mRNA is cleaved. In contrast, imperfect matches tend to 
result in the inhibition of protein translation, even if it is plausible that they can 
also reduce the amount of the mRNA target (Fig. 1.9).  
 
Figure 1.10 Schematic representation of miRNA target regulation 
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Few years ago, it has been shown that miRNAs also direct rapid deadenylation 
of target mRNAs, leading to rapid mRNA decay and reduction of transcript 
levels [40]. Since in animal cells miRNAs generally match complementary 
targets with a partial homology, the repression of translation represents their 
prevalent mechanism of regulating gene silencing [35,41].  
Several hundreds of miRNAs are estimated to be encoded within the human 
genome but many are still to be identified [42]. This reflects the complexity of 
their structural and functional characteristics, including low and variable 
expression levels and the heterogeneity of coding genes. A further level of 
complexity in miRNA-mediated gene silencing is introduced by the fact that 
each miRNA can interact with different mRNAs and a single mRNA can be 
targeted by diverse miRNAs, thus making it possible for a small number of 
miRNAs to concurrently regulate multiple factors involved in the same cellular 
pathway. Regulation by miRNAs guarantees rapid and reversible changes in 
protein synthesis without altering the transcription of the target mRNAs and is 
even more refined by the tissue- and time-dependent expression/functionality of 
miRNAs [43]. This is obtained by transcriptional (e.g., co-transcription of 
miRNAs with their target genes or binding of transcriptional factors to miRNA 
promoters) or post-transcriptional mechanisms [44], such as differential 
processing of primary or precursor transcripts to mature miRNAs [45], 
sequestration of miRNAs within specific cell compartments [46] or degradation 
events. Accessibility of target mRNAs can be also modulated by sequestration 
into P-bodies [47] or binding of specific proteins (i.e., Dnd1 [48]). In general, the 
numerous biochemical mechanisms that govern miRNA function are dependent 
on the availability of local regulatory factors [49].  
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It is estimated that up to one-third of protein-coding genes are susceptible to 
miRNA regulation [50] and, as a consequence, several miRNAs seem to play 
pivotal roles in crucial biological processes, such as development, 
differentiation, cell proliferation and apoptosis [35]. It is thus conceivable that 
the deregulation of miRNA expression may result in the onset of disease.  
 
 
1.3.2 miRNAs and cancer 
 
The first connection between miRNAs and cancer emerged from a study by 
Calin and colleagues [51], who showed that two clustered miRNAs, namely 
miR-15a and miR-16-1, were the targets of homozygous and heterozygous 
deletions and translocations at 13q14.3 in human B-cell chronic lymphocytic 
leukemias (B-CLL). Interestingly, the same group successively showed that this 
cluster of miRNAs is endowed with tumour-suppressive functions, as it 
negatively regulates the expression of B-cell lymphoma gene-2 (Bcl-2), a well-
known inhibitor of apoptosis [52]. As a consequence of deletions at the 13q14.3 
locus, miR-15a and miR-16-1 expression levels are reduced in a high 
percentage of B-CLL patients, and Bcl-2 is up-regulated, thus resulting in a 
global antiapoptotic and oncogenic effect. Altogether, these studies suggested 
a possible direct involvement of miRNAs in the pathogenesis of cancer, as 
abnormal expression of these molecules may result in a deregulation of their 
target genes. Hypothetically, overexpression of miRNAs that target tumour 
suppressor genes may have a pro-tumorigenic effect, which may also arise 
from the down-regulation of miRNAs targeting oncogenic factors. In this context, 
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deregulation of miRNA expression has been reported in a wide variety of solid 
and haematopoietic tumours, compared to normal tissues. For example, 
cancer-specific miRNA fingerprints were identified in B-CLL [53], breast 
carcinoma [54], primary glioblastoma [55], hepatocellular carcinoma [56], 
papillary thyroid carcinoma [57], lung cancer [58], colon carcinoma [59] and 
endocrine pancreatic tumours [60]. 
Recent evidence also supports the ability of miRNAs to regulate several steps 
during neoplastic cell transformation. Many aspects of tumorigenesis, defined 
also as a hallmark of cancer [61], are common to almost all, if not all, tumours: 
1) selfsufficiency of tumour cells, 2) insensitivity to antigrowth signals, 3) 
abnormal apoptosis, 4) limitless replicative potential, 5) induction and sustained 
angiogenesis, and 6) invasion and metastasis. For several miRNAs, a specific 
involvement in sustaining these features has been functionally validated in 
experimental models [62]. 
The origins of abnormalities in miRNA expression are multiple. Many miRNAs 
reside in genomic regions that are prone to alterations in cancer, including 
minimal regions of loss of heterozygosis, minimal amplicons, or breakpoint 
cluster regions [63]. The last are preferential sites of sister chromatid exchange, 
translocation, deletion, amplification. Recent findings indicate that epigenetic 
aberrations may also influence miRNA expression. In this context, it has been 
shown that half of miRNA genes are associated with CpG islands, thus 
suggesting that miRNAs may be targets of DNA methylation machinery. For 
instance, decreased miR-124a expression in colon, breast and lung carcinomas 
was attributed to DNA hypermethylation [64]. 
Changes in miRNA expression can arise from alterations in miRNA processing 
as well. Due to the short length of miRNA genes, mutations and polymorphisms 
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located in mature miRNA, pre-miRNA, or in adjacent genomic regions are rare, 
yet they have been described [65]. More frequently, defects in miRNA 
processing arise from aberrations in components of the processing machinery, 
namely Drosha [66] or Dicer [67], or from the binding of specific proteins, such 
as Lin-28 [45]. 
Given that binding of specific transcription factors has been proven for several 
miRNA promoters, as is the case of p53 for miR-34a [68] or c-myc for miR-17-
92 cluster [69], changes in miRNA expression may also arise from aberrant 
transcriptional programmes. 
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1.3.3 microRNA in Prostate Cancer 
 
In an attempt to investigate the role of miRNA deregulation in determining the 
onset and progression of PCa many studies analysed miRNA expression 
profiles in prostate cancer versus normal tissues [70–76]. In these studies, 
several miRNAs have been found to be differentially expressed in prostate 
cancer specimens compared to normal counterparts, suggesting an 
involvement of such miRNAs in the disease status. According to these findings, 
other studies investigated the causal role of miRNAs in the progression of 
prostate cancer, by studying the biological effect exerted by specific miRNAs 
upon their up- or down-regulation. Sun et al. demonstrated that up-regulation of 
miR-221 was involved in reprogramming the androgen receptor (AR) signalling 
promoting the transition to castration- resistant PCa (CRPC) [77]. More recently, 
the downregulation of miR-221/222 cluster was demonstrated to enhance 
migration and invasion in PCa cells thus leading to CRPC [78]. In another 
study, Spahn et al. demonstrated that down-regulation of miR-221 in 92 PCa 
patients was associated with clinicopathological parameters, including the 
Gleason score and the clinical recurrence [79]. In 2009, Tong et al examined 
the miRNA expression profile of 40 prostatectomy specimens, finding out that 
miR-23b, -100, -145, -221 and -222) were significantly downregulated in 
neoplastic tissues compared to non-involved areas of each specimen. Ectopic 
expression of these miRNAs significantly reduced PCa cell growth, suggesting 
that an altered miRNA expression signature in associated with prostate cancer 
progression [71].  
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miR-21 is one of the most over-expressed oncogenic miRNAs in many cancer 
types, including prostate cancer. The majority of miR-21 targets are related to 
angiogenesis and tumour invasiveness. Li et al. reported a positive correlation 
of miR-21 expression with poor biochemical recurrence-free survival and the 
risk of biochemical recurrence in patients with prostate cancer after radical 
prostatectomy, thus proposing miR-21 as a biomarker to predict prostate cancer 
progression [80].  
Another microRNA that have been extensively associated with prostate cancer 
is miR-205.  In 2009 our lab (Gandellini et al.) demonstrated that restoring the 
expression of miR-205 in prostate cancer cells resulted in counteracting the 
epithelial-to-mesenchymal transition by directly targeting protein kinase 
Cepsilon, thus ascribing to miR-205 an oncosuppressive role in PCa [81]. Later, 
Bhatnagar et al. reported that downregulation of miR-205 and miR-31 confers 
resistance to chemotherapy-induced apoptosis in advanced prostate cancer. 
Accordingly, Verdoodt et al. demonstrated that miR-205 promotes apoptosis in 
prostate cancer cells in response to DNA damage by cisplatin and doxorubicin 
by targeting the anti-apoptotic protein Bcl2 [82].  
Several different studies reported that the expression levels of miRNAs, 
including miR-224 [83,84], miR-18a [85], miR-126 [86], miR-34b [87] and miR-
15/16 [88], correlate with clinical outcome, thus suggesting a possible role of 
such miRNAs as novel prognostic biomarkers and therapeutic targets [89]. 
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1.3.4 miRNAs and Radiation Response 
 
As previously reported, due to their capacity to simultaneously regulate multiple 
targets thus disrupting several biological processes, including cell development, 
metabolism, proliferation, cell-cycle and apoptosis, miRNAs can play a pivotal 
role in contributing to the onset of pathological conditions, including cancer. 
Strong evidence suggests that miRNAs can take part in pathways sustaining all 
the diverse hallmarks of cancer and therefore actively contribute to determine 
tumour progression, also by affecting tumour response to conventional 
treatments, including radiotherapy.  
In this context, miRNAs have been demonstrated to be involved in the IR 
response network, as many of them directly regulate the expression of genes 
belonging to cellular pathways relevant to radioresponsiveness [90,91]. 
However, the causal role exerted by individual miRNAs in determining tumour 
response to radiation need to be better elucidated [34]. 
It has been widely reported and corroborated that miRNAs play a pivotal role in 
contributing to cancer cell sensitivity by regulating several cell stress-related 
pathways.  
One approach to identify miRNAs that could be implicated in radiation response 
is to analyse their modulation upon radiation exposure [92,93]. Mounting 
evidence demonstrates that exposure to radiation can significantly alter miRNA 
expression profile in cancer cells including PCa [94–96]. Leung et al. identified 
6 miRNAs upregulated (miR-9, miR-22, miR-25, miR-30a, miR-550a and miR-
548h) and 16 miRNAs downregulated (let-7c/d/e, miR-15a, miR-17, miR-30d, 
miR-92a, miR-125a, miR-197, miR-221, miR-320b, miR-342, miR-361, miR-
 	
	
INTRODUCTION 
	
	 	
56	
374a, miR-501 and miR-671) after exposure to 10 Gy of radiation, suggesting 
such miRNAs as candidates in contributing to radiosensitivity and proposing 
them as biomarkers for radiotherapy [97]. 
 
Using a miRNA microarray assay, Li et al. screened 132 tumour miRNAs in 
LNCaP cells in response to radiation treatment and reported that miR-106b was 
downregulated in PCa cells upon radiation exposure. Functionally, ectopic 
expression of miR-106b was able to suppress radiation-induced p21 activation, 
overriding radiation-induced cell cycle arrest and cell growth inhibition check 
points and finally resulting in a transient reduction of radiation-induced growth 
inhibition. These findings suggest miR-106b as a potential therapeutic target in 
those prostate cancer types whose radiation resistance is likely due to 
consistently elevated levels of the microRNA  [98].  
A recent study of Gong et al. reported that miR-145 modulates tumour 
sensitivity to radiation in prostate cancer. miR-145 was already known to reduce 
chemoradioresistance in glioblastoma and suppress prostate cancer 
proliferation, migration and invasion. By performing miRNA expression profile 
analyses in 30 prostate tumour tissue biopsies taken prior to neoadjuvant 
radiotherapy, they found miR-145 to be significantly upregulated in PCa 
patients demonstrating good response to neoadjuvant radiotherapy. 
Consistently, same specimens revealed a significantly decreased expression 
levels of miR-145-regulated DNA repair genes, suggesting a possible 
mechanism for miR-145 in modulating radiosensitivity, potentially through down 
regulating of DNA repair processes. Consistently, the ectopic reconstitution of 
the microRNA in prostate cancer cell models demonstrated that miR-145 
significantly sensitized cells to radiation, by reducing the efficiency of the repair 
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of radiation-induced DNA double-strand breaks, as suggested by the increased 
percentage of γ-H2AX foci and the enhanced mitotic catastrophe observed in 
miR-145 expressing cells. These findings supported a potential role of miR-145 
as a therapeutic target to enhance prostate cancer response as well as a novel 
clinical biomarker of radiation response [99].  
Another screening study reported a different miRNA modulation upon 
fractionated radiation compared to single-dose radiation in LNCaP, PC3 and 
DU145 prostate cancer cells. Specifically, miR-17-92 cluster was found to be 
downregulated in p53 positive LNCaP cells. Whereas miR-34a and let-7 
miRNAs were upregulated by fractionated radiation in both p53 -positive and –
null cell lines, indicating that radiation-induced miRNA expression may be 
regulated in a p53 independent manner [100].  
The above studies provided solid evidence that the expression of several 
miRNAs is affected by radiation in prostate cancer models. However, the 
modulation of specific miRNAs upon radiation does not directly imply a 
functional involvement of such microRNAs in regulating cell response to 
radiation the other way around.  
With the final purpose to identify miRNAs that are actively responsible of 
modulating cell sensitivity profile to radiation treatment, the artificial modulation 
of candidate miRNAs, by the use of miRNA mimetics or inhibitors, was 
performed in different functional studies.    
In 2008, Josson et al. identified several miRNAs altered in response to radiation 
response of prostate cancer cells. In particular, cell exposure to radiation 
causes significant changes in miR-521 and miR-34c. To investigate a functional 
role of such miRNAs in modulating radiation response, they transiently 
overexpressed miR-521 and observed a significant sensitization of prostate 
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cancer cells to radiation treatment. Conversely, inhibition of miR-521 resulted in 
radiation resistance of prostate cancer cells. Interestingly, they showed that the 
expression levels of CSA, a DNA repair protein, inversely correlated with the 
levels of the microRNA, suggesting CSA as the possible mediator of miR-521-
induced radiosensitizing effect [101].   
In 2015, Hatano et al. screened a library of 810 miRNA mimetics for the ability 
to modulate cellular sensitivity to ionizing radiation. They found that a large 
percentage of miRNA mimetics was able to increase PCa cell sensitivity to IR. 
Specifically, they reported that miR-890 and miR-744-3p significantly delayed 
IR induced DNA damage repair, and that both miRNAs were able to inhibit the 
expression of multiple components of DNA damage response and DNA repair, 
acting as radiosensitizer factors [102].  
Several miRNAs have been associated with cell proficiency in recovering from 
radiation-induced injury, by targeting genes involved in DNA damage repairing. 
It is widely recognized that c-Myc is reduced when cells are exposed to DNA 
damaging agents such as ionizing radiation.  In their study, Mao et al. recerntly 
demonstrated that miR-449a enhances radiosensitivity of LNCaP cells both in 
vitro and in vivo by targeting c-Myc. Specifically, they found that miR-449a was 
upregulated and c-Myc was downregulated in LNCaP irradiated cells. 
Consistently, overexpression of miR-449a or knockdown of c-Myc promoted the 
sensitivity of LNCaP cells to IR. Furthermore, miR-449a enhanced radiation-
induced G2/M phase arrest by directly targeting c-Myc which controls the 
Cdc2/CyclinB1 cell cycle signal by modulating Cdc25A [103].  
The miR-99 family has been shown to play ain important role in regulating DNA 
damage response by targeting SWI/SNF chromatin remodelling factors in 
different cell line models [104]. In their recent study, Rane at al. demonstrated 
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that miR-99a and miR-100 are downregulated in radioresistant prostate cancer 
stem cells and castration-resistant prostate cancer cells. Interestingly, they 
found that the upregulation of the two microRNAs, induced by the androgen 
receptor inhibitor Mifepristone, resulted in the sensitization of prostate cells to 
radiation [105]. 
Another strategy widely used for the identification of miRNAs to be investigated 
for their ability to affect radiation response in prostate cancer, consists of 
exploiting the knowledge of their involvement in cell stress-related pathways, 
including cell proliferation, DNA damage repair, autophagy, and hypoxia.  
It is well known that cancer cells undergoing hypoxia are prompted to trigger 
adaptive changes in cellular metabolism, such as altering autophagy. This 
might be a cause of enhanced radioresistance in some types of cancer, 
including prostate cancer, where mounting evidence suggests that irradiation-
induced autophagy acts as a protective mechanism.  
In 2016, Gu et al., by investigating hypoxia-responsive miRNAs in DU145 and 
PC3 cell lines, reported that hypoxia induces downregulation of miR-124 ad 
miR-144. Moreover, the overexpression of such miRNAs can inhibit hypoxia-
induced autophagy and enhance radiosensitivity, at least in part, by 
downregulating PIM1, a common target of the two microRNAs [106].  
Consistent with this link between autophagy and radiosensitivity, another study 
reported that miR-301-a and -b overexpression results in elevated autophagy 
and increased radioresistance in LNCaP cells, by targeting NDRG2 [107].  
Similarly, Wang et al. demonstrated that ectopic expression of miR-205 
substantially reduced the survival fraction of both DU145 and LNCaP cells to 
radiation, by directly targeting TP53INP1 and inhibiting irradiation induced-
autophagy [108].  
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In another study, it was found that miR-32 was able to induce autophagy 
resulting in a decreased radiosensitivity of prostate cancer cells.  Specifically, 
they showed that miR-32 mimics enhanced tumour cell survival leading to 
radioresistance, which was reversed by a miR-32 inhibitor. More significantly, 
the overexpression of miR-32 enhanced autophagy in the IR-treated PCa cells, 
regulating the expression of varius autophagy related protein, such as DAB2IP, 
Beclin 1 and LC3β I/II [109].  
Among the several pathways that have been hugely correlated with radiation 
response, is the epithelial to mesenchymal transition (EMT), a phenotypic 
switch that promotes the acquisition of a fibroblastoid-like morphology by 
epithelial tumour cells, resulting in enhanced tumour cell motility/invasiveness, 
increased metastatic potential and treatment resistance [110]. 
In this context, cumulative evidence has recently reported that specific miRNAs 
which are able to repress the EMT switch can act as radiosensitizers in different 
tumour types. Specifically, ectopic expression of such miRNAs targeting the 
EMT-inducing transcription factor zinc-finger E-box binding homeobox 1 
(ZEB1), which also promotes homologous recombination-mediated DNA repair, 
results in increased tumour radiosensitivity, at least in part, as a consequence 
of a reduced clearance of treatment-induced DNA damage [111,112]. Zhang et 
al. found that miR-205 promotes radiosensitivity and is downregulated in 
radioresistant breast cancer cells, and that loss of miR-205 is highly associated 
with poor relapse-free survival in breast cancer patients. In particular, they 
demonstrated that radiation suppresses miR-205 expression through ataxia 
telangiectasia mutated (ATM) and zinc finger E-box binding homeobox 1 
(ZEB1). Moreover, miR-205 inhibits DNA damage repair by targeting ZEB1. In 
this study they identified miR-205 as a radiosensitizing miRNA further 
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supporting the relevance of repressing EMT in order to increase sensitivity to 
radiation treatment [113].  
 
 1.3.5 Clinical applications of miRNAs 
 
Over the past years, it has become clear that alterations in miRNA expression 
are a widespread phenomenon in human cancer, thus suggesting a role for 
these molecules in tumourigenesis [114]. In some instances, the expression of 
selected miRNAs or miRNA profiles were found to correlate with diverse clinico-
pathological parameters and to predict patient clinical outcome or response to 
treatment [114]. Overall, these findings have highlighted the potential of 
miRNAs as new diagnostic or prognostic biomarkers. In addition, the evidence 
that specific miRNAs are endowed with oncogenic or tumour-suppressive 
functions has emerged from several studies conducted in experimental models, 
pointing to a possible role as novel targets or tools for anticancer therapy.  
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1.3.5.1	miRNAs	as	diagnostic	tools	
 
Evidence that miRNAs may represent new diagnostic markers for human 
cancer is rapidly accumulating. In fact, the expression profile of a number of 
miRNAs significantly differs between tumour and normal tissues of diverse 
histotype. For example, in tumour specimens of patients with lung cancer, a 
reduced expression of let-7 (a miRNA able to repress the proto-oncogene RAS) 
[115,116] and an increase in miR-155 expression levels [54] have been 
observed, as compared to adjacent normal tissue. Similarly, a reduced 
expression of miR-143 and miR-145 has been observed in precancerous and 
neoplastic lesions of colorectal tissue [59]. In papillary tumours of thyroid, miR-
221, miR-222 and miR-146 are highly up-regulated compared to normal tissue 
and their expression levels inversely correlate with KIT mRNA and protein 
expression levels [57]. These and other studies paved the way for studies 
aimed at investigating the potential of miRNA profiles in classifying tumour from 
normal tissues. In this context, a milestone was the study by Lu and colleagues 
[70], who showed that hierarchical clustering based on miRNA expression 
profiles can actually classify tumours of different developmental lineages 
(epithelial vs haematopoietic; tumours from the gastrointestinal tract vs other 
tissues) or differentiation states and distinguish between tumour and normal 
tissues with higher efficiency compared with that based on mRNA profiling. 
Actually, whereas mRNAs must be translated into proteins to have a biological 
effect, mature miRNA expression levels represent more closely the functional 
level of a gene. Rosetta Genomics recently showed that a classifier based on 
48 miRNAs, constructed by profiling 400 samples from 22 different tumour 
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tissues and metastases, had the potential to classify tumour type with an 
accuracy >90%. This finding has an impact for the identification of tissue of 
origin in metastatic cancers of unknown primary, which account for 3-5% of all 
new cancer cases in US [117]. As for cancer-specific diagnostic signatures, by 
analysing 76 breast carcinomas and 10 normal breast samples, Iorio and 
colleagues identified 29 miRNAs whose expression was significantly 
deregulated in tumours and a smaller set of 15 miRNAs (including miR-125b, 
miR-145, miR-21 and miR-155) that were able to correctly predict the nature of 
the sample analysed (i.e., tumour or normal breast tissue) with 100% accuracy 
[54]. In another study, a set of 21 over-expressed and 4 down-regulated 
miRNAs was reported to correctly classify pancreatic adenocarcinoma from 
benign tissue [60].   
MiRNA expression profiling was also used to distinguish tumour subtypes or 
histotypes. An unsupervised analysis of miRNA expression profiles in a set of 
38 estrogen receptor (ER)-positive primary breast tumours of patients with 
lymph node-negative disease identified three subgroups predominantly driven 
by three miRNA signatures: an ER-driven luminal B-associated miRNA 
signature, a stromal miRNA signature (composed of miRNAs predominantly 
expressed in stromal fibroblasts and endothelial cells and marginally in the 
epithelial breast cancer cell lines), and an overexpressed miRNA cluster (miR-
515–522) located on chromosome 19q23, though these intrinsic miRNA 
signatures were not associated with tumour aggressiveness [118]. 
By profiling miRNAs in 10 normal mucosa samples and 49 stage II colon 
cancers differing with regard to microsatellite status, Schepeler and colleagues 
[119] showed that several miRNAs were differentially expressed between 
normal tissue and tumour microsatellite subtypes, with miR-145 showing the 
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lowest expression in cancer relative to normal tissue. Microsatellite status could 
be correctly predicted based on miRNA expression profiles for the majority of 
cases. In a similar effort, a molecular signature consisting of 27 differentially 
expressed genes, comprising mRNAs and miRNAs, was reported to correctly 
distinguish colon cancers with and without microsatellite instability, thus 
suggesting that combining mRNA and miRNA expression profiling data may 
represent a further method to improve the molecular classification of cancer 
[120]. 
In some instances, single miRNAs, rather than miRNA profiles, have been 
proven to have a strong classification power. This is the case of miR-205, which 
was reported to be a highly specific marker for squamous cell lung carcinoma: 
the expression of this miRNA, measured using quantitative RT-PCR (qRT-PCR) 
reached a sensitivity of 96% and a specificity of 90% in discriminating 
squamous cell lung carcinoma from adenocarcinoma [121]. Similarly, in 
esophageal squamous cell carcinoma, the expression of selected miRNAs was 
shown to correlate with gross pathological classification (fungating vs 
medullary), as is the case of miR-335, miR-181d, miR-25, miR-7 and miR-495, 
or with grade (miR-25 and miR-130b) [122]. 
Overall, these studies suggested miRNA profiles or single miRNAs as possible 
future markers for cancer diagnosis and classification. The development of 
biomarkers that help detect cancer at an early stage is important since early 
detection has a direct impact on prognosis and clinical outcome. MiRNAs show 
great stability and maintain their expression profiles in archival formalin-fixed 
paraffin-embedded (FFPE) samples [123], due to their small size. In contrast, 
mRNAs tend to be fragmented in archival tissues. This represents a huge 
advantage over mRNA profiling and enables studies to take advantage of the 
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vast resources in routine diagnostic archives. Thanks to the recent advances in 
qRT-PCR methods, which can detect miRNAs starting from a few nanograms of 
total RNA, miRNA expression levels can be also measured in fine-needle 
aspiration biopsy samples [124]. In addition, the small size, relative stability and 
resistance to RNase degradation make the miRNAs superior molecular markers 
than mRNAs for the setting-up of non-invasive diagnostic tests, such as those 
on blood, plasma or serum. In this context, Mitchell et al. [73] demonstrated that 
both serum and plasma samples are suitable for investigations of miRNAs as 
blood-based biomarkers, as miRNAs can be detected in both compartments 
and the results correlate. Ng and colleagues examined the expression of 
miRNAs in plasma from a series of colorectal cancer patients and controls and 
showed that the expression of miR-92 could discriminate tumour patients from 
healthy individuals with 70% specificity and 89% sensitivity [125]. Similarly, 
eight miRNAs were found to be differentially expressed in sera from ovarian 
cancer patients compared to those from healthy individuals, with miR-21, miR-
92 and miR-93 being overexpressed in three patients with normal pre-operative 
CA-125 (the current marker used to assess the risk of having ovarian cancer) 
levels [126]. It is worth mentioning that most patients enrolled in these studies 
presented advanced stage tumours. At present it not clear whether cancer-
associated miRNAs can be detected in the blood only when the disease has 
already metastasised, thus being potentially used only for the diagnosis of 
advanced cancers, or if they are released into the circulation also in the 
presence of an early stage tumour. It is also still to be elucidated whether 
circulating miRNAs are mainly released from cells by lysis or whether they are 
encapsulated in small (40-100 nm) membrane vesicles of endocytoc origin 
referred to as exosomes. Exosomes are secreted by most cell types in vitro and 
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are also found in body fluids, such as blood, urine, malignant ascites, amniotic 
fluid and breast milk. Although their biological role is still to be clarified, it is 
conceivable that they can mediate communication between cells. Taylor and 
Gercel-Taylor [127] compared miRNA profiles of ovarian tumours to those of 
tumour exosomes isolated from the same patients and found that the levels of 8 
miRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 
and miR-214) were similar between cellular and exosomal miRNAs. In addition, 
whereas EpCAM-positive exosomes were detectable in both patients with 
benign ovarian disease and ovarian cancer, exosomal miRNA from ovarian 
cancer patients exhibited similar profiles, which were significantly distinct from 
profiles observed in benign disease. The same group showed that circulating 
exosomes are significantly more abundant in lung adenocarcinoma patients 
than in a control group, with a higher mean exosomal miRNA concentration in 
cancer patients [128].  In addition, they found that there is a close correlation 
between circulating miRNAs of tumour-derived exosomes and tumour miRNAs, 
confirming that miRNA expression in peripheral blood could be a surrogate of 
miRNA expression in the tumour biopsy. Overall, the evidence collected on 
miRNAs would suggest that combining the miRNA diagnostic biomarkers with 
other available screening tests may improve diagnostic accuracy. 
 
1.3.5.2	MiRNAs	in	cancer	prognosis	
 
The clinical utility of miRNAs in oncology extends beyond diagnostics, as 
different reports showed correlation between the expression of specific miRNAs 
with i) bio-pathological features of the tumour that are commonly used for 
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prognostication, ii) clinical outcome and iii) response to therapy. For example, in 
breast cancer, Iorio and colleagues showed that the expression of a number of 
miRNAs correlated with the expression of estrogen and progesterone receptors, 
tumour stage, nodal status, proliferation index and vascular invasion [54]. 
Similarly, Slaby et al. reported that miR-21 overexpression in colorectal cancer 
has a strong correlation with established prognostic factors, such as nodal 
stage, metastatic disease and stage [129]. 
In lung adenocarcinomas, including those classified as disease stage I, miRNA 
expression profiles were reported to correlate with patient’s survival [58]. 
Specifically, Kaplan-Meier survival estimates showed that patients with either 
high miR-155 or reduced let-7a-2 expression had a poorer survival than the 
patients with low miR-155 or high let-7a-2 expression, respectively. Using a 
multivariate Cox proportional hazard regression analysis, the same authors 
found that high miR-155 expression was a significantly unfavourable prognostic 
factor independent of other clinicopathological factors, such as age, sex, and 
smoking history [58]. Interestingly, 143 lung cancer cases that had undergone 
potentially curative resection could be classified into two major groups 
according to let-7 expression in unsupervised hierarchical analysis, showing 
significantly shorter survival after potentially curative resection in cases with 
reduced let-7 expression. Multivariate COX regression analysis showed this 
prognostic impact to be independent of disease stage [130].  
As far as squamous cell lung carcinoma is concerned, miR-146b alone was 
found to have a strong prediction accuracy (78%) in stratifying prognostic 
groups of patients and miRNA signatures were reported to be superior in 
predicting overall survival than a previously described 50-gene prognostic 
signature [131]. 
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Expression profiling of 157 miRNAs in 35 primary neuroblastoma tumours 
indicated that 32 were differentially expressed in favourable and unfavourable 
tumour subtypes. Many of these miRNAs were significantly underexpressed in 
tumours with MYCN amplification, which have particularly poor prognoses [132].  
In some instances, miRNA expression was reported to correlate to response to 
therapy, as is the case of let-7g and miR-181b in colorectal cancer, which were 
identified as significant indicators of chemoresponse to chemotherapy with 5-
fluorouracil-based antimetabolite S-1 [133]. 
In hepatocellular carcinomas, patients whose tumours had low miR-26 
expression levels, a miRNA whose abundance was found to be reduced in 
hepatic cancer compared to paired noncancerous tissue, had shorter overall 
survival but a better response to interferon therapy than did patients whose 
tumours had high expression of the miRNA [134]. Mishra and colleagues [135] 
identified the miR-24 binding site in the dihydrofolate reductase 3’-UTR as the 
target of a single nucleotide polymorphism (SNP), previously described as 
associated with methotrexate resistance in childhood leukemia and lymphoma 
patients [135]. Functionally, this SNP was demonstrated to impair miR-24 
binding to dihydrofolate reductase mRNA, with a consequent overexpression of 
the enzyme and increase of methotrexate resistance [136]. In this context, 
recent studies showed that SNPs in miRNA target sites may not only affect 
response to treatment but also cancer predisposition. For example, a SNP in a 
let-7 complementary site in the KRAS 3'-UTR was reported to be significantly 
associated with a 1.4- to 2.3-fold increased risk for non-small cell lung cancer 
among moderate smokers [137]. 
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1.3.5.3	MiRNAs	in	cancer	therapy	
 
Because of the clinical and biological significance of miRNAs in cancer, the 
management of miRNAs with altered expression in tumours should be 
considered as a therapeutic strategy. The rationale for using miRNAs as 
potential therapeutic targets comes from the several studies that have 
documented, through loss- or gain-of-function approaches, oncogenic or tumour 
suppressive functions of selected miRNAs in different human cancers [138]. 
The function of over-expressed oncogenic miRNAs has been successfully 
antagonized in experimental models using chemically modified antisense 
oligonucleotides, such as 2’-O-methyl-antisense oligonucleotides or ‘locked’ 
nucleic acids (LNA). The latter, which exhibit the highest affinity and specificity 
for complementary target RNA and show properties of cellular uptake and 
biodistribution adequate for being used in vivo [139], proved to efficiently inhibit 
the expression of specific miRNAs [140]. Similarly, intravenous injection of 
antagomirs, 2’-O-methyl-antisense oligonucleotides conjugated with a 
cholesterol moiety at the 3’ end, produced a long-lasting inhibition of specific 
miRNAs in mice [141]. In contrast, restoration of expression of down-modulated 
tumour-suppressive miRNAs is usually achieved using synthetic double-
stranded RNA molecules resembling precursor miRNAs or expression vectors 
carrying miRNA genes packed into lentiviral systems [141].  
Given that the role of a miRNA in the development cancer has to be preliminary 
ascertained by functional studies, the reconstitution of tumour-suppressive 
miRNAs or the knockdown of over-expressed, oncogenic miRNAs could offer 
an extraordinary opportunity to regulate the expression of disease-relevant 
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genes. Efficient in vivo delivery of miRNA precursors and miRNA-specific 
antisense oligonucleotides or antagomirs is a crucial factor for the development 
of successful miRNA-based treatment modalities. In this context, it is 
noteworthy that efficient reconstitution of miR-15a and miR-16-1 expression has 
been achieved by injecting a lentiviral vector expressing miRNA precursor into 
prostate tumour xenografts in mice [142]. In addition, a proof-of-concept of the 
antagomir treatment has been successfully demonstrated, as tumour growth in 
a neuroblastoma mouse model was abolished by the injection of antagomiR-17-
5p [143].  
 
As miRNAs have the potential to simultaneously modulate a cohort of cancer-
relevant gene networks, they might become therapeutically relevant in a ‘one-hit 
multitarget’ context against cancer, including PCa. However, the multi-specific 
nature of miRNA-based gene regulation is both a strength and a weakness as 
interfering with miRNA expression might give rise to unpredictable off-target 
effects on unintended mRNA targets and elicit immune-activating ‘danger 
signals’. This makes imperative i) the precise definition and validation of the 
genes targeted by a given miRNA in relevant cell types and tissues, as well as 
ii) the development of approaches to deliver miRNA-modulating agents 
specifically to the cells of interest. As far as the first issue is concerned, it is 
noteworthy that the identification of putative target genes is still problematic, 
since each miRNA can interact with several mRNAs and each mRNA can be 
targeted by several miRNAs. Prediction of miRNA/mRNA pairs is usually 
accomplished using dedicated software, which perform computational 
predictions based on a two-step process. In the first step potential miRNA 
binding sites are searched within the 3’-UTR of several genes, according to 
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specific base-pairing rules. Parameters that are usually evaluated by widely 
used target prediction software include the complementarity with miRNA seed, 
the binding-energy threshold and several empirically determined binding rules, 
so that each programme can predict different putative target genes for the same 
miRNA. In the second step, programmes implement cross-species conservation 
requirements, in order to predict only the target sites which are under selective 
pressure to preserve their sequence and their functionality. Each programme 
prioritises some specific requirements, thus furnishing predictions that rarely fit 
together. For this reason, a common practice is intersecting the results obtained 
on different platforms to increase the probability to find true miRNA-mRNA 
pairs. In addition, gene expression profiling [144] and proteomic analysis [145] 
associated to loss- and gain-of-function studies in in vivo or in vitro models 
might contribute to a better understanding of miRNA controlled cellular networks 
in a given disease and identify biologically relevant targets. In vivo knock-out or 
knock-in models should be helpful to understand the pathways that are affected 
by miRNA manipulations.  
As for the delivery of small RNAs, the two main strategies currently being 
developed rely on the use of viral vectors and non-viral, lipid-based complexes, 
such as liposomes and nanoparticles [146]. In our opinion, the use of delivery 
systems displaying carrier-defined specificity (as, for example, cell-specific 
immunoliposomes, which have been already used successfully to deliver small 
interfering RNAs by target-specific cell-surface receptors [147]) might represent 
a reliable approach for controlled delivery of miRNA-modulating agents to 
relevant tissues/organs, thereby avoiding cytotoxic side effects. In this context, 
prostate-specific membrane antigen (PSMA), which is specifically expressed on 
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prostate epithelial cells and strongly upregulated in PCa, has been proven to be 
a suitable surface molecule to drive PCa-specific delivery of small RNAs [148]. 
The interference with cancer related miRNAs, besides producing a possible 
direct anticancer effect, could be exploited to increase the sensitivity of tumour 
cells to conventional anticancer agents. In this context, it has been recently 
reported that specific miRNAs can contribute to chemoresistance in various 
cancer cell lines [149] and that antisense oligonucleotide-mediated inhibition of 
miR-21 and miR-200b was able to enhance the sensitivity of 
cholangiocarcinoma cells to the chemotherapeutic agent gemcitabine [150]. 
Again, ectopic expression of members of the let-7 family of miRNAs in lung 
cancer cells increased their in vitro radiation response [95]. Based on this 
evidence, the possibility to rationally design therapeutic approaches combining 
conventional treatments and specific miRNA modulators could be envisaged to 
improve therapeutic response.  
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2. STUDY AIMS AND EXPERIMENTAL DESIGN   
 
2.1. Study Aims 
 
Radiotherapy is a standard treatment for organ-confined prostate cancer (PCa). 
Although treatment technical optimization has greatly improved local tumour 
control, approximately 30% of patients still undergo recurrence. Thus, new 
strategies to increase radiotherapy effectiveness are needed. 
Radioresistance is a complex phenomenon that can arise as a result of various 
genetic and epigenetic abnormalities. microRNAs (miRNAs) are endogenous 
small non-coding RNAs that negatively regulate gene expression. Their 
documented dysregulation in cancer together with their potential to 
simultaneously regulate multiple oncogenic-oncosuppressive pathways, has 
aroused interest in defining a functional association between miRNAs and 
tumour radiation response. The few preclinical studies carried out thus far in 
PCa (mainly in cellular models) provided controversial results. 
The final goal of the project was to identify specific miRNAs acting as 
radiosensitizers in PCa that can be potentially exploited for designing novel 
strategies aimed at increasing radiotherapy effectiveness. To achieve this goal, 
we proposed to 1) identify miRNAs involved in radiation response and ii) dissect 
the underlying molecular mechanisms in order to substantiate their functional 
involvement in determining PCa response to radiation treatment.  
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2.2 Experimental Design  
 
To address the first aim of the study, consisting of the identification of specific 
miRNAs potentially contributing to radiation response in PCa, the very first step 
of this study consisted of the definition of the possible strategies to follow to 
select miRNAs related to radiation response. In order to consider all the 
miRNAs potentially matching our query, we followed two complementary 
approaches of miRNA sorting. The first approach is based on the identification 
of miRNAs modulated upon radiation exposure, since modulation in response to 
radiation stimulus could likely reflect an involvement in radiation response 
processes. However, it is worth noting that miRNA modulation upon radiation 
does not per se imply that such miRNAs play an active role in influencing 
radiation response. To investigate whether singled out miRNAs were 
functionally involved in the response, taking advantage of a panel of PCa cell 
lines and of subcutaneous PCa xenografts, miRNA expression was artificially 
modulated in PCa cells by transfection with specific miRNA modulators (i.e.: 
miRNA mimics) and transfected cells were exposed to radiation in order to 
check whether miRNA modulation induce changes in sensitivity profiles of both 
cell and animal PCa models. Taking advantage of an established collaboration 
with CNAO (Pavia), PCa cell lines exposed to photons were also exposed to 
carob ions in order to compare the effects induced by conventional radiotherapy 
and hadrontherapy, respectively.  
As a second approach of miRNA identification, we focused on miRNAs that i) 
are downregulated in PCa and ii) target genes belonging to pathways relevant 
to radiation response. This strategy is based on the evidence that miRNA 
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downregulation in PCa compared to normal prostate suggests a possible 
oncosuppressive function of the miRNA, which is compatible with a role of this 
molecules in making cells susceptible to a specific treatment. As for the second 
criterion, the evidence that a specific miRNA targets pathways relevant to 
radiation response support its putative role in influencing cell sensitivity to 
radiation. The intersection of these two criteria should accrue the reliability of 
miRNA sorting for the evaluation of their radiosensitizing effect.  
Once miRNAs were selected, by either the first or the second approach, their 
radiosensitizing effect was studied in order to dissect the underlying molecular 
mechanisms. To this aim, we sought to figure out, for each selected miRNA, the 
target genes that could be relevant to radiation response. Top targets were 
validated as actually implicated in mediating the radiosensitizing effect ascribed 
to the respective miRNA.  
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Figure 2.1 Schematic representation of the experimental design of the study 
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3. MATERIALS AND METHODS  
 
3.1. Cell culture 
3.1.1 Cell lines 
The following human prostate cancer cell lines were used: DU145, PC-3, 
LNCaP, 22Rv1, which represent the gold standard of PCa cell lines [151]. All 
cell lines have been purchased from American Type Tissue Culture Collection 
(ATCC, VA, USA). DU145 cell line derives from a brain metastasis of a 
Caucasian 69-year-old carcinoma patient and displays an epithelial 
morphology. According to the information provided by ATCC, DU145 cell line is 
not hormone sensitive and does express neither androgen receptor nor the 
prostate specific antigen (PSA). The doubling time is approximately 30 hours 
(h), therefore a subcultivation ratio of 1:5 was observed twice a week. PC-3 cell 
line derives from a bone metastasis of a grade IV prostatic adenocarcinoma 
from a 62-year-old Caucasian patient. As for DU145 cell line, it is hormone 
insensitive and presents no AR or PSA. This epithelial cell line has a doubling 
time of approximately 24 h, thus needing a subcultivation rate of 1:6 two times 
a week. Both DU145 and PC-3 cells are able to form adenocarcinoma when 
injected into nude mice. LNCaP cell line was isolated from the left 
supraclavicular lymph node of a 50-year-old Caucasian male with confirmed 
diagnosis of metastatic prostate carcinoma. Unlike the first two cell lines, 
LNCaP are characterised by a slow growth, doubling every 48-60 h, thus 
implying a subcultivation rate of 1:3 and a very modest success rate upon 
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xenograft transplantation. 22Rv1 cell line was isolated from the xenograft 
CWR22R derived from a patient with bone metastasis. The main characteristic 
of 22Rv1 is the presence of the AR-V7 variant, a splicing variant of the 
androgen receptor that results in a constitutive activation of the receptor in a 
ligand independent manner.  22Rv1 doubling time ranges from 36–40 h, 
needing a subcultivation rate of 1:4 twice a week. All cell lines were maintained 
in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), at 
37°C and 5% CO2. Cell lines were authenticated and periodically monitored by 
genetic profiling using short tandem repeat analysis (AmpFISTR Identifiler PCR 
amplification kit, Thermo Fisher Scientific Inc, Waltham, MA, USA).  
  
Figure 3.1 PCa cell lines morphology (up) and characteristics (down) 
 
  
DU145 PC-3 22Rv1 LNCaP 
CELL LINE       DERIVATION     MUTATIONAL STATUS 
ANDROGEN          
SENSITIVITY 
p53 PTEN AR 
PC-3 Vertebral metastasis Del/Mut Del/Del - Insensitive 
DU145 Brain metastasis Mut/Mut Wt/Del - Insensitive  
LNCaP Lymph Node Wt Del/Mut + Sensitive 
22Rv1 CWR22R xenograft line TS-Mut Wt + (mut) Sensitive 
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3.1.2 Cell transfection 
 
Cell transfection was performed to vehicle miRNA, siRNA and target protector 
molecules into the host cells (DU145 and PC-3). The expression of the miRNAs 
of interest was ectopically modulated by transfecting cells with respective 
miRNA mimics, small, chemically modified double-stranded RNAs that mimic 
endogenous miRNAs and enable miRNA functional analysis by up-regulation of 
miRNA activity. miRNA mimics were purchased from Thermo Fisher Scientific 
(Waltham, MA, USA) and resuspended in sterile RNase-free water, diluted to 
the appropriate stock solution (10 µM) and stored at −20 °C until use.  
siRNAs sequences were selected using the online siMAX design tool 
(www.eurofinsdna.com). A BLAST search for siRNA sequences was carried out 
to exclude any alignment with other sequences in the human genome. Control 
siRNAs made of mismatched sequences (with no significant homology to any 
known human mRNA) were included. SiRNAs were manufactured by Eurofins 
MWG Operon (Ebersberg, Germany) as pre-formed and purified duplexes, 
made of 19 bp-long RNA oligonucleotides with two extra-thymidine bases 
forming a 3 overhang on both strands. Each siRNA was resuspended in 
sterile RNase-free water, diluted to the appropriate stock solution (10 µM) and 
stored at −20 °C until use. 
 For miRNA and siRNA experiments, cells were transfected for 4 h at 37°C with 
20 nM mirVana miRNA mimic molecules (Thermo Fisher Scientific) or with 20 
nM siRNA molecules using Lipofectamine 2000 (Thermo Fisher Scientific), 
respectively. Specifically, cells were let to grow until reaching 80% confluence 
and then the medium was replaced with Opti-MEM medium (Thermo Fisher 
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Scientific), a reduced serum medium supplemented with hypoxanthine, 
thymidine, sodium pyruvate, L-glutamine, trace elements, and growth factors, 
thus resulting ideal to be used during cationic lipid transfections since the 
presence of serum inhibits transfection efficiency by reducing the amount of 
lipid DNA complexes associating with the target cells [152]. Transfection mix is 
composed by 2 solutions where the miRNA molecule and the lipofectamine, 
respectively, are diluted in Optimem. For each condition two mixes were 
prepared containing miRNA mimic and Lipofectamine RNAiMAX, rispectively. 
To allow miRNA-lipofectamine complex formation the two solutions were mixed 
and incubated for 15 minutes at room temperature, added to host cells and 
incubated for 4 h at 37 °C in 5% CO2. After incubation cells were washed with 
0.9% saline solution and serum supplemented medium was added in order to 
stop transfection and cells were incubated at 37 °C in 5% CO2 for further 
processing. Control experiments were performed in parallel by transfecting cells 
with 20 nM miRNA/siRNA negative controls. miR-875-5p synthetic mimic is 
referred to as miR-875-5p, miR-205 as miR-205, negative mock control 
oligomer as Neg, EGFR or PKCε miScript Target Protector as miR-Mask, ZEB1 
siRNA as siZEB1, PKCε siRNA as siPKCε, LAMP3 siRNA as siLAMP3 and 
RAB27A siRNA as siRAB27A. 
For target protection experiments, the target protector molecules (hereafter 
referred to as “miR-Mask”) were designed as “miScript Target Protectors” 
(Qiagen, Hilden, Germany) on Qiagen website, by indicating the REFseq ID of 
the target gene of interest (EGFR for miR-875-5p and PKCε for miR-205) and 
the seed region of the miRNA. The specific miR-Mask sequences were 
automatically generated and the respective custom product turned available for 
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purchase. Each miR-Mask was resuspended in sterile RNase-free water, 
diluted to the appropriate stock solution (10 µM) and stored at −20 °C until use. 
In order to allow the physical interaction between the target and the miR-Mask 
preventing its binding to the miRNA, a cotransfection with the miRNA mimic of 
interest and the miR-Mask was performed. Twenty nM EGFR or PKCε-miScript 
Target Protector (Qiagen, Hilden, Germany) were used alone or in 
cotransfection with miR-875-5p or miR-205 mimic, respectively.  
For the generation of a DU145 cell clone overexpressing miR-875-5p, pEZX- 
MR04 vector (GeneCopoeia, Rockville, MD, U.S.A) carrying the 230 bp DNA 
region encompassing the 76 bp miR-875-5p precursor sequence was used to 
stable transfect DU145 cell line. The plasmid containing a scramble sequence 
was used as negative control and referred to as Null. Cells were transfected 
according to Lipofectamine 3000 protocol (Thermo Fisher Scientific Inc). Briefly, 
cells were seeded in 6-well plate (5 x 105 cells/well) and 24 h later transfected 
with vectors (10 pg). After 72 h, cells were selected using 0.3 mg/ml puromycin 
for 5 weeks. Stable transfectants were stored in liquid nitrogen at 196°  C. 
When cultured, transfected cells were maintained in presence of 0.3 mg/ml of 
puromycin. As for the DU145 cell clone stably overexpressing miR-205, a clone 
previously established in the lab for a prior study on miR-205 has been used 
[153]. 
For IL-6 levels restoration in miR-23a-3p transfected DU145 cells, recombinant 
human IL-6 was purchased from Peprotech (Rocky Hill, NJ) and used at 50 
ng/ml as a single-supplementation.  
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3.1.3 Clonogenic assay  
 
To evaluate radiation-induced late effect, consisting of disrupting cell capacitiy 
to proliferate indefinitely upon DNA damage induction, cell clonogenicity was 
assessed by clonogenic assay. Transfected cells were exposed to increasing 
doses of radiation (2- 8 Gy) delivered as a single dose using the 137Cs γ-
irradiator IBL-437 (dose rate 5.2 Gy/min). Cell suspensions at increasing cell 
densities  (500 to 8000 cells/well) were prepared to allow colony formation even 
at the higher doses of radiation (Fig. 3.2).  
 
Figure 3.2 Schematic representation of clonogenic assay 
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Different cell suspensions were seeded in triplicate in RPMI medium containing 
10% FBS and let to form colonies for several days according to cell doubling 
time (approximately 8 days for DU145 and 12 days for PC-3), since a colony is 
defined to consist of at least 50 cells, and each cell line took different days to 
undergo the number of cell duplications needed to reach this cell number. Once 
colony formation occurred, colonies were fixed with 70% ethanol, stained with 
crystal violet in 70% ethanol, and counted. The colony plating efficiency (PE) 
was calculated as the ratio of the number of colonies to the number of single 
cells seeded. The surviving fraction (SF) was calculated as the ratio of the 
colony-forming efficiency of the irradiated sample to that of the non-irradiated 
one. 
 
Plating Efficiency (PE) = Number of counted colonies Number of seeded cells 
 
Surviving Fraction (SV) = PE of irradiated cells PE of non irradiated cells 
 
 
3.1.4 In vivo experiments 
 
All animal experiments were approved by the Ethics Committee for Animal 
Experimentation of Fondazione IRCCS Istituto Nazionale dei Tumori. 
For the xenotransplantation of DU145 cells stably expressing the miRNA of 
interest (miR-875 and miR-205), SCID mice were used for subcutaneous 
injection.  
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Specifically, ten million DU145 cells (negative control and stably expressing 
miR-875-5p/miR-205 clones) were injected into the right flank of eight-week-old 
male SCID mice, and when tumors reached ~300 mm3 (Width2 x Length/2) for 
miR-875-5p experiments and 100 mm3 for miR-205, mice were randomly 
assigned to control or radiation treatment groups (n=8). Mice received 5 Gy 
single dose irradiation using a micro-CT/microirradiator (225Cx, Precision X-
ray) capable of image-guided radiation delivery at the small-animal.  
Specifically, mice were anesthetized with an intraperitoneal injection of a 
solution containing ketamine (100 mg/kg) and xylazine (5 mg/kg). After 
approximately 20 minutes, anesthetized mice were placed on the carbon-fibre 
support platform, which is under the control of stepper motors used to precisely 
drive the stage in the correct position, where the tumour to be irradiated is 
centred by the gantry. The first imaging acquisition aimed at positioning both 
the stage and the gantry was done with a photon energy of 40 kVp, 1 mA, and a 
resolution of 0.2 mm. To select the desired targeting location, and plan the 
treatment, CBCT images were acquired with the animal in the treatment 
position, by using SmART Plan software, which is an executable program on a 
Linux-based platform. The CBCT images were imported in the CT upload 
module and cropped and resized, reconstructing the 3D image by integrating 
the imaging information deriving from each dimension (axial, sagittal and 
lateral).  A specific contouring of the target area to be irradiated was done and, 
once the target was selected, an appropriate irradiation protocol was designed, 
starting from a beam-definition step, which includes isocentre definition, and 
beam angles and size setting. Dose distribution and treatment parameters were 
automatically calculated by the software, based on Monte Carlo calculation 
algorithms. In particular, to administer 5 Gy single dose to the xenografts, 2 
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opposing (angle=180°) beams of 2.5 Gy each were set in order to minimize the 
dose absorbed by the surrounding normal tissues yet delivering the desired 
dose to the target tumour. According to the restrained volume of the tumour, a 
rectangular collimator of 1.0 cm×1.0 cm was used in order to precisely sharpen 
the beams towards the target by limiting radiation scattering. Once radiotherapy 
is delivered, mice are retrieved from the irradiator stage and placed in their 
cages under controlled conditions [154].  
At day of the treatment  (31 and 20 for miR-875-5p and miR-205, respectively) 
and after ~50 and 40 days (for miR-875-5p and miR-205, respectively), 
representative X-ray images were collected. In order to perform ex vivo 
evaluations, tumour specimens were removed from 4 additional mice 24 h after 
irradiation and immediately disaggregated for ex-vivo clonogenic assay and 
RNA/protein collection or fixed in 10% buffered formalin for 
immunohistochemical analysis.  
 
3.2 Molecular biology analyses 
 
3.2.1 RNA isolation 
 
To perform miRNA and gene expression analysis, total RNA was extracted by 
using miRNeasy mini kit (Qiagen, Valencia, CA, U.S.A.), which combines 
phenol/guanidine-based lysis of cell samples and silica-membrane–based 
purification of total RNA, including miRNAs.    
Specifically, cell pellets were disrupted and homogenised by resuspension with 
700µl of QIAzol Lysis Reagent (Qiagen), a monophasic solution of phenol and 
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guanidine thiocyanate, designed to facilitate lysis of fatty tissues and inhibit 
RNases and also to remove most of the cellular DNA and proteins from the 
lysate by organic extraction. The homogenate was incubated at room 
temperature for 5 minutes. Subsequently 140 µl of chloroform were added and 
the homogenate was separated into aqueous and organic phases by 
centrifugation (15 minutes at 12000 x g at 4°C). RNA partitions to the upper 
aqueous phase, while DNA remains in the interphase and proteins in the lower, 
organic phase. The upper aqueous phase was transferred to a new collection 
tube avoiding transferring any interphase. 1.5 volumes of 100% ethanol were 
added and mixed thoroughly by pipetting in order to precipitate RNA from the 
aqueous phase. Then, 700 µl of each sample, including any precipitate, were 
transferred into an RNeasy Mini column in a 1.5 ml collection tube, and then 
centrifuged at ≥ 8000 x g at room temperature for 15 seconds.  
The flow-through was discarded and 700 µl of Buffer RWT were added to the 
columns and centrifuged for 15 seconds at ≥ 8000 x g at room temperature. 
Then the columns were washed with 500 µl of Buffer RPE by two centrifugation 
steps. Finally, columns were transferred to a new 1.5 ml tube and 30 µl of 
RNase-free water were pipetted directly into the column membrane and 
centrifuged for 1 minute at ≥ 8000 x g to elute RNA. 
The total amount of RNA was quantified through Nanodrop, a 
spectrophotometer that allows nucleic acid quantification, by a modification of 
the Beer-Lambert equation. The determination of nucleic acid concentrations is 
based on the absorbance at 260 nm, corrected for the extinction coefficient 
specific for RNA (=40 ng-cm/µL). Moreover, purity ratios were verified for each 
sample, by considering as “pure” a value of ~ 2.0 for 260/280 ratio (indicative of 
the presence of protein, phenol or other contaminants that absorb strongly at or 
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near 260 nm) and 1.8-2.0 for 260/230 ratio (the presence of residual phenol, 
guanidine, magnetic beads, carbohydrates or proteins). Quantified RNA 
samples were stored at -20° C until use.  
3.2.2 Reverse Trancription 
 
Conversion of RNA to cDNA was performed by using miScript II RT kit 
(Qiagen).  
For reverse transcription, miRNAs and other noncoding RNAs (ncRNAs) 
included in the total RNA are polyadenylated by poly(A) polymerase and 
converted into cDNA by reverse transcriptase with oligo-dT priming. mRNAs are 
converted into cDNA by reverse transcriptase using both oligo-dT and random 
priming. Detection of mature miRNAs and mRNAs was performed using specific 
assays. Detection of mature miRNA, precursor miRNA, other ncRNA, and 
mRNA can be performed using the appropriate assays (Fig. 3.3). 
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Figure 3.3 Reverse transcription of mRNAs and miRNAs using miScript II RT kit 
 
 
For each sample, a total amount of 1 µg of RNA was reverse transcribed in the 
reverse-transcription master mix containing all components required for first-
strand cDNA synthesis, except template RNA. The master mix was prepared as 
following: 4 µl of 5x miScript HiFlex Buffer, 2 µl of 10x miScript Nucleic Mix, 1 µl 
of Reverse Transcriptase, 3 µl RNase-free water to a final volume of 10 µl 
(volumes for 1 reaction).  
A thermal cycler was used to perform the retrotranscription reaction using the 
conditions: 60 minutes at 37°C followed by 5 minutes at 95° to inactivate 
miScript Reverse Transcriptase. cDNA was stored ad -20°C until use.  
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3.2.3 miRNA and mRNA expression analysis  
 
Quantification of miR-875-5p or miR-205 expression levels was assessed by 
qRT-PCR using miScript SYBR Green PCR kit (Qiagen), which includes the 
QuantiTect SYBR Green PCR Master Mix and the miScript Universal Primer, a 
reverse primer that allows detection of miRNAs in combination with the 
following specific miScript Primer Assays:  
Detector Assay ID 
miR-875-5p Hs_miR-875-5p_1 
miR-205 Hs_miR-205_1 
RNU6 Hs_RNU6-2_11 
  
Table 3.1 SYBR Green PCR Assays 
 
RNU6 was used as endogenous control, as it is an ncRNA that show a 
relatively constant expression level across a variety of cells and tissues. An 
ideal endogenous reference RNA for normalisation of data in real-time PCR 
quantification of miRNA should have the following features: 
• A constant expression level across all samples in the study 
• A similar small size as the miRNA under study 
• A similar expression level in the sample as the miRNA under study 
• Should not be regulated under the experimental conditions. 
The mix was prepared using: 12.5 µl of master mix (QuantiTect SYBR Green 
PCR Master Mix), 2.5 µl of universal primer (10x miScript Universal Primer), 2.5 
µl of specific primer, 2.5 µl of diluted cDNA and 5 µl of water (volumes for 1 
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reaction). The amplification reaction was performed by 7900HT Fast Real-Time 
PCR System as following: 95°C for 15 minutes followed by 40 cycles of 
denaturation at 94°C for 15 seconds, annealing at 55°C for 30 seconds and 
extension at 70°C for 30 seconds.  
For gene expression analyses, qRT-PCR was assessed using the specific 
following TaqMan gene expression assays (Thermo Fisher Scientific):  
Detector Assay ID 
CDH1 Hs00170423_m1 
CTNNB1 Hs00355045_m1 
EGFR Hs01076078_m1 
ZEB1 Hs00232783_m1 
PKCε Hs00178455_A1 
LAMP3 Hs01111316_m1   
RAB27A Hs00608302_m1   
GAPDH Hs02786624_g1   
 
Table 3.2 TaqMan Gene Expression Assays 
 
GAPDH was used as endogenous control. For each gene, a mix was prepared 
in 1.5 ml tubes using: 5 µl of Taqman master mix (TaqMan Fast universal 
master mix, Applied Biosystems), 0.5 µl of specific primer, 2.5 µl of diluted 
cDNA and 2 µl of water (volumes for 1 reaction). The amplification reaction was 
performed as following: 95°C for 15 minutes, 40 cycles of denaturation at 95°C 
for 15 seconds and annealing at 55°C for 30 seconds, and a final step of 
extension at 72°C for 30 seconds. Amplifications were run on the 7900HT Fast 
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Real-Time PCR System. Data were analyzed by SDS 2.2.2 software (Thermo 
Fisher Scientific Inc) and reported as relative quantity with respect to a 
calibrator sample using the 2-∆∆Ct method. The 2-∆∆Ct method is a comparative 
method that relies on comparing the differences in CT (threshold cycles) values 
obtained with normal (negative control) versus experimental (transfected) 
samples. Specifically, the CT for each sample was determined. Next, the ΔCT 
value was calculated as the difference between the CT value of the target 
miRNA and the CT value of the endogenous control (RNU6/GAPDH). 
ΔCT = CT (target) - CT (endogenous control) 
In the next steps, the ΔΔCT value and the normalized target expression were 
calculated:  
ΔΔCT = ΔCT (sample [i.e.: transfected cells]) - ΔCT (calibrator [e.g., negative 
control cells])  
The relative quantification (RQ), which allows to analyse changes in 
miRNA/gene expression in the sample of interest relative to the reference 
sample, is calculated as  2-ΔΔCT. 
 
3.3 Biochemical analyses  
 
3.3.1 Western blotting  
 
Western blotting analysis was performed to evaluate protein expression levels 
upon different transfection and irradiation conditions. The total protein content 
was considered for all the experiments except for the assessment of phospho-
DNA-PK, phospho-ATM, and the subcellular localization of EGFR upon 
 	
	
MATERIALS AND METHODS 
	
	 	
98	
irradiation, where a sub-fractionation was performed. For the assessment of 
EGFR nuclear translocation, DU145 cells were transfected with miR-875-5p or 
miR-205 mimic and the respective negative control as described. Twenty-four 
hours after transfection, cells were irradiated at 4 Gy and harvested for 
subcellular protein distribution by Subcellular Protein Fractionation Kit 
(ThermoFisher Scientific) after 30 minutes and 60 minutes from irradiation. As 
for ATM and DNA-PK evaluation, 48 h after transfection, cells were irradiated at 
4 Gy and harvested at 0.5, 2 and 4 h later for subcellular protein fractionation.  
As for the western blotting analysis where the fractionation was not needed, 
total proteins were extracted from DU145 cells at different time points after 
radiation. Pellets were washed in ice PBS (Lonza) and homogenized in 4 mL 
Laemli lysis buffer mix composed as in table 3.3: 
 
 
 
 
 
 
 
 
 
 
 
Reagent Quantity 
TRIS HCL 0,5 M PH 6.8 1 ml 
SDS 10% 2 ml 
Leupeptina 4 µl 
Pepstatina 4 µl 
A protein 4 µl 
PMSF 100 nM 40 µl 
H20 948 µl 
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Table 3.3 Composition of Laemli lysis buffer. 
 
Lysed samples were cooled in ice and stored at -20° C.  
For both total and fractionated contents, protein concentration was determined 
using spectrophotometer POLARstar OPTIMA at a wavelength of 562 nm using 
Pierce BCA Protein Assay Kit as colorimetric assay. To perform protein 
quantification, the Bovine Serum Albumin according to scale of dilutions from 
0.01 µg/µl to 0.05 µg/µl was used as a standard reference. Quantification was 
performed using the spectrophotometer. 
After quantisation, samples were prepared to be resolved on polyacrylamide gel 
and then transferred into Hybond nitrocellulose membranes (Amersham, 
Pittsburgh, PA). 30 µg of protein were loaded into the gel. Running buffer was 
prepared using: Tris-glycine 100 ml, SDS 10% 10 ml and water to a final 
volume of 1 L. The electrophoretic run was performed at 110 V for the time 
necessary to allow the separation of proteins.  
Then the gel was transferred to the nitrocellulose filter using transfer buffer 
composed by: Tris-glycine 100 ml, methanol (96%) 200 ml and water to a final 
volume of 1 L. The presence and the integrity of the extract in the nitrocellulose 
were verified by treatment with Red Ponceau making proteins visible upon 
direct binding. Filters were blocked in PBS-Tween/0,5% skim milk and probed 
overnight with the appropriate primary antibodies (table 3.4): 
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Table 3.4 Primary Antibodies. 
 
The filters were then incubated with the respective secondary peroxidase-linked 
whole antibodies (Life Technologies) 1 h at room temperature. Bound 
antibodies were detected using the Novex ECL, HRP Chemiluminescent 
substrate Reagent Kit (Life Technologies) and filters were autoradiographed.  
For the preparation of figures, the original western blots were cropped to 
generate the figure panels with the relevant lanes. Cropped images were then 
subjected to uniform image enhancement of contrast and brightness. Molecular 
weights were determined using the colorimetric Precision Plus Protein Standard 
(Bio-Rad) and standard protein bands were removed from the 
chemoluminescent blot image. 
  
Antibody Company Code 
RAB27A Abcam Ab55667 
LAMP3 Abcam Ab83659 
PKC-ε Santa Cruz Sc-1681 
β actin Abcam Ab8226 
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3.3.2 Immunofluorescence 
 
To perform immunofluorescence analysis, cells were immobilized on a solid 
support that is optically suitable for microscopy. For this purpose, we prepared a 
cellular solution of 300.000 cells/ml.  
Then slides and filters were placed into appropriate slots in the cytospin with the 
cardboard filters facing the centre of the cytospin and we subsequently 
aliquoted 200 µl of cellular solution for each sample. Centrifugation was 
performed at 8000 rpm for 3 minutes.  
Slides were carefully removed from cytocentrifuge and cells were fixed with 4% 
formaldehyde and permeabilised with cold methanol/acetone solution. Cells 
were probed with primary antibodies for phospho-Histone H2A.X (ab11174, 
Abcam) and with Alexa Fluor488-labeled secondary antibodies (Thermo Fisher 
Scientific Inc.) for 1 hour at room temperature. Nuclei were stained with DAPI 
(Thermo Fisher Scientific Inc) and images were acquired by Nikon Eclipse E600 
microscope using ACT-1 software (Nikon). For each sample, only the cells with 
at least 10 γH2AX nuclear foci were counted at different time points from 
irradiation (0, 1, 4 and 8 hours). 
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3.3.3 Immunohistochemistry 
 
To assess distribution and localisation of specific cellular components (γ-H2AX 
and ZEB1) within cells and within their proper histological context, 
immunohistochemical analysis was performed. Briefly, tumours were removed, 
formalin-fixed and paraffin-embedded. Tumour sections of 4-µm were 
deparaffinized in xylene, rehydrated through graded alcohols to water, and 
subjected to immunohistochemical analysis using the following antibodies: anti-
ZEB1, rabbit polyclonal antibody (H102, Santa Cruz) at the dilution of 1:100 and 
the anti-phospho-H2AX (Ser139), mouse monoclonal antibody (clone JBW301, 
Millipore) at the dilution of 1:1200, respectively. Nuclei were counterstained with 
hematoxylin. 
 
3.3.4 Comet assay  
 
To assess DNA-damage at the level of a single cell, the alkaline Comet assay 
was performed. Comet assay is a microgel electrophoresis technique where a 
small number of cells suspended in a thin agarose gel on a microscope slide 
are lysed, electrophoresed, and stained with a fluorescent DNA-binding dye. 
Indeed, comet assay allowed the detection of DNA breaks induced by radiation, 
based on the different migration of damaged DNA compared to intact one when 
submitted to electrophoresis migration. For instance, cells with increased DNA 
damage display an increased DNA migration from the nucleus toward the 
anode, resembling the shape of a comet (Fig. 3.4). Specifically, 4 h upon 
irradiation at 4 Gy, transfected DU145 cells were resuspended in low-melting 
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agarose, layered on microscope slides and treated with a hypertonic lysis 
solution to disrupt and remove cell membranes, cytoplasm, and nucleoplasm 
and dissolve nulceosomes releasing their DNA content. Subsequently, the 
leftover nucleoid was treated with high alkaline solution, and let to migrate by 
electrophoresis for 10 minutes at 1 V/cm. Migration under alkaline conditions 
led to DNA unwinding and consequent exposure of alkali sites of DNA breaks. 
Such breaks migrated towards the anode when exposed to current during 
electrophoresis thereby producing the aforementioned ‘comet’-like appearance. 
The extent of such a comet is proportional to the extent of DNA damage. To 
visualise comets, DNA was stained with SYBR Green and comets were imaged 
using a fluorescence microscope equipped with a video camera (Jai Pulnix, 
Sunnyvale, CA), and quantitative assessment of DNA damage was obtained 
using the Comet Assay IV software (Perceptive Instruments, Suffolk, UK). To 
estimate the extent of DNA damage, length and intensity of the comet tail were 
measured and the tail moment was calculated as the product of tail length and 
tail intensity. Tail moment was determined by counting at least 200 comets. 
 
 
Figure 3.4 Schematic representation of Comet assay  
 
Cells are mixed with 
agarose at 37°C 
Cells-agarose dots are 
immobilized on 
CometSlidesTM 
Lysis treatment 
removes membranes 
and histones from DNA 
Cells treated with alkli 
unqind and denature 
DNA 
DNA stained with 
SYBRGreen revealing 
DNA damage 
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3.3.5 Luciferase assay 
 
To validate EGFR as a direct target of miR-875-5p, a luciferase assay was 
performed. Luciferase assay allows the validation of a specific target as a direct 
target of a miRNA of interest, as it relies on miRNA capacity to directly and 
specifically bind to the complementary sequence of the target mRNA. In the 
assay, a reporter activity is used as indicator of miRNA capacity to regulate the 
reporter expression in vitro. For instance, cells were cotransfected with the 
miRNA and a plasmid containing Firefly or Renilla luciferase coding sequence 
upstream of an mRNA 3'UTR from the gene of interest. If the mRNA 3'UTR is a 
target of the miRNA, the luminescence of the reporter will be altered, as a 
reflection of the changes in the transcript’s stability and/or translation efficiency. 
Specifically, a 1285 nt-long portion of EGFR 3’ UTR containing the predicted 
miR-875-5p binding site was amplified by PCR from cDNA obtained from 
DU145 cells, by using the following primers:  
- forward 5’-AATTTCTAGACCACGGAGGATAGTATGAG-3’  
- reverse 5’-AATTTCTAGAGCTACTGTCATTCGCACCT-3’.  
PCR product was cloned into the XbaI site downstream of the FireFly luciferase 
gene carried in the pGL3-Basic. pGL3-Basic reporter plasmids (3.6 fmol) and  
pRL-Reporter (500 ng for normalization; Promega, Madison, Wisconsin, USA) 
were transfected with Lipofectamine 2000 (Thermo Fisher Scientific Inc) into 
DU145 cells (Fig. 3.5). Cells were collected after 24 h, lysed using Passive 
Lysis Buffer and the DLR Assay was performed according to the manufacturer's 
protocol (Promega E1910). For normalization, the ratio of Luciferase activity to 
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Renilla activity was measured. All experiments were performed in triplicate with 
data pooled from at least two independent experiments. 
 
Figure 3.5 Schematic representation of Luciferase assay 
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3.4 Bioinformatics analyses  
 
To assess miRNA expression in PCa tissues compared to normal matched 
tissues, normalised miRNA expression data of tumour and non-neoplastic 
prostate samples from prostate cancer patients were retrieved from GEO 
repository with accession number GSE76260. Data were filtered keeping only 
probes with a detection p-value < 0.01 in at least one sample and probes not 
associated to known mature miRNA transcripts were removed. Differentially 
expressed miRNAs between tumour and normal samples were identified using 
a moderated paired t-test as implemented in the limma package, considering 
only the 26 patients for which matched tumour and normal samples were 
available. miRNAs showing an FDR < 0.05 were considered significantly 
differentially expressed. The Pearson’s correlation coefficient between miRNA 
and E-cadherin mRNA expression (as measured by qRT-PCR) was calculated 
for a subset of 44 samples (19 tumour and 25 normal), for which leftover RNA 
was available in the laboratory. miRNAs with a nominal p-value < 0.05 
associated to the Pearson’s correlation coefficient were selected.  
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To identify miRNAs modulated by radiation, as putative miRNAs related to 
radiation response, a miRNA expression profiling was performed. For photon 
irradiation experiment, all the 4 PCa cell lines were exposed to 10 Gy of 
irradiation and RNA was collected at various time points from treatment (4, 8 
and 24 h). As for carbon ion irradiation, DU145 and LNCaP cells were exposed 
to 5 Gy of irradiation at CNAO and RNA was collected at 4, 8 and 24 h. Since 
intact RNA is a key element for successful microarray analysis, RNA integrity  
was assessed by the Agilent 2100 Bioanalyzer System, which generated RNA 
profiles allowing a visual inspection of RNA integrity, and generating ribosomal 
ratios. Briefly, using electrophoretic separation on microchips, RNA samples are 
separated and detected by fluorescence. The Bioanalyzer software generates a 
gel-like image and displays results including RNA concentration and the 
ribosomal ratio. Indeed, ribosomal ratio is an indicator of RNA degradation, 
since, as degradation proceeds, there is a decrease in the 18S to 28S 
ribosomal band ratio. However, although ribosomal ratios play an important role 
in determining the level of sample degradation in gel electrophoresis, a more 
standardized parameter called RNA Integrity Number (RIN) is used. The RIN 
system, by taking the entire electrophoretic trace into account, attributes an 
integrity score, ranging from 1 to 10, with 1 being the most degraded profile and 
10 being the most intact.  According to their RIN value, intact RNA samples 
were considered for microarray analysis, which was performed using Agilent 
Human miRNA Microarray System Release 19.0. Agilent’s miRNA microarray is 
a highthroughput system based on direct labelling method, where 40–60-mer 
oligonucleotide probes are directly synthetized on the microarray surface (Fig. 
3.6).  
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Figure 3.6 Agilent miRNA-microarray probe design 
 
Raw intensity values obtained from the Agilent Feature Extraction (AFE) 
software, were processed using Robust Multi-array Average (RMA) algorithm 
for background correction. Data were then log2 transformed and quantile 
normalized. Based on detection information from the AFE software, only miRNA 
probes detected in at least 1 sample were considered for further processing. 
The remaining probe sets were mean summarised as a single miRNA 
expression value. Significant changes in miRNA profiles across time course 
were evaluated for each treatment (i.e., photons or carbon ions). To this end, 
we employed the linear model functions implemented within the limma package 
to compute log2 fold-changes and moderated t-statistics on pair-wise 
comparisons between time points. On continuation, we applied a Benjamini & 
Hochberg adjustment for multiple testing on each comparison. miRNAs with 
introduced	in	labeling.	This	
addi3onal	G-C	pair	in	the	probe-
target	interac3on	region	stabilizes	
targeted	miRNAs	rela3ve	to	
homologous	RNAs.	Addi3onally,	
all	probes	contain	a	5'	hairpin	
(blue),	abuDng	the	probe-target	
region,	to	increase	target	and	size	
miRNA	speciﬁcity.		
	
Probes are anchored to the glass slide 
surface by a stilt (brown). Inclusion of a G 
residue (black) to the 5' end of the 
hybridization sequence complements the 
3' end C residue (yellow) introduced in 
labeling. This additional G-C pair in the 
probe-target interaction region stabilizes 
targeted miRNAs relative to homologous 
RNAs. Additionally, all probes contain a 5' 
hairpi  (blue), abutting the probe-target 
region, to increase target and size 
miRNA specificity.  
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log2 fold-changes >1.5 and adjusted p-value < 0.2 were considered as 
differentially expressed (DE). 
To determine to which pathway the selected modulated miRNAs belong, 
functional over-overrepresentation of Gene Ontology (GO) Biological Process 
terms were generated for each set of predicted gene targets. Statistical 
significance of terms enrichment was determined by a hypergeometric test with 
Benjamini & Hochberg adjustment for multiple testing. For that purpose, we 
used the functions implemented within the clusterProfiler package in R. 
Enrichments with adjusted p-value <0.05 were considered significant. 
Construction of Circos plots was performed using the GOplot library. 
 
To identify miR-875-5p and miR-205 relevant targets, the presence of putative 
miRNA binding sites in a given mRNA was predicted using MiRWalk 
(http://www.ma.uni-heidelberg.de/apps/zmf/mirwalk), which performs a 
comparison of the information produced by ten established miRNA target 
prediction programs. Only targets simultaneously predicted by at least three 
programs were considered as reliable. To sharpen the identification of miR-875-
5p relevant targets, the list of predicted targets was then intersected with the list 
of genes found to be downregulated by a gene expression analysis performed 
on DU145 cells transfected with miR-875-5p and compared to Neg-transfected 
cells. 
For gene expression profiling, RNA samples were processed for microarray 
hybridisation by the Functional Genomics core facility at Fondazione IRCCS 
Istituto Nazionale dei Tumori, Milan, Italy. Briefly, 800 ng of total RNA was 
reverse transcribed, labeled with biotin and amplified overnight (14 h) using the 
Illumina RNA TotalPrep Amplification kit (Thermo Fisher Scientific Inc) 
 	
	
MATERIALS AND METHODS 
	
	 	
110	
according to manufacturer’s protocol. One µg of the biotinylated cRNA sample 
was mixed with the Hyb E1 hybridization buffer containing 37.5% (w/w) 
formamide and then hybridized to Illumina HumanHT-12-v4 expression Bead 
Chip (Illumina, Inc., San Diego, CA, USA) at 58°C overnight (18 h). Arrays were 
washed with manufacturer’s E1BC solution, stained with 1 µg/ml Cy3-
streptavidine (Amersham Biosciences; GE Healthcare, Piscataway, NJ, USA) 
and eventually scanned with Illumina BeadArray Reader. 
Raw expression data were collected from scanned images using Illumina 
BeadStudio v3.3.8 (Illumina) and processed using the lumi package from 
Bioconductor v3.0. Raw data were log2-transformed, normalized with Robust 
Spline Normalization and filtered, keeping only probes with a detection p-value 
< 0.01 in at least one sample. Multiple probes mapping to the same gene were 
collapsed selecting the probe with the highest detection rate, i.e., the 
percentage of samples in which the probe had a detection p-value < 0.01. In 
case of equal detection rates, the most variant probe according to interquartile 
range was selected. Gene expression data were deposited in the Gene 
Expression Omnibus repository (GEO) with accession number GSE68883. 
Differentially expressed genes were identified using the limma package. 
Multiple-testing correction was performed using the Benjamini-Hochberg false 
discovery rate (FDR) method. Genes with FDR < 0.05 and absolute fold-change 
(FC) ≥ 1.5 were considered significantly differentially expressed.  
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3.5 Statistical analyses 
 
If not otherwise specified, data are presented as mean values ± SD from at 
least three independent experiments. Statistical analysis was performed by 
one-tailed Student's t test. Student’s t test was chosen for statistical analysis 
since it is a statistical analysis technique used to test whether there is a 
significant difference between two independent sample means. Specifically, 
independent t-test was used, as in all cases the two groups under comparison 
were independent of each other. The test was applied to the compared groups 
by using the excel T.TEST function: T.TEST(array1,array2,tails,type), where 
Array 1 and 2 indicate the two data sets to be compared, tails specifies the 
number of distribution tails, referring to 1 tail if a specific direction (up or down) 
of the difference between the groups is expected. Specifically, all experiments 
in the study required a 1-tail test, as the effect of transfection/treatment was 
case-by-case expected to be more effective than the respective negative 
control, thus foreseeing the direction of the difference between the 
transfected/treated and the control group. Finally, type refers to the kind of 
T.TEST, with 2 being the independent T.TEST with equal variance between 
samples. Running the T.TEST function, a p-value was returned, a value that is 
defined as the probability, under the null hypothesis, of obtaining a result equal 
to or more extreme than what was actually observed, and that basically 
indicates the statistical significance of the difference observed between the 
compared groups. P-values <0.05 were considered statistically significant. 
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4. RESULTS I: miRNAs modulated in PCa cells upon radiation 
 
With the aim of sorting miRNAs functionally involved in mediating PCa response 
to radiation, the very first step of this study was the definition of the possible 
strategies to follow in order to select miRNAs related to radiation response. In 
order to consider all the miRNAs potentially matching our query, we adopted 
two complementary approaches of miRNA identification. The first approach is 
based on the identification of miRNAs modulated upon radiation exposure, 
since they could represent a class of miRNAs that are responsive to radiation 
therefore displaying an involvement in radiation response processes.  It is worth 
noting that miRNA modulation upon radiation does not indicate per se a 
functional role in radiation response, as miRNAs could be modulated upon 
radiation stimulus yet not having a functional role in influencing the response to 
the treatment.  To investigate whether specific identified miRNAs actually play a 
functional role in determining cell responsiveness to radiation, their expression 
was artificially modulated in PCa cells by transfection with specific miRNA 
modulators (i.e.: miRNA mimics) and transfected cells were exposed to 
radiation in order to check whether miRNA modulation induced changes in cell 
sensitivity profiles.  
To compare the effect induced by photon radiotherapy and hadrontherapy on 
miRNA profiling, PCa cell lines exposed to photon were also exposed to carbon 
ions and miRNA modulation was assessed.  
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4.1 miRNAs modulated upon photon irradiation 
Following the first approach fort the identification of radiation response-related 
miRNAs, we evaluated the expression changes in the miRNome of PCa cells 
upon exposure to photon irradiation. Specifically, the 4 PCa cell lines available 
for the study (DU145, PC-3, 22Rv1 and LNCaP) were exposed to 10 Gy 
radiation delivered by the 137Cs irradiator. For miRNA profiling, the total RNA, 
including miRNAs, from irradiated cells was isolated at different time points (4, 8 
and 24 hours) from irradiation in order to obtain a kinetics of miRNA modulation. 
 
4.1.1 RNA isolation 
 
The use of an RNA extraction method in which small RNA species, including 
miRNAs, were conserved, was instrumental to start the miRNA expression 
analysis in PCa cells. For this purpose, RNA collected at 4, 8 and 24h from 
exposure to radiation was isolated using the miRNA isolation kit. Since the 
integrity of isolated RNA is a key element for successful microarray analysis, 
RNA integrity was verified by the Agilent 2100 Bioanalyzer System, which 
generated RNA profiles allowing a visual inspection of RNA integrity (Fig. 4.1). 
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Figure 4.1 Integrity profiles of RNA isolated from PCa cell lines irradiated with 
photons. (A) Electrophoretic trace of the 48 samples of RNA isolated from DU145, PC-
3, 22RV1 and LNCaP exposed to photon irradiation. The gel-like image reports the 
18S to 28S ribosomal bands, which are indicative of RNA degradation presence, as in 
degraded RNA an increase in the baseline signal between the two ribosomal peaks 
and the lower marker is observable. Intact RNA shows a greater distance between 
ribosomal peaks and the lower marker. Samples were randomized into 4 groups of 12 
samples/each. Each group was run on a different microarray chip taking into account 
intra-cell line variability. (B) RIN scores of RNA samples, ranging from 1 to 10, with 1 
being the most degraded profile and 10 being the most intact.  According to their RIN 
value, intact RNA samples were considered for microarray analysis, whereas non-
intact RNA samples were replaced with new-isolated intact ones.  
		
  
 	
	
RESULTS I 
	
	 	
121	
4.1.2 Microarray profiling  
 
Quality-checked RNA was used for microarray analysis using Agilent platform 
and data were normalized and filtered as described in Materials and Methods 
section, thus generating a lists of miRNAs significantly up- and down-regulated, 
compared to non-irradiated cells, for each time point within each cell lines. In 
order to identify miRNA candidates responsive to irradiation, a differential 
expression analysis between different time points within each cell line was 
performed. Of importance, we detected two main miRNA subsets based on the 
temporal shift of expression changes along the whole-time series (i.e., at 4, 8 
and 24 hours). For convention, we defined these subsets as “up-modulated”, 
characterized by bottom-up shift at 4 and 24 h, and “down-modulated”, 
characterized by a top-down shift at 4 and 24 h. To refine our analysis, we 
investigated which differentially expressed (DE) miRNAs in our initial lists are 
members of conserved miRNAs families (i.e., characterized by sharing a 
common conserved seed region). 
4.1.2.1	Identification	of	miRNAs	differentially	expressed	in	each	PCa	cell	line	
  
DU145 
With regards to the profile of temporally modulated miRNAs by photons in 
DU145, we found 66 miRNAs differentially expressed. From this list, 21 miRNAs 
were discovered to be up-modulated; while the remaining 45 miRNAs were 
down-modulated. The mapping against the data base of members of conserved 
miRNAs families (TargetScan) revealed 12 up-modulated and 19 down-
modulated conserved miRNAs (Fig 4.2).  
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Figure 4.2 miRNAs in conserved miRNA families temporally modulated by 
photons in DU145 cells. (Left) Heatmap showing the expression levels of significantly 
modulated conserved miRNAs in DU145 along time, clustered according to their 
dynamic changes at 4, 8 or 24 h after photons irradiation as up-modulated (C1) or 
down-modulated group (C2). (Right) Line plots representing the average miRNA 
expression in the indicated group at each time point. 
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PC-3  
 
The analysis for PC-3 cell line revealed only 16 miRNAs temporally affected by 
photon irradiation. As before, we clustered together these miRNAs based on 
their temporal shift across time and detected two main subsets. One of these 
subsets is composed of 10 Up-regulated miRNAs and is distinguished by a 
continuous increase in their expression at 4, 8 and 24 h. The second one is 
composed of 6 down-modulated miRNAs displaying a downward shift at 4 h, 
which gradually increases at 8 and 24 h (Fig 4.3). After the filtering process for 
conserved miRNAs, we obtained a final list of 6 up-modulated and 6 down-
modulated miRNAs. 
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Figure 4.3 miRNAs in conserved miRNA families temporally modulated by 
photons in PC-3 cells. (Left) Heatmap showing the expression levels of significantly 
modulated conserved miRNAs in PC-3 cell line along time, clustered according to their 
dynamic changes at 4, 8 or 24 h after photons irradiation as up-modulated (C1) or 
down-modulated group (C2). (Right) Line plots representing the average miRNA 
expression in the indicated group at each time point. 
 
 
  
 	
	
RESULTS I 
	
	 	
125	
22Rv1 
 
Regarding the results for the 22RV1 cell line, we detected 67 miRNAs 
temporally regulated by photons. At defining the two main subsets of miRNAs 
based on the structure of their time-course expression, 35 up-modulate miRNAs 
showed a gradual increase at 4 ,8 and 24 h; while 32 down-modulated miRNAs 
showed a behaviour characterized by a top-down shift at 4 and 24 h. Following 
the filtering strategy to detect members of conserved miRNAs families, we 
detected 14 up-regulated and 7 down-modulated conserved miRNAs (Fig 4.4). 
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Figure 4.4 miRNAs in conserved miRNA families temporally modulated by 
photons in 22Rv1 cells. (Left) Heatmap showing the expression levels of significantly 
modulated conserved miRNAs in 22Rv1 cell line along time, clustered according to 
their dynamic changes at 4, 8 or 24 h after photons irradiation as up-modulated (C1) or 
down-modulated group (C2). (Right) Line plots representing the average miRNA 
expression in the indicated group at each time point. 
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LNCaP 
Trough differential expression analysis between different time points in LNCaP, 
we were able to identify 109 miRNAs that were differentially expressed after cell 
irradiation. The “up-modulated” set was composed of 47 miRNAs, whereas the 
“down-modulated” was composed of 62 miRNAs. Among those, we identified 
29 and 30 conserved miRNAs within the up-modulated and down-modulated 
subsets, respectively (Fig 4.5). 
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Figure 4.5 miRNAs in conserved miRNA families temporally modulated by 
photons in LNCaP cells. (Left) Heatmap showing the expression levels of significantly 
modulated conserved miRNAs in LNCaP cell line along time, clustered according to 
their dynamic changes at 4, 8 or 24 h after photons irradiation as up-modulated (C1) or 
down-modulated group (C2). (Right) Line plots representing the average miRNA 
expression in the indicated group at each time point. 
	
	
4.1.2.2	Identification	of	miRNAs	consistently	modulated	across	PCa	cell	lines	
 
In order to identify miRNAs modulated by radiation, we narrow our analysis on 
those miRNAs found to be consistently (up or down) modulated across cell 
lines, with the aim of obtaining a reliable list of potentially relevant miRNAs. 
Since we were looking for consistently modulated miRNAs, we compared all the 
miRNAs of the up-modulated sets or those of the down-modulated ones, 
separately.  
With regards to the up-modulated miRNAs, no miRNAs were found to be 
regulated in all four cell lines. However, a great proportion of up-modulate 
miRNAs was found at the intersection between LNCaP and DU145 (9 miRNAs), 
making up 60% of all overlaps (Table 1). The comparison between down-
modulated miRNAs among the different cell lines examined, revealed that 15 
miRNAs follow a similar expression profile in LNCaP and DU145 (Table 4.1 and 
Fig. 4.6), which makes up 74% of all the overlapping subsets representing 
common regulated miRNAs among two or more cell lines.  
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Up_modulated Down_modulated 
hsa-let-7a-5p hsa-let-7i-5p 
hsa-let-7b-5p hsa-miR-10a-5p 
hsa-let-7e-5p hsa-miR-130a-3p 
hsa-miR-125b-5p hsa-miR-181a-5p 
hsa-miR-193b-3p hsa-miR-182-5p 
hsa-miR-200c-3p hsa-miR-21-5p 
hsa-miR-7-5p hsa-miR-22-3p 
hsa-miR-99a-5p hsa-miR-221-3p 
hsa-miR-99b-5p hsa-miR-222-3p 
  hsa-miR-23a-3p 
  hsa-miR-24-3p 
  hsa-miR-31-5p 
  hsa-miR-424-5p 
  hsa-miR-4465 
  hsa-miR-6088 
 
 
Table 4.1. List of conserved miRNAs temporally modulated in LNCaP and DU145 
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Figure 4.6 Venn diagram showing the intersection of conserved miRNAs down-
modulated by photons in PCa cell lines 
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4.1.2.3	Identification	of	relevant	modulated	miRNAs		
 
Based on these findings, we focused on miRNAs down-regulated by both 
DU145 and LNCaP in at least 2 time points. Specifically, considering the 
premise that miRNA modulation upon radiation does not per se imply a 
functional role of such miRNAs in radiation response, we sought to focus on 
those miRNAs that are known, from literature, to be involved in pathways 
related to radiation response. For this purpose, for each of the miRNAs 
belonging to the aforementioned intersection, we looked for their validated 
targets in order to identify which miRNAs regulate genes involved in processes 
relevant to radiation response. As a result, among miRNAs found to be 
downregulated in both DU145 and LNCaP cells, at 4 and 24h, we focused on 
miR-23a-3p and miR-24-3p, based on the evidence that they i) belong to the 
same miRNA cluster, and therefore are likely to be involved in the regulation of 
same cell processes, and ii) were reported to target genes linked to radiation 
response. In particular, according to literature data, we found that miR-23a-3p 
directly targets pathways known to be associated with PCa radioresistance, and 
that miR-24-3p, in turn, is indirectly regulated by miR-23a-3p [155]. Considering 
these data, we were prompted to study the role of miR-23a-3p and miR-24-3p 
in the radiation response of PCa cells.   
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4.1.3 Validation of microarray data  
 
Before investigating the potential influence of miR-23a-3p and miR-24-3p on the 
radiosensitivity profile of PCa cells, we first validated the data obtained from 
microarray analysis to assess the reliability of our starting point. For this 
purpose, the expression of miR-23a-3p and miR-24-3p was evaluated by qRT-
PCR. Overall, we observed a good correlation between the modulation on the 
array and the expression trend obtained by qRT-PCR, although to a different 
extent, thus confirming the reliability of microarray results and consequently 
demonstrating that our miRNA profiles were actually informative.  For instance, 
we carried out both a technical and a biological validation, performing the qRT-
PCR analysis on the same samples used for microarray and samples deriving 
from a different experiment, respectively (Fig. 4.7). In both cases we found that 
miR-23a-3p and miR-24-3p were downregulated in DU145 and LNCaP cells at 
4 and 24 h upon irradiation, even if to a different extent compared to the 
modulation observed by microarray. Consistent with microarray results, the 
expression levels of both miRNAs were not decreased at 8h, recapitulating a 
trend of expression kinetics that has been previously observed in association 
with radiation, likely suggesting a failed attempt of the cell to contrast radiation-
induced miRNA modulation.   
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Figure 4.7 Validation of expression data obtained by microarray. The expression 
levels of miR-23a-3p and miR-24-3p upon irradiation of DU145 and LNCaP cells were 
evaluated by qrt-PCR. For technical validation (left panel) the RNA samples used for 
microarray analysis were tested to assess the reproducibility of the obtained data 
across different techniques. For biological validation (right panel) a new experiment 
was performed by exposing DU145 and LNCaP cells to 10 Gy of irradiation and 
collecting RNA in an independent setting. RNA collected at the same time points to 
microarray experiment (4, 8 and 24 h) was isolated and used for qrt-PCR analysis. 
Data are reported as RQ values with respect to Neg. 
 
 
4.2 miR-23a-3p and miR-24-3p sensitize PCa cells to radiation 
 
4.2.1 miR-23a-3p and miR-24-3p radiosensitize PCa cells 
Considering the premises on the potential relevance of miR-23a-3p and miR-
24-3p in determining the radiation response of PCa cells, we hypothesized that 
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 a.       Technical validation 
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the observed downregulation of such miRNAs upon radiation is functional for 
the cell to overcome radiation-induced injury, and that their reconstitution could 
in turn affect cell response to radiation.  
To test the hypothesis that miR-23a-3p and miR-24-3p play a functional role in 
affecting cell response to radiation, the levels of miR-23a-3p and miR-24-3p 
were reconstituted in DU145 cells in order to evaluate their ability in enhancing 
cell radiation response. Specifically, DU145 cells were transfected with the 
mimic of miR-23a-3p or miR-24-3p and transfected cells were exposed to 
increasing doses of radiation (2 to 8 Gy) in order to test cell clonogenicity. 
Interestingly, both miRNAs showed a significant enhancement in DU145 cell 
sensitivity to radiation, as indicated by the reduced surviving fraction (Fig. 4.8).  
Figure 4.8 miR-23a-3p and miR-24-3p enhanced DU145 radiosensitivity. 
Clonogenic assay of DU145 cell transfected with miR-23a-3p (left) and miR-24-3p 
(right) mimic and respective negative controls. The surviving fractions following the 
indicated doses of irradiation are reported as mean ±SD, n=3. 
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An ideal radiosensitizer should exert an effect only when combined with the 
treatment towards which the sensitization is intended, without affecting per se 
cell viability. To assess whether the two miRNAs alone have an effect on cell 
clonogenicity, we evaluated cell plating in non-irradiated cells. As a result, miR-
23a-3p did not show any effect on plating efficiency, thus allowing to conclude 
that the observed radiosensitizing effect is solely imputable to its role in 
enhancing radiation response, rather than inhibiting cell clonogenicity via other 
mechanisms (Fig. 4.9, top). In contrast, miR-24-3p was able to impact on cell 
clonogenicity even in absence of radiation exposure, as indicated by the 
significantly reduced plating efficiency (Fig. 4.9, bottom). This result suggests 
that the enhanced response to radiation observed upon miR-24-3p 
reconstitution, is not merely imputable to a radiosensitizing effect of miR-24-3p. 
It rather means that, at lest in part, the enhancement is due to an additive effect 
of transfection and treatment. For this reason, and for the central role of miR-
23a-3p in the hypothesised axis, we focused our attention on miR-23a-3p as a 
putative promising radiosensitizer in PCa.   
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Figure 4.9 miR-23a-3p and miR-24-3p effects on DU145 cell plating efficiency. 
Plating efficiency of non-irradiated DU145 cells transfected with miR-23a (top) and 
miR-24-3p (bottom) was calculated as the ratio of the number of colonies counted to 
the number of cells seeded.  
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4.2.2 miR-23a-3p targets IL-6 pathway  
 
The choice of investigating the role of miR-23a-3p in PCa radiation response 
was based on literature data reporting a role of the miRNA in targeting 
pathways known to be associated with radioresistance. Specifically, we found 
that miR-23a-3p negatively regulates the IL-6 pathway, known to be associated 
with radioresistance in PCa [156], by downregulating IL-6 receptor (IL-6R) in 
PCa cells [157], and directly targeting IL-6R in other tumour types [158]. As for 
miR-24-3p, it was reported to be upregulated as a consequence of IL-6 
downregulation [155], thus prompting us to expect a positive correlation with the 
expression of miR-23-3p. To test our hypothesis, we assessed whether the 
hypothesized loop was verified in our models. As a first step, to confirm miR-
23a-3p role in affecting IL-6 pathway, we reconstituted the miRNA in DU145 
and PC-3 cells and assessed the expression levels of some of the main players 
belonging to IL-6 pathway (i.e.: IL-6, IL-6R, AKT and STAT1). In agreement with 
literature data, miR-23a-3p downregulated the expression levels of all the 
tested genes, even if to a different extent, in both DU145 and PC-3 cells (Fig. 
4.10). Interestingly, the most downregulated were IL-6 and IL-6R, thus 
confirming miR-23a-3p reported role in regulating those two molecules.   
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Figure 4.10 Expression levels of IL-6 pathway related genes upon miR-23a-3p 
reconstitution. miR-23a-3p downregulated the expression levels of IL-6, IL-6R, AKT 
and STAT1 as assessed by qRT-PCR. Data are reported as RQ values with respect to 
Neg.  
  
IL-6R was validated as a direct target of miR-23a-3p [157]. In contrast, IL-6 is 
reported to be downregulated by the miRNA, yet not being a direct target. To 
investigate whether IL-6 was a predicted target of miR-23a-3p, we carried out in 
silico prediction tools as described in Materials and Methods section. 
Interestingly, IL-6 emerged as a potential target of miR-23a-3p, which is in line 
with our downregulation results, thus supporting the potential relevance of this 
miRNA in regulating IL-6 pathway.    
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4.2.3 miR-23a-3p induced radiosensitization relies on IL-6 targeting  
 
Considering the already known and demonstrated role of IL-6 in determining 
radioresistance in PCa cells, and that, in our hands, miR-23a-3p was able to 
both radiosensitize PCa cells and to downregulate IL-6, we hypothesised that 
the radiosensitizing effect of the miRNA could rely, at least in part, on the 
induced downregulation of IL-6, thus disrupting its associated radioresistance 
and finally resulting in radiosensitization. To verify this hypothesis, we sought to 
counteract IL-6 downregulation induced by the miRNA by ectopically 
supplementing cells with recombinant IL-6, with the final aim of restoring IL-6 
levels and evaluating whether the restoration was able to abrogate miR-23a-3p 
induced radiosensitization, which would indicate a central role of IL-6 
downregulation in mediating such effect. For this purpose, 50 ng/ml IL-6 were 
added to DU145 cells transfected with miR-23a-3p. The concentration of 
recombinant IL-6 was established based on previous experiments of a different 
study run in the lab. DU145 cells with or without miR-23a-3p and/or IL-6 were 
exposed to increasing doses of radiation for clonogenic assay. Interestingly, the 
restoration of IL-6 levels was able to almost completely abrogate the 
radiosensitizing effect induced by miR-23a-3p, indicating that IL-6 
downregulation is indeed crucial in mediating miR-23a-3p effect, thus 
confirming our hypothesis and providing insights on the mechanism underlying 
miR-23a-3p ability to enhance PCa cell sensitivity to radiation (Fig. 4.11).  
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Figure 4.11 IL-6 supplementation abrogated miR-23a-3p induced radiosensitivity. 
Clonogenic assay of DU145 cells transfected with miR-23a-3p, with or without IL-6 
supplementation and respective controls. The surviving fractions following the indicated 
doses of irradiation are reported as mean ±SD, n=3. 
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4.3 miRNA expression profiling upon carbon ions irradiation 
 
Carbon ions are heavy charged particles that have the physical advantage of 
giving improved depth-dose distributions for deep-seated tumours. Much of 
their energy is deposited in tissue at the end of particle tracks (i.e., in the region 
of the Bragg peak). This characteristic allows the delivery of a high radiation 
dose to the target, yet significantly spearing surrounding normal tissues, which 
is the major challenge in radiotherapy. 
Considering how promising are carbon ion beams in radiotherapy, and that 
almost nothing is known about their impact in modulating tumour miRNome, in 
this study we sought to investigate the miRNA expression profiling of PCa cells 
exposed to carbon ion irradiation. For this purpose, based on the results 
obtained by photon irradiation, DU145 and LNCaP cell lines were selected for 
carbon ions studies. In order to compare miRNA modulation following carbon 
ion irradiation to that induced by photons, the same treatment settings were 
maintained  (relative dose and time points). Of importance, to have comparable 
doses, we considered the definition of RBE, based on the knowledge that 
different radiation sources need different doses to produce the same biological 
effect. Taking this aspect into account, we irradiated DU145 and LNCaP cells at 
5 Gy of carbon ions at CNAO (Pavia). For miRNA expression analysis, RNA 
was collected at the same time point of photon experiments (i.e.: 4, 8 and 24 h). 
As for photon irradiation analysis, we identified miRNAs differentially expressed 
upon radiation across time within each of the two cell lines.  
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4.3.1 Definition of carbon ions RBE by clonogenic assay 
 
As previously pointed out, because of their specific physical carachteristics, 
carbon ions produce the same effect of photons at lower doses, thus requiring 
the implementation of RBE definition. Specifically, to determine the RBE 
between carbon ions and photons, a specific biological endpoint should be 
selected in order to find out at which doses the two radiation sources are able to 
cause the same effect. As radiation cell toxicity in vitro is conventionally 
evaluated in terms of cell clonogenicity impairment, by clonogenic assay, we 
sought to compare the reduction of clonogenic survival induced by photons and 
carbon ions in order to compute the RBE of carbon ions with respect to 
photons. As shown in Fig. 4.12, lower doses (≈ ½ of photon dose) of carbon ion 
radiation was able to induce a similar impairment of cell clonogenicity to that 
caused by photons, resulting in an RBE value of ≈ 2.8, which is very close to 
that known in literature (RBE=3). This data confirmed in our hands what was 
expected from literature, namely that, at comparable absolute doses, carbon 
ions display a greater biological effect than photons.  
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Figure 4.12 Clonogenic curves of DU145 exposed to increasing doses of carbon 
ions. (Left) Clonogenic curves of DU145 exposed to increasing doses (2, 4, 6 and 8 
Gy) photon irradiation. (Centre) Clonogenic curves of DU145 exposed to increasing 
doses of carbon ions (0,5, 1, 2 and 4 Gy) (Right) Comparison between clonogenic 
curves of DU145 exposed to photons and carbon ions, and calculation of RBE of 
carbon ions to photons.  
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4.3.2 RNA isolation 
 
As for RNA isolation from PCa cells exposed to photon irradiation, RNA 
collected at 4, 8 and 24h from exposure to radiation was isolated using the 
miRNA isolation kit and its integrity was verified by the Agilent 2100 Bioanalyzer 
System, which generated RNA profiles allowing a visual inspection of RNA 
integrity (Fig. 4.13). 
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Figure 4.13 Integrity profiles of RNA isolated from PCa cell lines irradiated with 
carbon ions. (A) Electrophoretic trace of the 48 samples of RNA isolated from DU145 
and LNCaP exposed to carbon ion irradiation. The gel-like image reports the 18S to 
28S ribosomal bands, which are indicative of RNA degradation presence, as in 
degraded RNA an increase in the baseline signal between the two ribosomal peaks 
and the lower marker is observable. Intact RNA shows a greater distance between 
ribosomal peaks and the lower marker. Samples were randomized into 2 groups of 12 
samples/each. Each group was run on a different microarray chip taking into account 
intra-cell line variability. (B) RIN scores of RNA samples, ranging from 1 to 10, with 1 
being the most degraded profile and 10 being the most intact.  According to their RIN 
value, intact RNA samples were considered for microarray analysis, whereas non-
intact RNA samples were replaced with new-isolated intact ones.  
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4.3.3 Identification of miRNA modulated upon exposure to Carbon Ions 
 
DU145 
 
With the purpose of following the temporal modulation of miRNAs by carbon 
ions, we performed a differential expression analysis to detect significant 
changes in miRNAs expression at 4, 8 and 24 h against 0 h, considered as the 
basal state. A total of 145 miRNAs showed significant changes at either time 
point. In order to identify miRNAs following a similar temporal pattern, we 
clustered miRNAs according to the temporal shift of expression changes along 
the whole-time series (i.e., at 4, 8 and 24 h). We discovered 73 up-modulated 
miRNAs, which show a bottom-up shift in expression at 4 h which slowly 
decreases at 8 and 24 h. The second subset we detected was composed of 72 
down-modulated miRNAs. This subset, by contrast, follows a downward shift at 
4 h, which continued to increase in a slowly manner until 24 h. The mapping 
against the database of members of conserved miRNAs families, revealed 46 
up-modulated and only 14 down-modulated conserved miRNAs (Fig. 4.14). 
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Figure 4.14 miRNAs in conserved miRNA families temporally modulated by 
carbon ions in DU145 cells. (Left) Heatmap showing the expression levels of 
significantly modulated conserved miRNAs in DU145 cell line along time, clustered 
according to their dynamic changes at 4, 8 or 24 h after carbon ions irradiation as up-
modulated (C1) or down-modulated group (C2). Line plots on the right side represents 
the average miRNA expression in the indicated group at each time point. 
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LNCaP 
 
In LNCaP cells, a total of 120 miRNAs showed significant changes at either 
time point. The subset of up-modulated miRNAs is composed of 40 up-
modulated miRNAs and is characterized by an initial upward shift at 4 h, which 
remains sustained until the end of the time course. The second subset is 
composed of 80 down-modulated miRNAs and is distinguished by a marked 
top-down shift at 4 h, which gradually decrease until the 24 h point. Among 
those miRNAs we identified 40 conserved miRNAs within the up-modulated 
subset and 4 making part of the down-modulated subset (Fig. 4.15). 
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Figure 4.15 miRNAs in conserved miRNA families temporally modulated by 
carbon ions in LNCaP cells. (Left) Heatmap showing the expression levels of 
significantly modulated conserved miRNAs in LNCaP cell line along time, clustered 
according to their dynamic changes at 4, 8 or 24 h after carbon ions irradiation as up-
modulated (C1) or down-modulated group (C2). Line plots on the right side represents 
the average miRNA expression in the indicated group at each time point. 
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4.3.4 Comparative analysis of miRNAs modulated by photons and carbon 
ions  
 
With the aim of comparing miRNA expression changes induced by different 
radiation sources –a study never pursued in the available literature– and 
identify commonalities and differences, the PCa cell lines that were exposed to 
both photons and carbon ions, at RBE-adjusted comparable doses, were 
considered for comparative analysis. Specifically, we considered the lists of 
miRNAs significantly modulated upon photons and those modulated by carbon 
ions in DU145 and LNCaP cells, and compared them to investigate whether 
specific miRNA were jointly modulated by both sources.  
To explore the commonalities, we compared the subsets of miRNAs 
consistently modulated by photons and carbon ions. As a result, we found that 
only 14 miRNAs were modulated by both radiation sources in the two 
considered PCa cell lines (Fig. 4.16). Noteworthy, miRNAs found in the 
intersection, still being modulated by both sources, are not consistently 
modulated. Almost all 14 miRNAs showed an opposite modulation direction (i.e. 
those up-modulated by photons were down-regulated by carbon ions and vice 
versa) (Fig. 4.17). Although it could seem unexpected that only few miRNAs are 
modulated by both sources, and that, moreover, those few miRNAs are 
inversely modulated by the two radiation modalities, indeed such partial overlap 
is likely reflecting the different relative biological effectiveness of photons and 
carbon ions. In keeping with this finding is that carbon ions display a greater 
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ionizing potential than photons, thus causing a more intense damage to the 
DNA helix and likely inducing different response mechanisms within the cell.  
 
 
Figure 4.16 miRNAs modulated by photons and carbon ions. Venn diagram 
showing the intersection of miRNAs differentially expressed after photon (10 Gy) and 
carbon ion (5 Gy) irradiation, in DU!45 and LNCaP cells. Log2FC>1.5 and FDR<0.2 for 
any time point. 
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Figure 4.17 Dynamic expression changes of miRNAs modulated by either 
photons or carbon ions in DU145 and LNCaP. Log2 Fold changes (y-axis) relative to 
0 h are plotted against time (x-axis). Photon treatment: dotted line; Carbon ions; 
continuous line. 
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4.3.5 Pathways modulated by both photons and carbon ions  
 
To assess whether different pathways were triggered by the two different 
sources, we investigated the biological functions of the selected miRNAs. To 
that end, we searched for putative target genes and performed an over-
representation analysis of GO biological processes. The top 10 enriched GO 
biological processes, which included negative regulation of amide metabolism, 
response to TGF-β and regulation of protein kinase activity (Fig. 4.18), revealed 
to be predominantly associated with 12 miRNAs, indicating a central role for this 
subgroup of radio-sensitive miRNAs in the regulation of such biological 
processes. Notably, among these is miR-24-3p, previously studied in the 
context of miRNAs modulated by photons. 
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Figure 4.18 Top 10 GO biological process over-represented in target genes of 12 
selected miRNAs. Over-representation analysis of GO biological processes in the set 
of miRNAs modulated by both photons and carbon ions. The Circos plot displays the 
relationship between the list of selected miRNAs and terms enriched within the set of 
target genes of the respective miRNA. Coloured ribbons link miRNAs with GO 
biological terms significantly enriched (adjusted p-value <0.1 from a hypergeometric 
test).  
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5. RESULTS II: the role of miR-875-5p in PCa radiation response  
 
With the same aim of identifying miRNAs functionally involved in determining 
cell radiation response, we pursued a second strategy based on considering 
those miRNAs that i) are downregulated in PCa and ii) target genes involved in 
pathways relevant to radiation response. The strategy is based on the 
knowledge that the evidence of being downregulated in PCa suggests a 
possible oncosuppressive function of the miRNA, which is compatible with a 
role in making tumour cell susceptible to a specific treatment. As for the second 
criterion, focusing on miRNAs targeting pathways relevant to radiation response 
support their putative role in influencing cell sensitivity to radiation. The 
intersection of these two criteria should improve the reliability of miRNA 
selection for the evaluation of their radiosensitizing effect.    
Following this strategy, we picked-up miR-875-5p. No information concerning its 
role in human tumours was available in the literature when we undertook this 
study. However, results from a miRNA expression profiling we carried out using 
the Agilent miRNA Microarray System in carcinoma and matched normal 
prostate samples obtained from 30 untreated PCa patients, showed reduced 
miR-875-5p expression in tumours with respect to normal counterparts (fold-
change 0.706; adjusted P = 0.035) (Table 5.1). The possible relevance of the 
miRNA in PCa radiation response is based on the observation, coming from 
results obtained in our laboratory in the context of a previous independent 
study, that miR-875-5p showed a high positive correlation with E-cadherin, one 
of the main markers of the epithelial to mesenchymal transition (EMT), in clinical 
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specimens (Table 5.1). The relevance of such a correlation in supporting miR-
875-5p interest as a possible radiosensitizer is given by the evidence that EMT 
is a phenotypic switch associated with radioresistance [159]. In support of this, 
is the story of miR-205, another miRNA highly correlated with E-Cadherin, that 
we previously demonstrated to exert a prominent role in repressing EMT in PCa 
cells [81] and that was successively found to act as a tumour radiosensitizer. 
The link between EMT and radiation response, further supported by the 
example of miR-205, prompted us to exploit such a correlation as a strategy to 
investigate miR-875-5p as a potential modulator of EMT and radiation 
response.  
 
 
Differential expression 
Tumor vs Normal 
Correlation with                   
E-cadherin expression 
miRNA logFC p-value Coefficient p-value 
hsa-miR-875-5p -0.66 0.013094 0.49 0.000736 
hsa-miR-518b -0.36 0.042304 0.45 0.002134 
hsa-miR-149 -0.33 0.041602 0.40 0.007156 
hsa-miR-1206 -0.14 0.026804 0.40 0.007405 
hsa-miR-507 -0.22 0.004878 0.37 0.013232 
hsa-miR-187 -1.36 0.006249 0.36 0.015330 
hsa-miR-659 -0.33 0.004097 0.35 0.020540 
hsa-miR-220a -0.14 0.035549 0.33 0.026902 
hsa-miR-548c-3p -0.16 0.014834 0.33 0.027333 
hsa-miR-30e* -0.25 0.004097 0.32 0.036824 
hsa-miR-222 -0.34 0.004410 0.31 0.037493 
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hsa-miR-296-5p -0.63 0.014938 0.31 0.038876 
hsa-miR-7-2* -0.31 0.021906 0.30 0.048642 
hsa-miR-1228 0.12 0.049020 -0.32 0.034506 
hsa-miR-612 0.73 0.005305 -0.33 0.029485 
hsa-miR-183* 0.59 0.007684 -0.34 0.022297 
hsa-miR-1244 0.57 0.005204 -0.36 0.015390 
hsa-miR-1245 0.34 0.030052 -0.40 0.007752 
 
Table 5.1. miRNAs showing differential expression in tumors compared to 
matched normal tissues and correlated with CDH1. miRNAs differentially expressed 
in tumors compared to matched non-neoplastic tissues and also found positively or 
negatively correlated (Spearman correlation) with E-cadherin in clinical specimens.  
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5.1 miR-875-5p expression in PCa cell lines  
To both check the suitability and reliability of our cell models for the following 
experiments and to further confirm miRNA downregulation in PCa, we tested 
miR-875-5p expression levels in PCa cell lines with respect to normal prostate 
tissues as a reference. As shown in Fig.5.1, miR-875-5p was found to be 
significantly downregulated in both PC-3 and DU145 cell lines, supporting the 
suitability of our cell models for pursuing the study of this miRNA.   
 
 
 
 
Figure 5.1 miR-875-5p is differentially expressed in normal and cancer tissues. 
miR-875-5p expression in PC-3 and DU145 tumor cell lines compared to normal 
prostate tissue. Expression was normalized to RNU48. 
  
 	
	
RESULTS II 
	
	 	
161	
5.2 miR-875-5p reconstitution impairs EMT 
5.2.1 miR-875-5p reconstitution resulted in marked morphological and 
cytoskeletal changes in DU145 cells 
 
As suggested by the high correlation between miR-875-5p and E-Cadherin, and 
knowing that such epithelial gene is one of the most reliable markers of the 
EMT switch, we were prompted to postulate a role of miR-875-5p in regulating 
EMT. In particular, given that E-Cadherin is associated with the epithelial 
phenotype, which is more represented when EMT is reverted, we hypothesized 
that miR-875-5p could negatively affect EMT, counteracting the transition from 
a more epithelial to a mesenchymal phenotype. To test our hypothesis, we 
reconstituted miRNA levels in DU145 cells, and observed the biological effect 
exerted on transfected cells.  
From a morphological point of view, we observed that miR-875-5p reconstituted 
cells display a more epithelial-like morphology, as suggested by the acquisition 
of polygonal, enlarged and packed-down appearance, and loss of filopodia and 
stress fibers, concomitant to a redistribution of F-actin to the subcortical level 
(Fig. 5.2).  
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Figure 5.2 miR-875-5p reconstitution resulted in marked morphological and 
cytoskeletal changes in DU145 cells. Phase contrast microscopy (upper panel, scale 
bar 100 µm), phalloidin F-actin staining (middle panel, scale bar 10 µm) and tubulin 
immunostaining (lower panel, scale bar 10 µm) showing morphological changes and 
cytoskeleton architecture rearrangements in DU145 cells upon miR-875-5p 
reconstitution.  
 
 
5.2.2 miR-875-5p increased E-cadherin and β-catenin expression levels 
 
To further investigate miR-875-5p role in influencing the epithelial to 
mesenchymal switch, molecular analysis were performed in order to assess the 
expression levels of E-Cadherin and β-catenin, the two most important markers 
of EMT, associated with a more epithelial like phenotype. In accordance with 
the postulate role of miR-875-5p in promoting the epithelioid morphology, we 
found that the miRNA significantly increased the expression levels of the two 
markers, at both mRNA and protein levels (Fig. 5.3). 
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Figure 5.3 miR-875-5p reconstitution increased E-Cadherin and β-catenin levels. 
(Upper panel) Expression of the epithelial markers CDH1 and CTNNB1 assessed by 
qRT-PCR in DU145 cells transfected with miR-875-5p and negative control. Data are 
reported as relative quantity (RQ) ± SD with respect to Neg cells. (Lower panel) 
Western blot analysis showing E-cadherin and β-catenin protein levels upon miR-875-
5p reconstitution in DU145 cells. Cropped images of selected proteins are shown. The 
level of significance was represented as *p<0.05, Student’s t-test. 
 
To explore such an effect at an in situ level, we performed an 
immunofluorescence analysis on transfected DU145 cells, to assess cell 
positivity to such markers. Consistent with previous results, we found that the 
presence of the miRNA is associated with an intense immunoreactivity for E-
Cadherin and β-catenin staining, suggesting that miR-875-5p results in an 
upregulation of such markers. More interestingly, the immunostaining allowed 
us to appreciate cell localization of the proteins. Consistent with their role in 
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mediating cell-cell junction formation, the two markers were found to be co-
localized at the cell membrane level, thus supporting a functional role of their 
upregulation mediated by the miRNA (Fig. 5.4). 
 
 
 
 
 
Figure 5.4 miR-875-5p promoted E-Cadherin and β-catenin co-localization at cell-
cell adhesions. Immunofluorescence staining of E-cadherin (green) and β-catenin 
(red) in DU145 cells upon miR-875-5p ectopic expression. DAPI (blue) was used to 
stain nuclei. Scale bar 10 µm. 
  
Neg miR-875-5p 
β-
C
at
en
in
 
M
er
ge
 
E-
C
ad
he
rin
 
 	
	
RESULTS II 
	
	 	
165	
5.2.3 miR-875-5p decreased DU145 cell migration ability 
 
Consistent with their role of leading cell migration and invasion, thus promoting 
tumour metastatization, mesenchymal cells display increased migration ability 
compared to their epithelioid counterpart. As a consequence, the evidence of 
the loss of such a migratory ability could reflect a reversion of the EMT switch.  
Compatible with miR-875-5p envisaged role of counteracting EMT, we 
hypothesised that miRNA reconstitution would result in a decreased migration 
potential. Migration ability could be recapitulated by cell capacity of healing a 
wound gap created by a scratch in the cell monolayer. Cells that are 
characterized by a high migration capacity, display a greater rate of gap 
healing. On the contrary, cells that are unable to “fill the gap” are likely showing 
an impairment of their migration potential. Reconstitution of miR-875-5p in 
DU145 cells showed a greater opening of the wound then negative cells, thus 
suggesting that the miRNA impairs cell migration (Fig. 5.5). Considering that 
this is a crucial property of mesenchymal cells, this result further supports the 
role of miR-875-5p in counteracting the EMT process, reverting the 
mesenchymal phenotype in a more epithelial-like one.    
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Figure 5.5 miR-875-5p decreased DU145 cell migration ability. Wound healing 
assay performed on miR-875-5p- and Neg-transfected DU145 cells, reported as wound 
opening percentage at different time points (24, 48 and 72 h) compared to t=0. The 
level of significance was represented as *p<0.05, Student’s t-test. 
5.3 miR-875-5p enhances radiosensitivity in PCa cells 
5.3.1 miR-875-5p enhances radiosensitivity in vitro  
 
Based on the finding that miR-875-5p counteracts EMT and considering the 
premises indicating that such transdifferentiation process is associated with an 
increased resistance to radiation, we were further encouraged to ascribe a 
putative radiosensitizing role to miR-875-5p. To explore this scenario, we 
assessed the sensitivity profile of miRNA reconstituted cells exposed to 
increasing doses of photon radiation and performed a clonogenic assay. 
Interestingly, miR-875-5p significantly enhanced the sensitivity of both PC-3 
and DU145 cells to radiation with respect to negative control, as indicated by 
the markedly reduced surviving fractions (Fig. 5.6).  
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Figure 5.6 miR-875-5p enhanced PC-3 and DU145 cell sensitivity to radiation. 
Clonogenic cell survival of miR-875-5p- or Neg-transfected PC-3 and DU145 cells 
exposed to increasing doses of γ-irradiation (2, 4, 6 and 8 Gy). The surviving fraction is 
reported as mean±SD, n=3. 
 
 
As previously done for the assessment of cell clonogenicity upon transfection 
with miR-23a-3p and miR-24-3p, we evaluated the effect of miR-875-5p alone 
on cell capacity to generate colonies, in order to exclude that the miRNA 
intrinsically displays a cytotoxic effect rather than a radiosensitizing one. 
Interestingly, the plating efficiency of both PC-3 and DU145 cells transfected 
with miR-875-5p compared to that of control cells (0.30 vs 0.28 and 0.21 vs 
0.22, respectively) showed that the transfection did not modify the proliferative 
potential of PCa cells, confirming that the observed increased response to 
radiation exposure, actually relies on a miRNA-induced enhancement of 
susceptibility to the treatment, thus supporting the role of miR-875-5p as a 
promising radiosensitizer molecule.  
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5.3.2 miR-875-5p impairs radiation-induced DNA damage repair 
 
The main lethal lesion induced by ionizing radiation consists of the generation 
of double strand breaks (DSBs). Radiosensitizing molecules are able to 
enhance the response to the treatment mainly by interfering with cell proficiency 
in repairing the lesion induced by radiation. To assess whether miR-875-5p-
mediated radiosensitization is ascribable to such interference, we evaluated 
whether the persistence of radiation-induced injury was affected by the miRNA. 
For this purpose, we assessed the formation of DSBs through evaluation of γ-
H2AX foci. H2AX is a histone variant that is phosphorylated on its Serine139-
residue upon irradiation, accumulating in nuclear foci at the level of the DSBs. 
Actually, the phosphorylation of H2AX acts as a sensor of DNA damage that 
persists until activation of DNA-damage repair mechanisms. This role as an 
early player in the DNA damage response makes the phosphorylated form of 
the histone (γ-H2AX) one of the most reliable markers of DSBs formation and 
repair [29].  Therefore, the higher the number of unrepaired DSBs is, the higher 
will be the number of γ-H2AX foci. In light of this, we evaluated the kinetics of 
accumulation and resolution of γ-H2AX nuclear foci in miR-875-5p transfected 
cells compared to controls, in order to investigate whether the miRNA was able 
to interfere with the persistence of DNA damage. As appreciable in the 
immunofluorescence results shown in Fig. 5.7, control cells displayed a rapid 
accumulation of γ-H2AX foci, with almost 100% cells presenting more than 10 
foci/nucleus at 1 hour from radiation exposure. Over time, the accumulation is 
markedly lost demonstrating rapid foci resolution, which suggests cell 
proficiency in repairing the radiation-induced DNA damage. In contrast, in miR-
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875-5p cells the accumulation of γ-H2AX that is observed at 1 hour from 
irradiation persisted up to 8 hours, with a very low rate of foci resolution. This 
result indicates that miR-875-5p indeed interferes with cell capacity to repair the 
radiation-induced damage, thus justifying the enhanced susceptibility to 
radiation.  
 
 
 
Figure 5.7 miR-875-5p impairs radiation-induced DNA damage repair. (Upper 
panel) Representative immunofluorescence images of nuclear γ-H2AX foci (cell nuclei: 
blue; γ-H2AX foci: green) in PC-3 and DU145 cells at 1, 4 and 8 h after exposure to 4 
Gy of γ-irradiation. (Lower panel) Kinetics of γ-H2AX foci resolution in Neg- or miR-
875-5p-reconstituted PC-3 and DU145 cells, calculated as mean number of cells 
containing >10 γ-H2AX foci at 1, 4, 8, 12 and 24 h after exposure to 4 Gy of γ-
irradiation. 
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In addition, to directly assess DNA damage at a single cell level we performed 
experiments using the comet assay. Results indicated that the reconstitution of 
miR-875-5p allowed an increased extent of DNA damage at 4 h following 
radiation exposure. Indeed, in line with our hypothesis, miR-875-5p 
reconstitution resulted in an increased persistence of radiation-induced damage 
(Fig. 5.8).  
 
 
 
Figure 5.8 miR-875-5p increased radiation-induced DNA damage. (Left panel) 
Photomicrographs showing formation of Comets in Neg- or miR-875-5p-transfected 
PC-3 and DU145 cells at 4 h after exposure to 4 Gy of γ-irradiation. (Right panel) 
Quantification of tail moments counted in at least 100 cells per group, reported as 
mean±SD.The level of significance was represented as  ***p<0.001, Student’s t-test. 
 
 
These findings suggest that miR-875-5p enhances cell susceptibility to 
radiation, by impairing cell-repair of treatment-induced DNA damage.  
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5.3.3 miR-875-5p enhanced PCa radiosensitivity in vivo 
 
To further confirm these promising results supporting a role of miR-875-5p as a 
radiosensitizer in PCa, we carried out in vivo experiments aimed at verifying 
whether the radiosensitizing effect observed in PCa cells is also maintained in 
animal models. For this purpose, a DU145 clone stably expressing the miRNA 
was established. DU145 cells stably expressing the miRNA were 
subcutaneously injected into the right flank of SCID mice, and let to generate 
PCa tumours. When tumours reached ~300 mm3, mice were exposed to 5 Gy 
single dose of irradiation by conformational radiotherapy, as detailed in 
Materials and Methods section. Tumour growth was monitored and tumour 
volumes were measured. As observed in Fig. 5.9, tumours deriving from cells 
expressing miR-875-5p and exposed to radiation showed a significantly 
enhanced tumour growth delay compared to irradiated control cell-derived 
xenografts. Interestingly, the presence of the miRNA alone (orange curve), in 
absence of treatment, did not impact on tumour growth, further confirming the in 
vitro findings and supporting the hypothesis that miR-875-5p is indeed a 
radiosensitizer as it acts enhancing the response to radiation, yet not displaying 
a cytotoxic effect per se.  
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Figure 5.9 miR-875-5p significantly enhanced tumour growth delay induced by 
irradiation. DU145 cells stably transfected with miR-875-5p or Null vector were 
implanted subcutaneously into the right flank of SCID mice. When tumors reached 
~300 mm3, mice were randomly separated into four groups (8 mice/group) and were 
treated with 5 Gy single dose irradiation locally delivered to the tumor area. (Upper 
panel) Tumor growth volume (mm3) measured with a Vernier caliper on indicated days 
after cell injection. (Lower panel) Representative X-ray images of the subcutaneous 
tumour masses at the day of radiation treatment and after 50 days. 
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In agreement with tumour growth curves, miR-875-5p reconstitution significantly 
increased the time for DU145 xenografts to reach 1000 mm3 tumour burden 
compared to control cell-derived xenografts (Fig. 5.10). 
 
Figure 5.10 miR-875-5p significantly increased the time for DU145 xenografts to 
reach 1000 mm3 tumor burden. Kaplan-Meier plot of mouse tumor growth to 1000 
mm3, n=8. 
 
Moreover, to confirm that the effect associated with tumour growth delay is 
indeed ascribable to miRNA-induced radiosensitization, we performed en ex 
vivo clonogenic assay, with DU145 cells obtained from disaggregated tumours 
deriving from mice sacrificed 24 h upon irradiation. Tumour-derived cells were 
seeded and let to grow and form colonies, and the surviving fraction at 5 Gy 
(the single dose available from the in vivo treatment) was calculated. Strikingly, 
tumour-derived cells corroborated in vitro results. DU145 cells deriving from 
miR-875-5p-xenografts showed an enhanced radiation response, to an extent 
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superimposable to that observed in cell-lines assessment. This finding suggests 
that the enhancement observed in tumour growth delay actually relies on miR-
875-5p ability to exert its radiosensitizing effect also in animal models. 
Moreover, the observation that the reduction in cell clonogenicity is almost 
superimposable to that observed in vitro, confirm that the in vivo effect fully 
recapitulates the behaviour of transfected cell model. This encouraged us to 
postulate that the molecular mechanism underlying miR-875-5p sensitization is 
maintained in animal models.  
To further support this assumption, we also evaluated the levels of γ-H2AX in 
tumour sections obtained from miR-875-5p- xenografts (Fig. 5.11). In 
accordance with our hypothesis, the immunostaining  revealed increased γ-
H2AX levels compared to control xenografts, indicating that the radiosensitizing 
effect exerted in vivo is ascribable to an impairment of DNA damage repair as 
well as what has been observed to occur in vitro.  
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Figure 5.11 miR-875-5p reduced irradiated tumour-derived cell clonogenicity and 
increased γ-H2AX levels in irradiated xenografts. Ex-vivo clonogenic assay carried 
out in DU145 cells obtained through disaggregation of xenografts removed from SCID 
mice 24 h after exposure to 5 Gy or mock γ-irradiation. (E) Immunohistochemical 
staining of γ-H2AX shown in immunohistochemical analysis in tumor samples 
harvested 24 h after radiation treatment. Tumors were removed, formalin-fixed and 
paraffin-embedded. Tumor sections were subjected to immunohistochemical analysis 
using an anti-γ-H2AX (Ser139) mouse monoclonal antibody. Nuclei were 
counterstained with hematoxylin. 
 
5.4 EGFR is a direct target of miR-875-5p 
 
5.4.1 EGFR is a relevant predicted target of miR-875-5p 
 
Once established that miR-875-5p is able to radiosensitize PCa both in cell and 
animal models, and that such effect relies on miRNA capacity to impair cell-
proficiency in repairing radiation induced-DNA damage, the next step of the 
study was the dissection of the underlying molecular mechanisms. Specifically, 
known that miRNAs act by modulating the expression of specific target genes, 
to address this aim we focused on the identification of miR-875-5p targets that 
could be relevant in influencing radiation response, with the final aim to figure 
out the main mediator of the observed radiosensitization.  
To narrow the list of putative mediator targets, we followed a strategy based on 
the intersection of: 
• genes found to be downregulated in PCa cell lines transfected with miR-
875-5p (as downregulation is compatible with miRNA targeting); 
• genes predicted as miR-875-5p targets by using in silico prediction tools 
based on different algorithms.  
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According to this strategy, we first pursued the identification of genes 
downregulated in DU145 cells transfected with miR-875-5p compared to control 
transfectants, by performing gene expression analysis through microarray 
platform as described in Material and Methods section. Among differentially 
expressed genes, (FDR < 0.05 and FC ≥ 1.5) 195 were downregulated.  
On the other hand, to identify miR-875-5p predicted targets, the presence of 
putative miR-875-5p binding sites in a given mRNA was predicted using 
MiRWalk algorithm, which performs a comparison of the information produced 
by ten established miRNA target prediction programs. Eighty-three targets 
simultaneously predicted by at least six programs were considered as reliable. 
Once performed the described analysis separately, we merged the two gene 
sets and obtained a list of 19 genes (Table 5.2).  
 
To further sharpen the selection of putative relevant targets, we reviewed the 
literature of the genes hunting those involved in any pathway known to be 
associated with radiation response. Interestingly, among possible relevant 
targets was EGFR, a tyrosine kinase receptor that, among its multiple functions, 
was also reported to be involved in influencing response to ionizing radiation, by 
activating DNA repair mechanisms following radiation exposure. Specifically, it 
has been demonstrated that, in response to radiation, EGFR is rapidly 
internalized and translocates to the nucleus, where it interacts with the DNA-
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dependent protein kinase (DNA-PK) and increases the enzyme activity by 
stabilizing the phosphorylated form of DNA-PK catalytic subunit at the serine 
residue (S2056), which is essential for DNA double-strand break repair by non 
homologous end joining (NHEJ) pathway [160]. Therefore, the nuclear 
translocation of EGFR results in cell resistance to radiation. This link between 
EGFR and radiation response prompted us to pursue the hypothesis that miR-
875-5p exerts its radiosensitizing effect by downregulating its target EGFR, thus 
interfering with EGFR-associated radioresistance. 
Symbol GeneName logFC FDR 
NFE2L3 nuclear factor, erythroid 2-like 3 -1.52686 2.33E-12 
MED20 mediator complex subunit 20 -1.27655 6.29E-12 
USF2 upstream transcription factor 2, c-fos 
interacting 
-1.14178 4.04E-08 
RAB11FIP2 RAB11 family interacting protein 2 (class I) -1.11633 5.11E-11 
SLC25A21 
solute carrier family 25 (mitochondrial 
oxoadipate carrier), member 21 
-1.0997 2.98E-11 
WSB2 WD repeat and SOCS box containing 2 -0.91723 5.17E-06 
EGFR epidermal growth factor receptor -0.81115 6.62E-09 
DIRC2 disrupted in renal carcinoma 2 -0.76956 6.98E-08 
SH3YL1 SH3 and SYLF domain containing 1 -0.76146 5.42E-07 
NMT2 N-myristoyltransferase 2 -0.74431 5.82E-08 
PM20D2 peptidase M20 domain containing 2 -0.72606 1.62E-05 
DDX50 DEAD (Asp-Glu-Ala-Asp) box polypeptide 
50 
-0.69708 3.5E-06 
HLTF helicase-like transcription factor -0.6863 1.97E-06 
SH3D19 SH3 domain containing 19 -0.62052 2.26E-07 
TAF5 
TAF5 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
100kDa 
-0.57288 3.73E-05 
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ZNF280B zinc finger protein 280B -0.56791 0.000113 
LIN7C lin-7 homolog C (C. elegans) -0.55586 0.004092 
SYPL1 synaptophysin-like 1 -0.54958 0.000205 
CASD1 CAS1 domain containing 1 -0.50051 0.00038 
 
 
Table 5.2. Putative miR-875-5p targets. List of genes arisen from the intersection 
between genes found to be downregulated in miR-875-5p cells (evaluated by 
microarray analysis performed in miR-875-5p reconstituted DU145 cells) with the list of 
genes predicted to be target of the miRNA by at least 6 different miRNA target 
prediction tools. 
 
 
Notably, among the list of 19 genes was also LIN7C, which is known to favour 
the localization of EGFR at the baso-lateral membrane of epithelial cells 
[161,162]. The presence of two members of the same pathway in such a small 
list of 19 genes, further encouraged us to focus on EGFR for following 
investigation.  
 
5.4.2 EGFR is a direct target of miR-875-5p 
 
We found EGFR as a predicted target of miR-875-5p, however no validation 
data about its real direct targeting were available when we pursued the study. 
Hence, we assessed whether EGFR is directly bound and negatively regulated 
by miR-875-5p, by performing a luciferase assay. Specifically, we cloned a 
1285 nt-long portion of EGFR 3’ UTR containing the predicted miR-875-5p 
binding site downstream the FireFly luciferase gene. After 24 h from co-
transfection with miR-875-5p, we evaluated Luciferase activity to assess 
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whether it was influenced by the presence of the miRNA. As showed in Fig. 
5.12, luciferase activity was significantly reduced upon miR-875-5p co-
transfection, indicating that the miRNA bound EGFR 3’UTR portion thus leading 
to the downregulation of luciferase expression and consequent activity.  This 
result validated EGFR as a direct target of miR-875-5p.  
 
 
 
 
Figure 5.12 EGFR is a direct target of miR-875-5p. Luciferase assay confirming 
EGFR as a direct target of miR-875-5p. EGFR 3’ UTR containing the predicted miR-
875-5p binding site was amplified by PCR from cDNA obtained from DU145 cells and 
cloned in the reporter vector downstream of the FireFly luciferase gene. Cells were 
collected after 24 h and the luciferase activity was assessed. The ratio of FireFly 
activity to that of Renilla is reported as mean±SD. 
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5.4.3 EGFR is downregulated by miR-875-5p in PCa cells 
 
Accordingly with the fact that miR-875-5p directly targets EGFR, we found that 
expression levels of EGFR were downregulated upon miRNA transfection with 
respect to control cells. Specifically, we evaluated the expression levels of 
EGFR transcript upon 24 h, a time point that allows detecting any change in 
transcription levels, and we found that indeed EGFR transcript was 
downregulated by miR-875-5p.  
Moreover, we assessed the expression levels of EGFR protein, to confirm that a 
functional downregulation was occurring. Accordingly, EGFR levels were 
reduced also at protein levels, thus suggesting that miR-875-5p leads to a 
functional downregulation of EGFR in PCa cells (Fig. 5.13). 
 
Figure 5.13 EGFR is downregulated by miR-875-5p. (Left panel) qRT-PCR showing 
EGFR mRNA amount in PC-3 and DU145 cells after miR-875-5p reconstitution, 
compared to control cells, normalized to GAPDH. Data are reported as a percentage of 
Neg-transfected cells. (Right panel) Western blot analysis showing EGFR protein 
amount in PC-3 and DU145 cells upon Neg- or miR-875-5p-transfection, normalized to 
β-Actin. Cropped images of selected proteins are shown. 
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Moreover, to appreciate EGFR downregulation at its cell site of localization, we 
performed an immunofluorescence staining along a wound healing assay. First 
of all, we could actually observe that EGFR is markedly downregulated upon 
miRNA transfection, as indicated by the low immunoreactivity (Fig. 5.14, upper 
panel).  Interestingly, we could monitor EGFR localization and we found that 
miR-875-5p delocalizes EGFR from cellular invasive front, where it is normally 
highly expressed in control cells (Fig. 5.14, lower panel).  
 
 
 
Figure 5.14 EGFR is downregulated and delocalized by miR-875-5p. (Upper panel) 
Images showing reduction of EGFR staining (green) and delocalization from the cell 
membrane in DU145 cells overexpressing miR-875-5p. DAPI (blue) was used to stain 
nuclei. (Lower panel) Representative images from a wound healing assay carried out in 
DU145 cells showing staining of EGFR (red), F-actin (green) and nuclei (blue) at 32 h 
following the scratch. Scale bar 100 µm. 
 
 
 
 
 
 
D
U
14
5	
Neg	 miR-875-5p	
EG
FR
/P
ha
llo
id
in
	
Neg	 miR-875-5p	
Neg miR-875-5p 
DU
14
5	
Neg	 miR-875-5p	
EG
FR
 
 	
	
RESULTS II 
	
	 	
182	
Considering that EGFR was found to be delocalized upon miRNA transfection, 
and that among the 19 possible targets of miR-875-5p we also found LIN7C, we 
postulated that there might be a correlation between those two events. To verify 
our hypothesis we tested whether there was any modulation in LIN7C upon 
miR-875-5p reconstitution, which is expected based on gene expression 
analysis. In accordance with LIN7C gene downregulation upon gene 
expression, and in agreement with EGFR delocalization from the membrane, 
reduced mRNA and protein levels of LIN7C were found in miR-875-5p-
overexpressing PC-3 or DU145 cells (Fig. 5.15), thus further supporting the 
relevance of the EGFR signalling pathway in mediating miR-875-5p biological 
effect. 
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Figure 5.15 miR-875-5p down-regulates LIN7C. (Upper panel, left) qRT-PCR 
showing LIN7C mRNA amount in PC-3 and DU145 cells after miR-875-5p 
reconstitution, compared to control cells, normalized to GAPDH. Data are reported as a 
percentage of Neg-transfected cells. The level of significance was represented as 
*p<0.05, **p<0.01, Student’s t-test. (Upper panel, right) Western blot analysis showing 
LIN7C protein amount in DU145 cells upon Neg- or miR-875-5p-transfection, 
normalized to Vinculin. Cropped images of selected proteins are shown. (Lower panel) 
Images showing reduction of LIN7C staining (green) in DU145 cells overexpressing 
miR-875-5p. DAPI (blue) was used to counterstain nuclei.  
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5.5 EGFR-ZEB1 axis mediates miR-875-5p radiosensitizing effect 
5.5.1 EGFR contributes to mediate miR-875-5p-induced	radiosensitization	
	
The identification and validation of EGFR as a target that is known to play a role 
in radiation response, does not per se demonstrate that EGFR is actually 
responsible of miR-875-5p-radiosensitization. To investigate and provide	
evidence of EGFR involvement in miR-875-5p impact on radiation response,	we 
performed a very specific experiment based on target protection strategy.  
This approach consists of masking miRNA binding site within the target thus	
impeding the physical interaction between the miRNA and its target. To	achieve 
this, we designed an oligonucleotide (miR-Mask) fully complementary to miR-
875-5p binding site within EGFR 3’UTR, able to protect the site from miR-875-
5p binding. First of all, we tested whether the designed miR-Mask was actually 
able to prevent miRNA-mRNA interaction, by evaluating EGFR expression 
levels upon co-transfection with both miR-875-5p and miR-Mask molecules. We 
found that the miR-Mask was able to significantly recover EGFR expression at 
both mRNA and protein level in miR-875-5p-reconstituted cells (Fig. 5.16). This 
result gave us the proof of masking ability to protect EGFR from miRNA 
targeting and consequent	downregulation.		
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Figure 5.16 EGFR miR-Mask recovered EGFR expression levels in miR-875-5p 
cells. (Upper panel) Western blot analysis showing EGFR protein amount in DU145 
cells upon Neg or miR-875-5p transfection, in presence or absence of EGFR miR-
Mask, normalized to Vinculin. Cropped images of selected proteins are shown. (Lower 
panel) qRT-PCR showing EGFR mRNA amount in DU145 cells after miR-875-5p 
reconstitution in the presence or absence of miR-Mask, normalized to GAPDH. Data 
are reported as a percentage of Neg-transfected cells. 
 
To examine whether EGFR is a key factor in determining the radiosensitizing 
effect induced by miR-875-5p, we transfected miRNA-reconstituted DU145 cells 
with the miR-Mask, with the aim of assessing whether the abrogation of EGFR 
downregulation influences miR-875-5p-induced effect. Strikingly, we found that 
miRNA mask was able to almost completely abrogate the radiosensitizing effect 
induced by miRNA reconstitution (Fig. 5.17). This result indicates that, upon 
EGFR recovering, the miR-875-5p is no longer able to influence cell sensitivity, 
suggesting that the downregulation of EGFR is a crucial step in the 
radiosensitizing process.  
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Figure 5.17 EGFR contributes to mediate miR-875-5p-induced radiosensitization. 
Clonogenic cell survival of DU145 cells transfected with miR-875-5p alone or co-
transfection with miR-Mask. The surviving fractions following the indicated doses of 
radiation are reported as mean±SD, n=3. The level of significance was represented as 
*p<0.05, **p<0.01, Student’s t-test. 
 
5.5.2 miR-875-5p reduces DNA-PK activation via EGFR downregulation 
 
As previously reported, EGFR role in radiation response relies on its 
internalization into the nucleus where it binds and activates DNA-PK, thus 
leading to NHEJ guided DNA-repair.  The activation of DNA-PK occurs by 
phosphorylation of a specific residue (S2056), which is therefore considered a 
flag of DNA-PK active status. To verify whether EGFR mediates miR-875-5p 
effect by its participation to this pathway, we assessed EGFR levels in the 
nucleus with the purpose to monitor whether, following irradiation, a 
translocation has occurred. 
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According to the overall significantly reduced EGFR abundance, and the almost 
complete absence of the protein in the nuclear fraction observed in miR-875-5p-
reconstituted DU145 cells under basal conditions, negligible EGFR levels were 
detected in the nucleus of these cells after 5 Gy irradiation (Fig. 5.18). In line 
with its role in influencing DNA damage-repair, miR-875-5p ectopic expression 
counteracted radiation-induced activation of ATM, as suggested by a slightly 
reduced activation of ATM as detected by the lower expression levels of the 
phosphorylated form of the enzyme at S1981 (ATM-S1981) (Fig. 15.19), which 
is consistent with previous results obtained in non-small cell lung cancer cells 
exposed to the EGFR inhibitor gefitinib before irradiation [163]. 
Surprisingly, any significant reduction in the activation of DNA-PK, assessed in 
terms of the phosphorylated form of the enzyme at S2056 (DNA-PK2056), was 
observed following irradiation of miR-875- 5p-reconstituted compared to control 
cells. This result prompted us to postulate the involvement of other effectors 
downstream EGFR, other than DNA-PK. 
 
Figure 5.18 EGFR translocation to the nucleus is reduced upon miR-875-5p 
mediated downregulation. Western blot analysis showing EGFR subcellular 
localization in DU145 cells transfected with Neg or miR-875-5p. Forty-eight h after 
transfection, cells were irradiated at 4 Gy and 60 min later harvested for subcellular 
protein fractionation and Western blot assay. Insulin R-β and HDAC2 were used as 
control for membrane and nuclear fractionations, respectively. Cropped images of 
selected proteins are shown.  
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Figure 5.19 ATM and DNA-PK activation is reduced by miR-875-5p reconstitution. 
(Upper panel) Western blot analysis showing ATM and DNA-PK expression in DU145 
cells transfected with Neg or miR-875-5p. Forty-eight hours after transfection, cells 
were irradiated at 4 Gy and harvested 0.5, 2 and 4h later harvested for Western blot 
assay. Vinculin was used as control for loading. (Lower panel) Quantification of protein 
expression levels of DNA-PK-S2056 and ATM-S1981 normilized to endougenous 
control (Vinculin) and to corresponding total protein (i.e. DNA-PK and ATM, 
respectively).  
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5.5.3 EGFR-mediated ZEB1 downregulation plays a main role in miR-875-
5p-induced radiosensitization 
 
Since, although present, the involvement of EGFR-DNA-PK pathway seemed to 
be almost neglectible with respect to the important effect induced by miR-875-
5p, we were prompted to suppose that some other players were involved in 
determining the final effect.  
As previously anticipated, recent results indicate that ZEB1 is associated with 
tumor radioresistance [159], and that its expression can be suppressed by 
EGFR inhibitors [164,165]. The merge of these findings fostered us to 
investigate a possible role of ZEB1 in miR-875-5p radiosensitizing effect of 
EMT-impairment, postulating that, yet not being a direct target of the miRNA, it 
could be indirectly downregulated via EGFR suppression. To test our 
hypothesis, we evaluated the expression levels of ZEB1 in miR-875-5p 
transfected cells. A significant reduction in ZEB1 protein expression was found 
in miR-875- 5p-reconstituted DU145 cells (Fig. 5.20, left). Moreover, taking 
advantage of tumour-sections of xenografts originating from DU145 cells stably 
expressing miR-875-5p, we could also appreciate such reduction in ex vivo 
tissues, thus confirming that ZEB1 downregultion is maintained in in vivo 
settings.  (Fig. 5.20, centre). In addition, the recovery of ZEB1 expression 
observed when cells where transfected with the miR-Mask specifically blocking 
the interaction between miR-875-5p and EGFR mRNA suggests that, at least in 
part, the reduced ZEB1 expression in miRNA-reconstituted cells was 
consequent to miR-875-5p- induced EGFR down-regulation.  
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Recent data obtained in cell lines of tumor types other than PCa showed that 
ZEB1 induces radioresistance not only through EMT but also playing a direct 
role in homologous recombination-mediated repair of DNA breaks by regulating 
CHK1 expression levels [166]. Such a regulation is mediated by the interaction 
of ZEB1 with the deubiquitinase USP7, which promotes the enzyme ability to 
stabilize CHK1 protein [166].  
In light of these findings, we tested the possible involvement of CHK1 in the 
cascade downstream of EGFR-ZEB1 axis. Interestingly, a reduced expression 
of CHK1 was found to parallel ZEB1 down-regulation in miR-875-5p- 
transfected cells (Fig. 5.20, right).  
 
 
 
Figure 5.20 miR-875-5p induced ZEB1 repression via EGFR downregulation. (Left 
panel) Western blot analysis showing ZEB1 protein amount in DU145 cells upon Neg 
or miR-875-5p transfection, in presence or absence of EGFR miR-Mask, normalized to 
β-Actin. Cropped images of selected proteins are shown. (Centre panel) Expression 
and subcellular localization of ZEB1 in tumor xenografts of Null and miR-875-5p stably 
expressing DU145 cells grown in SCID mice, as assessed by IHC. Nuclei were 
counterstained with hematoxylin. (Right panel) Western blot analysis showing CHK1 
protein expression levels in DU145 cells transfected with miR-875-5p- compared to 
Neg-transfected cells. β-actin was used for normalization. Cropped images of selected 
proteins are shown. 
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As we proceeded for demonstrating EGFR functional involvement in mediating 
miR-875-5p radiosensitization, we similarly wanted to assess the contribution of 
ZEB1 in determining the final effect on radiation response. Therefore, we 
transfected DU145 cells with a specific siRNA molecule against ZEB1, in order 
to evaluate whether ZEB1 silencing was able to phenocopy miR-875-5p in 
increasing cell sensitivity to radiation. 
First of all, we compared the extent of ZEB1 inhibition by the two strategies 
(miRNA vs siRNA) in order to exclude that any difference in the evaluated effect 
could be due to a major/minor downregulation. Interestingly, the siRNA 
molecule was able to inhibit ZEB1 mRNA expression to an extent comparable 
to that observed following miR-875-5p reconstitution (Fig. 5.21). Strikingly, 
clonogenic assay results showed that ZEB1 silencing was able to fully 
reproduce the radiosensitizing effect induced by the miRNA (Fig. 6D), 
suggesting a main role of the EGFR-ZEB1-CHK1 axis inhibition in promoting 
PCa cell radiation response. 
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Figure 5.21 EGFR-mediated ZEB1 downregulation plays a main role in miR-875-
5p-induced radiosensitization. (Upper panel) qRT-PCR showing ZEB1 mRNA 
amount in DU145 cells after transfection with miR-875-5p or siZEB1 and respective 
controls, normalized to GAPDH. Data are reported as a percentage of Neg- or siCTRL-
transfected cells, respectively. (Lower panel) Clonogenic cell survival of DU145 cells 
transfected with miR-875-5p or siZEB1 and respective negative controls. The surviving 
fractions following the indicated doses of γ-irradition are reported as mean±SD, n=3. 
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6. RESULTS III: the role of miR-205 in PCa radiation response  
 
In the framework of miRNAs sorted by following the second approach, we singled 
out miR-205. 
Previous studies undertaken by our group reported that miR-205 is a tumour-
suppressor miRNA, the expression of which is reduced or lost in prostate tumours 
compared to normal tissues. We also found that miR-205 regulates pathways that 
are known to affect radiation response, such as autophagy and epithelial to 
mesenchymal transition (EMT). Specifically, we previously observed that 
restoration of miR-205 in DU145 cells was able to impair the autophagic flux by 
downregulating RAB27A and LAMP3 lysosome-associated proteins, thus resulting 
in an enhancement of cisplatin cytotoxic activity  [153].  
The possible relevance of the miRNA in PCa radiation response is also based on 
the well-established role of miR-205 in counteracting EMT, mainly by targeting 
ZEB1/2 EMT-transcription factors, as demonstrated by Gregory et al. [167] for the 
first time and, shortly after, by Gandellini et al. [81]. In particular, our group 
demonstrated that miR-205 plays a crucial role in EMT-regulation in the context of 
PCa, at least in part through the down-regulation of protein kinase Cepsilon (PKC-
ε).  
Interestingly, the relevance of PKC-ε in determining cell response to radiation-
induced injury is also supported by the study of Wanner et al [168]. The authors 
demonstrated that the activation of PKC-ε stimulates DNA-repair by promoting the 
nuclear accumulation of EGFR, leading to activation of DNA-PK, a protein kinase 
essential for DNA-repair [169].  
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Based on this premises, to examine whether miR-205 is able to enhance PCa 
cells, presumably by regulating one of the mentioned target pathways, we first 
reconstituted miR-205 in PCa cells and investigated its impact on radiation 
response, and dissected the underlying molecular mechanism.  
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6.1 miR-205 reconstitution enhanced PCa cell response to radiation 
 
6.1.1 Transient transfection of DU145 with miR-205 significantly increased 
miRNA expression levels 
 
 As a very first step of this part of the study, we reconstituted miR-205 in DU145 
and PC-3 cells by transient transfection. To verify that transfection actually 
increased miR-205 levels in PCa cells, we assessed the kinetics of miR-205 
expression levels over the course of 10 days (Fig. 6.1). As showed, in both DU145 
and PC-3 cells, miR-205 was upregulated beginning at 24 h after transfection, with 
an expression peak at 48 h. Afterwards, miRNA levels gradually decreased, still 
maintaining a high expression at least up to 10 days from transfection. This data 
led us to assume that any biological effect observed within this time window can 
still be imputable to the verified upregulation of miR-205 in PCa cells.  
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Figure 6.1 miR-205 was upregulated up to 10 days upon transient transfection. 
Expression of miR-205 assessed by qRT-PCR in DU145 cells transfected with miR-205 
compared to negative control cells. Data are reported as relative quantity (RQ) ± SD with 
respect to Neg cells. 
 
6.1.2 miR-205 enhances PCa cell response to radiation 
 
Once verified that ectopic transfection allowed miR-205 overexpression to an 
extent sufficient to appreciate the biological effects exerted the miRNA, we 
exposed transfected cells to radiation and evaluated miR-205 capacity to influence 
cell sensitivity to the treatment. Remarkably, miR-205 reconstitution was able to 
significantly enhance radiation response of DU145 cells, as indicated by reduced 
clonogenic cell survival (Fig.6.2). 
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Figure 6.2 miR-205 enhanced DU145 cell sensitivity to radiation. Clonogenic cell 
survival of miR-205- or Neg-transfected DU145 cells exposed to increasing doses of γ-
irradiation (2, 4, 6 and 8 Gy). The surviving fraction is reported as mean±SD, n=3. 
	
Considering the established role of miR-205 in prostate cancer tumorigenesis, we 
wanted to exclude that such effect on cell-clonogenicity actually relies on miR-205 
capacity to enhance cell sensitivity to radiation, rather to on an intrinsic cytotoxic 
effect of the miRNA. To address this, we compared the plating efficiency of 
negative transfected cells with this of miR-205 transfectants, in non-irradiated 
cells, as any significant difference would have reflected a cytotoxic effect of the 
miRNA regardless of radiation involvement.  
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Interestingly, the PE of miR-205 (PE=0.21), measured as the ratio of counted 
colonies to the number of seeded cells, was almost completely identical to that of 
negative cells (PE=0.22). This indicated that miR-205 alone does not exert any 
effect on cell viability and clonogenicity. Therefore, the totality of the effect 
observed in miR-205 cells upon irradiation is completely imputable to miRNA 
ability to make cells more susceptible to radiation, which is completely compatible 
with its postulated role of radiosensitizer molecule. Indeed, this finding is in 
accordance with miR-205 involvement in PCa tumorigenesis, since the major 
tumour-suppressive effect of the miRNA was demonstrated to be exerted in terms 
of impairment of EMT/migration/invasion abilities of the cell, rather than of cell 
viability and proliferation capabilities.  
 
6.1.3 miR-205 impairs radiation-induced DNA damage repair 
 
Considering i) the crucial role of DNA damage repair in influencing cell response to 
radiation, and that ii) miR-205 targets pathway related to DNA repair, we sought to 
investigate whether miR-205-radiosensitizing effect was mediated by miRNA 
capacity to interfere with such mechanisms. To that aim, we assessed the kinetics 
of γ-H2AX foci resolution upon exposure to 4 Gy of irradiation, as previously done 
for miR-875-5, in order to understand whether miR-205 affect DSBs repair 
mechanisms.  
As expected, negative transfected cells displayed a rapid accumulation and 
resolution of γ-H2AX foci (<20% foci within 8h from irradiation), thus confirming 
that DU145 cells are basally proficient in repairing radiation-induced damage. On 
the contrary, miR-205 transfected cells, showed a markedly delayed foci 
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resolution, with almost 90% of cells presenting more than 10 foci within the 
nucleus (Fig. 6.3). This indicates that miR-205 was able to significantly reduce 
DSBs clearance by interfering with cell repair mechanisms, thus ultimately 
extending the persistence of radiation-induced injury. This result confirms that 
miR-205 acts as a sensitizer molecule in PCa by enhancing the effect caused by 
radiation treatment. 
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Figure 6.3 miR-205 impairs radiation-induced DNA damage repair. (Upper panel) 
Representative immunofluorescence images of nuclear γH2AX foci (cell nuclei: blue; 
γH2AX foci: green) of DU145 cells at 1, 4 and 8 h after exposure to 4 Gy radiation. (Lower 
panel) Kinetics of γH2AX foci resolution of miR-205 reconstituted and control DU145 cells, 
calculated as mean number of cells containing >10 γH2AX foci at 1, 4, 8 hours after 
exposure to 4 Gy of irradiation. 
	
To assess DNA damage at a single-cell level, we performed comet assay on 
negative/miR-205 transfected DU145 cells after 4 h from radiation exposure (4 
Gy). In line with our previous evidence that miR-205 is able to counteract the 
repair of radiation-induced damage, we observed that comet tail moments were 
markedly extended in miR-205 transfectants compared to normal cells, thus 
further supporting the role of miR-205 in interfering with DNA-repair processes 
(Fig. 6.4).  
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Figure 6.4 miR-205 increased radiation-induced DNA damage. (Left panel) 
Photomicrographs showing formation of Comets in Neg- or miR-205-transfected DU145 
cells at 4 h after exposure to 4 Gy of γ-irradiation. (Right panel) Quantification of tail 
moments counted in at least 100 cells per group, reported as mean±SD.The level of 
significance was represented as  ***p<0.001, Student’s t-test. 
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6.1.4 miR-205 enhances PCa response to radiation in vivo 
 
Considering the promising results supporting miR-205 relevance in determining 
PCa radiation response, and taking advantage of a previously established DU145 
clone stably expressing miR-205, we tested miRNA-induced radiosensitizing effect 
in vivo. First of all we verified miR-205 overexpression in DU145 stable cells by 
qRT-PCR. As expected, miR-205 was consistently upregulated in DU145 stable 
clone with respect to the negative control harbouring an empty vector (Fig. 6.5).  
 
 
 
Figure 6.5 miR-205 was upregulated in a DU145 clone stably expressing the miRNA. 
Expression of miR-205 assessed by qRT-PCR in DU145 cells stably transfected with a 
vector encoding miR-205 compared to negative control cells with empty vector. Data are 
reported as relative quantity (RQ) ± SD with respect to Neg cells. 
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To assess whether the clone stably expressing miR-205 displays a higher 
sensitivity to radiation treatment than control clone as observed for transient 
transfected cells, we exposed clones to increasing doses of radiation (from 2 to 8 
Gy) and evaluated their clonogenic ability. Interestingly, the stable expression of 
miR-205 was still able to influence cell sensitivity to radiation, as demonstrated by 
the decreased clonogenic cell survival (Fig. 6.6).  
 
 
 
 
 
Figure 6.6 miR-205 stably expression enhanced DU145 cell sensitivity to radiation. 
Clonogenic cell survival of DU145 stably transfected with miR-205- or Neg-vector, 
exposed to increasing doses of γ-irradiation (2, 4, 6 and 8 Gy). The surviving fraction is 
reported as mean±SD, n=3. 
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Once the suitability of the cell model for in vivo experiment was verified, the 
DU145 clone stably expressing miR-205 and the respective negative control were 
injected into the right flank of SCID mice, and let to engraft and grow thus leading 
to the onset of subcutaneous PCa tumours. Tumour growth was monitored to 
determine when to administer radiation treatment. Noteworthy, a delay in tumour 
growth was observed in miR-205 xenografts compared to matched negative 
controls, indicating that the miRNA was per se able to impact on tumour growth, 
unlike what observed in vitro. Despite what it might seem, this finding is not that 
surprising in light of miR-205 known role in PCa. As anticipated, miR-205 is well 
known to play a relevant role in PCa tumourigenesis, with particular reference to 
EMT impairment. Although EMT final outcome is mainly appreciable in terms of 
tumour migration and invasion potential, it should be taken into account that 
preliminary transition steps occur within the tumour, manifesting in different tumour 
behaviour changes, conceivably also influencing tumour growth rate. Moreover, 
despite the established role of miR-205 in EMT/migration/invasion, and 
considering that a miRNA modulates multiple target processes, we can not 
exclude that miR-205 is implicated in other mechanisms that take place only in the 
complex tumour context (such as interaction with the microenvironment) and that 
are not perceivable in the in vitro settings, thus manifesting only in vivo. 
As a result, it is not that unexpected that miR-205 exerts an effect on in vivo 
tumour growth, yet not displaying a cytotoxic effect in in vitro settings.  
For this reason we decided to deliver radiation treatment when tumours reached a 
comparable volume (~150 mm3), without waiting them to reach a pre-established 
volume (generally ~300 mm3) in order to avoid to administer treatment on different 
starting points.   
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Mice were exposed to 5 Gy single dose of irradiation by conformational 
radiotherapy. Tumour volumes were determined at fixed intervals by direct 
measurement with a Vernier caliper. In consonance with what observed before 
starting the treatment, xenografts deriving from DU145 clone expressing miR-205 
showed tumour growth delay, thus confirming that miR-205 exerts toxic effects on 
tumours. However, upon radiation, miR-205 xenografts showed a markedly 
increased sensitivity to the treatment, suggesting that, despite its in vivo toxicity, 
miR-205 is still able to act as a radiosensitizer. (Fig. 6.7).  
 
Figure 6.7 miR-205 significantly enhanced tumour growth delay induced by 
irradiation. DU145 cells stably transfected with miR-205 or Neg empty vector were 
implanted subcutaneously into the right flank of SCID mice. When tumours reached 
similar volumes (~150 mm3), mice were randomly separated into four groups (8 
mice/group) and were treated with 5 Gy single dose irradiation locally delivered to the 
tumour area. (Upper panel) Tumour growth volume (mm3) measured with a Vernier 
caliper on indicated days after cell injection and Kaplan-Meier plot of mouse tumor growth 
to 1000 mm3. (Lower panel) Representative X-ray images of the subcutaneous tumour 
masses at the day of radiation treatment and after 40 days. 
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6.2 miR-205 mediated radiosensitivity: role of putative targets 
6.2.1 miR-205 targets genes related to autophagy and EMT 
 
miR-205 was demonstrated to enhance PCa sensitivity to radiation both in vitro 
and in vivo. According to literature data and to the results obtained in our previous 
studies, miR-205 is known to regulate pathways associated to radiation response, 
including autophagy and EMT. miR-205 involvement in autophagy is supported by 
miRNA ability to target RAB27A and LAMP3. As for EMT, miR-205 is largely 
implicated in regulating this process by targeting important EMT-related genes, 
such as ZEB1 and PKC-ε. To understand which of these targets is actually 
responsible of mediating miR-205-induced radiosensitization, we sought to 
perform a phenocopy experiment, by silencing those targets and finding out with 
which we are able to resemble miR-205 phenotype.  
Specifically, we transfected DU145 cells with specific siRNA molecules against 
each of the putative mediators (RAB27A, LAMP3, ZEB1 and PKC-ε). Cells 
transfected with each siRNA or miR-205 were then exposed to 2 Gy of irradiation 
in order to calculate the surviving fraction (SF2), and evaluate target-silencing 
effect of DU145 sensitivity profile (Fig. 6.8). 
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Figure 6.8 siPKC-ε  enhanced DU145 radiosensitivity. Clonogenic cell survival of 
DU145 transfected with miR-205- or siRNA molecules against PKC-ε, ZEB1, LAMP3, and 
RAB27a, and exposed to 2 Gy of γ-irradiation. The surviving fraction is reported as 
mean±SD, n=3. 
 
Silencing of PKC-ε, ZEB1 and LAMP3 showed a significant decrease of 
clonogenic cell survival at 2 Gy of irradiation, thus substantiating their putative role 
in influencing radiation response. However, PKC-ε silencing showed the greatest 
effect on radiation sensitivity, thus indicating that it could be the main mediator of 
miRNA-induced radiosensitization.  
On these grounds, we focused our attention on PKCε to better uncover its role in 
miR-205-induced sensitization.  
DU145
0.0
0.2
0.4
0.6
0.8
1.0 CTRL no RT
Neg
miR-205
siPKCe
siZEB1
siLAMP3
siRAB27A
0 Gy 2 Gy
Dose of Irradiation (Gy)
Su
rv
iv
in
g 
Fr
ac
tio
n 
(2
G
y)
***
***
** **
 	
	
RESULTS III 
	
	 	
209	
6.2.2 PKC-ε  is downregulated by miR-205 
 
To characterize PKC-ε role in mediating the radiosensitizing effect induced by 
miR-205, we first evaluated miRNA capacity to downregulate its target in PCa 
cells. For this purpose, PKC-ε expression levels were assessed upon miR-205 
transfection, at both transcript and protein levels. Compatible with being miR-205 
target, PKC-ε transcript was found to be significantly downregulated after 48 h 
from miRNA transfection (Fig. 6.9).  
 
 
Figure 6.9 PKC-ε  transcript is downregulated by miR-205. Expression levels assessed 
by qRT-PCR in DU145 cells transfected with miR-205 compared to negative control cells. 
Data are reported as relative quantity (RQ) ± SD with respect to Neg cells. 
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Considering that PKC-ε potential relevance in mediating miR-205 radiosensitizing 
effect relies on protein function implicated in EGFR nuclear translocation, to 
assess whether the miRNA leads to the downregulation of its protein levels is 
instrumental. To this aim, protein levels of PKC-ε upon transfection were assessed 
by western blotting analysis, revealing that actually the target is significantly 
downregulated at the protein level and that miR-205 mediates a functional 
downregulation of the target (Fig. 6.10). 
 
 
 
 
 
Figure 6.10 miR-205 reconstitution decreased PKC-ε protein levels. Western blot 
analysis showing PKC-ε  protein levels upon miR-205 reconstitution in DU145 cells. 
Cropped images of selected proteins are shown.  
 
 
Once the downregulation of PKC-ε in PCa cells has been demonstrated, we 
moved to further explore its ability in mediating miR-205 radiosensitizing effect, in 
order to implement the previous exploratory clonogenic assay.  
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6.2.3 PKC-ε  mediates miR-205 induced radiosensitization 
 
A previous clonogenic assay upon 2 Gy of irradiation was performed with the aim 
to single out the target that better recapitulates miR-205 induced 
radiosensitization. To confirm that PKC-ε silencing actually enhances PCa 
sensitivity to radiation, we performed an extended clonogenic assay by exposing 
cells to increasing doses of irradiation, up to 8 Gy. As previously suggested by the 
evaluation of SF2, siPKC-ε was able to completely reproduce the radiosensitizing 
effect of miR-205, thus supporting our hypothesis that PKC-ε could be the main 
mediator of miRNA effect (Fig. 6.11).   
 
 
Figure 6.11 siPKC-ε recapitulated miR-205 radiosensitizing effect. Clonogenic cell 
survival of DU145 cells transfected with miR-205 or siPKC-ε. The surviving fractions 
following the indicated doses of γ-irradition are reported as mean±SD, n=3. 
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To verify that the silencing obtained by the use of the siRNA molecule is not far 
greater than that induced by the miRNA, and also to test siRNA ability to efficiently 
silence the target, we evaluated PKC-ε expression levels upon miR-205 and 
siRNA transfection. Interestingly, the downregulation levels induced by the two 
molecules were almost identical (RQ=0.65 Vs RQ=0.60), thus indicating that the 
siRNA and the miRNA were able to downregulate the target to a similar degree 
(Fig. 6.12).  
 
 
Figure 6.12 PKC-ε  downregulation upon transfection with miR-205 or siPKC-ε. 
Expression levels assessed by qRT-PCR in DU145 cells transfected with miR-205 or 
siRNA compared to negative control cells. Data are reported as relative quantity (RQ) ± 
SD with respect to Neg cells 
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The evidence that PKC-ε silencing leads to a radiosensitization that is comparable 
to that induced by miR-205 does not per se demonstrate that PKC-ε is actually 
responsible of such radiosensitizing effect. The most specific way to ascertain 
PKC-ε implication is target protection experiment.  
To this aim, we designed a miR-Mask molecule fully complementary to miR-205 
binding site within PKC-ε 3’UTR, able to protect the site from miRNA binding. First 
of all, we tested whether the designed miR-Mask was actually able to prevent 
miRNA-mRNA interaction, by evaluating PKC-ε expression levels upon co-
transfection with both miR-205 and miR-Mask molecules. We found that the miR-
Mask was able to significantly recover PKC-ε expression at both mRNA and 
protein level in miR-205-reconstituted cells (Fig. 6.13). This result gave us the 
proof of miR-Mask ability to protect PKC-ε from miRNA targeting and consequent 
downregulation.		
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Figure 6.13 PKC-ε miR-Mask recovered PKC-ε expression levels in miR-205 cells. 
(Left panel) qRT-PCR showing PKC-ε mRNA amount in DU145 cells after miR-205 
reconstitution in the presence or absence of miR-Mask, normalized to GAPDH. Data are 
reported as relative quantity (RQ) ± SD with respect to Neg cells. (Right panel) Western 
blot analysis showing PKC-ε protein amount in DU145 cells upon Neg or miR-205 
transfection, in presence or absence of PKC-ε miR-Mask, normalized to β-actin. Cropped 
images of selected proteins are shown.  
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To investigate whether PKC-ε is the main mediator in determining the 
radiosensitizing effect induced by miR-205, we transfected miRNA-reconstituted 
DU145 cells with the miR-Mask, with the aim of testing whether the abrogation of 
PKC-ε downregulation influences miR-205-induced radiosensitization. Strikingly, 
we found that the miR-Mask molecule was able to almost completely abrogate the 
radiosensitizing effect induced by miRNA reconstitution (Fig. 6.14). This result 
indicates that, upon PKC-ε recovering, miR-205 is no longer able to boost cell 
response, suggesting that the downregulation of PKC-ε is actually essential for 
determining miR-205 radiosensitization.  
 
 
 
Figure 6.14 PKC-ε contributes to mediate miR-205-induced radiosensitization. 
Clonogenic cell survival of DU145 cells transfected with miR-205 alone or co-transfection 
with miR-Mask. The surviving fractions following the indicated doses of radiation are 
reported as mean±SD, n=3. The level of significance was represented as *p<0.05, 
Student’s t-test. 
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6.2.4 miR-205 reduces DNA-PK activation via PKC-ε downregulation 
 
As previously reported, PKC-ε role in radiation response relies on its ability to 
phosphorylate EGFR in the tyrosine residue T654. Consequent to 
phosphorylation, EGFR is internalized into the nucleus where it binds and 
activates DNA-PK, thus leading to NHEJ DNA-repair mechanism.  The activation 
of DNA-PK occurs by phosphorylation of a specific residue (S2056), which is 
therefore considered an indicator of DNA-PK active status. To assess whether 
PKC-ε implication in miR-205-induced radiosensitization relies on EGFR nuclear 
translocation and consequent DNA-PK activation [170], we evaluated i) phospho-
EGFR (pEGFR) levels with the purpose to monitor whether, following irradiation, 
PKC-ε promotes its phosphorylation and ii) DNA-PK specific phosphorylation to 
investigate whether PKC-ε downregulation leads to a decreased activation of 
DNA-PK.  
To address these aims, we first assessed EGFR specific phosphorylation (T654) 
in siPKC-ε cells upon 30 or 60 minutes of 4 Gy irradiation. In keeping with the 
premise that EGFR is known to be specifically phosphorylated by PKC-ε upon 
radiation exposure, we observed that pEGFR levels increased at 60 minutes from 
irradiation, with total EGFR levels being equal. Interestingly, such increase was 
abrogated upon PKC-ε silencing, thus suggesting that EGFR phosphorylation 
relies, at least in part, on PKC-ε activity (Fig. 6.15, upper panel). This was 
paralleled by a slightly reduced activation of DNA-PK, as detected by the lower 
expression levels of the phosphorylated form of the enzyme at S2056 (DNA-
PK2056) observed following irradiation of PKC-ε-silenced compared to control 
cells (Fig. 6.15, lower panel).  
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Figure 6.15 EGFR and DNA-PK phosphorylation is reduced by PKC-ε silencing. 
Western blot analysis showing EGFR (upper panel, total protein extract) and DNA-PK 
(lower panel, nuclear fractionation) phosphorylated levels in DU145 cells transfected with 
Neg or miR-205. Forty-eight hours after transfection, cells were irradiated at 4 Gy and 
harvested 30 and 60 minutes later for Western blot assay. Vinculin and HDAC were used 
as control for loading. Cropped images of selected proteins are shown. 
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7. CONCLUSIONS AND DISCUSSION  
 
7.1 miRNAs modulated in PCa cells upon radiotherapy 
 
7.1.1 Photon irradiation 
 
Radiotherapy is one of the gold standard treatments for organ-confined and 
locally advanced PCa [171]. In the last decades, several advancements have 
been made in both treatment planning and delivery, specifically with the 
introduction of 3D-conformal radiation therapy (CRT) and the intensity 
modulated radiation therapy (IMRT). However, development of radioresistance 
significantly limits treatment effectiveness and a fraction of patients, 
approximately 30%, still experience biochemical failure [172].  
One promising approach to improve the likelihood of durable tumour control is 
to combine radiotherapy with targeted agents able to interfere with molecular 
pathways relevant to radiation response, thus ultimately resulting in an 
enhanced sensitivity to the treatment [91].  
Various genetic and epigenetic alterations have been associated with the onset 
of radioresistance, including deregulation of miRNAs, small endogenous RNA 
molecules endowed with regulatory functions. This ability of miRNAs to act as 
negative gene regulators allow them to modulate signalling pathways that 
control multiple cellular processes [34], including those involved in response to 
radiation [34]. In keeping with this, results from experimental models of different 
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human tumour types showed that miRNAs directly affect radiosensitivity [92]. 
Consequently, they have the potential to be used as radiosensitizers.  
The aim of this project was to identify specific miRNAs, if any, functionally 
involved in influencing PCa response to radiation, with the final goal of 
characterizing them as promising radiosensitizing molecules to be exploited for 
the design of miRNA-based approaches aimed at increasing radiotherapy 
effectiveness.  
As a very first step, we established the strategy to pursue in order to pick-up all 
the miRNAs potentially matching our query. We therefore proposed to follow 
two complementary approaches of miRNA sorting. The first approach consisted 
of the identification of miRNAs modulated upon radiation exposure, since 
modulation after the radiation stimulus can likelihood reflect an involvement in 
radiation response processes.  
However, it is worth mentioning that the modulation upon treatment does not 
intrinsically and definitely reflect a functional involvement in influencing the 
response to radiation, as it is conceivable that treated cells undergo molecular 
changes, as a mere consequence of the induced-injury, that are not all actively 
influencing the final outcome in terms of treatment response.  Hence, among all 
miRNAs found to be modulated upon radiation, we focused on those that are 
known, by literature data as well as prediction analysis, to target genes 
implicated in pathways relevant to radiation. This criterion was instrumental for 
increasing the reliability of our selection approach, as miRNAs regulating this 
kind of pathways are more likely to be endowed with a functional role in the 
response phase.  Moreover, to characterize selected modulated miRNAs from a 
functional perspective, their expression has been artificially modulated through 
transfection of PCa cells with specific miRNA modulators (i.e.: miRNA mimics). 
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Transfected cells were then exposed to radiation and assessed for changes in 
their sensitivity profile. Finally, to dissect the underlying mechanisms, miRNAs 
showing ability in enhancing cell response to radiation were studied from a 
mechanistic point of view, by the identification of their targets relevant to 
radiation.  
By following this first approach, we exposed all the four PCa cell lines (DU145, 
PC-3, LNCaP and 22RV1) to 10 Gy of irradiation, and collected total RNA, 
including miRNAs, at different time points (4, 8 and 24 h), in order to obtain a 
kinetics of miRNome modulation. As a result of miRNA profiling, we observed 
that several miRNAs showed significant changes in their expression in all cell 
lines, even if different miRNA were modulated at different extents across cell 
lines and over time. Therefore, to select specific miRNAs that could be reliably 
relevant, we focused on miRNAs consistently modulated (up or down) by 
photon irradiation in both DU145 and LNCaP cells, the two cell lines that 
showed a higher number of consistently modulated miRNAs (Figg. 4.1 and 4.5). 
As a result, we obtained a list of 9 up-regulated and 15 down-regulated miRNAs 
(Table 4.1 and Fig. 4.6). Among downregulated ones, we focused on miR-23a-
3p and miR-24-3p, since, according to literature data, they are known to be 
associated with radiation-response related pathways. Specifically, miR-23a-3p 
was reported to negatively regulate the IL-6 pathway, by downregulation of IL-6 
receptor (IL-6R) in PCa [158]. The relevance of this finding is based on the 
evidence that the IL-6 pathway was reported to be associated with 
radioresistance in PCa [156]. In this study, Wu and collaborators demonstrated 
that IL-6 is important in the biological sequelae following irradiation, since i) IL-6 
expression was found to be positively linked to radiation resistance and, 
conversely, ii) IL-6 inhibition enhanced the radiation sensitivity of prostate 
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cancer. In accordance with this evidence, we observed that reconstitution of 
miR-23a-3p in PCa cells led to a significant downregulation of various 
components of IL-6 pathway, including IL-6 (Fig. 4.10). This result prompted us 
to further investigate whether the interleukin itself, and not only its receptor, 
could be a direct target of the miRNA. According to initial assessments, IL-6 
was not included in the list of miR-23a-3p predicted targets. However, 
extending the analysis to genes with a poorly conserved site, IL-6 emerged as a 
predicted target of the miRNA, presenting a 7mer site for miRNA recognition in 
its 3’ UTR region. Encouraged by these findings, we pursued the investigation 
of miR-23a-3p as a potential radiosensitizer in PCa. Interestingly, miR-23a-3p 
reconstitution was able to significantly enhance DU145 sensitivity to radiation, 
showing a radiosensitizing effect that was not biased by an intrinsic cytotoxic 
effect of the miRNA (Fig. 4.8, left panel and Fig. 4.9, upper panel). To 
substantiate the hypothesis that miR-23a-3p induced radiosensitization was 
actually imputable to IL-6 downregulation, we counteracted IL-6 modulation 
caused by the miRNA, through ectopic supplementation of interleukin with a 
recombinant IL-6 molecule. Indeed, the restoration of IL-6 levels endorsed by 
supplementation, almost completely abrogated the radiosensitizing effect 
assigned to the miRNA (Fig. 4.11), thus persuasively supporting a central role 
of IL-6 in mediating miR-23a-3p radiosensitizing effect.  
Along with miR-23a-3p, miR-24-3p was also picked-up as a possible 
radiosensitizer miRNA in PCa. The potential relevance of miR-24-3p was based 
on the evidence that this miRNA was reported to be upregulated as a 
consequence of IL-6 downregulation in plasma cells [155], thus suggesting that 
it could be somehow influenced by miR-23a-3p-IL-6 axis. Accordingly, miR-24-
3p expression levels were expected to be consistent with those of miR-23a-3p, 
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thus being both concomitantly down-regulated upon irradiation. Indeed, both 
miRNAs were in the list of down-regulated ones among those considered. 
Moreover, when miR-23a-3p was reconstituted, miR-24-3p levels were 
increased (data not shown), further supporting a correlation between the two 
miRNAs. Based on this evidence, we assessed miR-24-3p ability to actively 
influence PCa sensitivity profile, and observed that miRNA reconstitution 
significantly enhanced DU145 cell response to radiation. However, unlike what 
observed with miR-23a-3p, miR-24-3p displayed an intrinsic cytotoxic effect as 
suggested by the impact on plating efficiency (Fig.4.9). On account of this 
evidence, we decided not to pursue the study of miR-24-3p, since an ideal 
sensitizer should exert an effect only when combined with the treatment 
intended to be enhanced. Noteworthy, miR-23a-3p and miR-24-3p belong to the 
same miRNA cluster, namely miR-23a~27a~24-2 cluster, therefore being the 
regulation of their expression subjected to the control of the same promoter. 
This information could further substantiate the relevance of miR-23a-3p and 
miR-24-3p in the response of radiation, as they are included in the same 
primary transcript, which allows the concomitant modulation of both miRNAs 
upon the same stimulus, with their interdependent regulation suggesting that 
they might work in combination to accomplish their function in response to 
radiation exposure [173].  
Overall, by following the first strategy of miRNA identification we could single-
out miR-23a-3p as a potential radiosensitizer in PCa.  
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7.1.2 Carbon ion irradiation 
 
Conventional radiation therapy, either alone or combined with surgery, can 
produce enduring loco-regional disease control in a wide variety of cancers. 
The chance of tumour eradication with radiation depends on various factors 
related to the tumour, such as radiosensitivity, volume and location, as well as 
factors related to the irradiation modality, such as the treatment plan and 
targeting accuracy. Intuitively, the higher is the dose delivered to the tumour, 
the better is the local control and the related disease-free survival [174]. 
However, a balance should be maintained to ensure that the radiation tolerance 
of adjacent normal tissues is not exceeded. 
Impressive developments have been achieved through the introduction of CRT 
and IMRT, thus ameliorating treatment planning and delivery. The adoption of 
these techniques ultimately allowed the delivering of higher doses of photon 
radiation to a more precisely defined target volume, while leaving adjacent 
normal tissues and organs relatively unscathed [174].  However, despite these 
improvements, because of the intrinsic physics of photon beams, the treatment 
doses are still maintained at sub-optimal levels, in order to counterbalance the 
benefit and the harm of the treatment, thus limiting the potential of radiation-
associated benefits. To address these limits that constraint the application of 
radiotherapy, a novel radio-therapeutic approach based on heavy charged 
particles has emerged. These particles have physical and radiobiological 
characteristics differing from those of photon beams, which offer a number of 
advantages over conventional radiotherapy [20]. Specifically, protons and 
carbon ions interact more readily with matter allowing well-defined distribution of 
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the dose in depth, depositing a large fraction of their energy at the end of their 
track, resulting in intense local ionisation that is considered highly effective 
against radiation-resistant tumours [175].  
Taking advantage of an established collaboration with the National Centre for 
Oncological Hadrontherapy (CNAO), equipped with a synchrotron able to 
produce and deliver protons and carbon ions, we had the opportunity to perform 
an exploratory experiment aimed at investigating carbon ion capacity to 
influence PCa miRNome, a study never pursued before. In particular, we 
sought to compare miRNA modulation induced by carbon ions with that 
obtained upon photon irradiation, in order to unravel commonalities and 
differences between the two sources. To that aim, comparable treatment 
settings were maintained between the two modalities of irradiation, for both time 
points of RNA collection and dose delivery, taking into account the definition of 
RBE, based on the knowledge that different radiation sources need different 
doses to reach the same extent of a certain biological effect [20]. Hence, 
considering that DU145 and LNCaP were the two cell lines with the major 
number of consistently modulateted miRNAs, and also due to the high costs of 
carbon ion experiments, we evaluated miRNA modulation only in these two cell 
lines. Despite expectations, we found that only 14 miRNAs were modulated by 
both photon and carbon ion irradiation (Fig. 4.13). Moreover, all of these 
miRNAs displayed opposite direction of modulation, meaning that those found 
to be downregulated by photons were upregulated by carbon ions, and vice 
versa. This curious result can be justified by the notion that the two sources of 
irradiation have different impact on cells, being the ionization of carbon ions 
more intense than that produced by photons. Hence, it is reasonable that, still 
inducing the same type of DNA damage (i.e.: predominantly DSBs), the two 
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sources trigger diverse mechanisms of cell response, thus implying the 
modulation of different miRNAs. In keeping with this hypothesis is our finding 
that different pathways were found to be associated with miRNAs modulated by 
carbon ions compared to those linked to photons (Fig. 4.15).  Moreover, it is 
also conceivable that a distinct kinetics in inducing DNA damage is associated 
with the two irradiation sources. In particular, it is likely that carbon ions do exert 
a certain effect in a shorter period of time than what took to photons, implying 
that at the same time point, different steps of repair mechanisms are occurring, 
which is paralleled by different patterns of miRNA modulation. This 
consideration entails that, as well as for doses, different time points should be 
considered in order to carry out comparative analysis between photons to 
carbon ions. To that aim, it would be informative to stretch and extend the 
timing of RNA collection following exposure to both sources, in order to 
investigate whether the same pathways, and then likely the same miRNAs, are 
modulated by both treatments at different time points. So far, because of the 
limited accessibility to the synchrotron, and due to the unaffordable costs 
related to the use of the accelerator, we had not the possibility to test these 
hypotheses in the context of this project.  
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7.2 The role of miR-875-5p and miR-205 in PCa radiation response 
 
As anticipated, two different approaches were followed for the identification of 
miRNAs potentially involved in determining PCa response to radiation. In the 
framework of the first approach of miRNA sorting, we considered those miRNAs 
that i) are downregulated in PCa compared to normal tissues, thus suggesting 
an oncosuppressive role of the miRNA, and ii) target genes known to be 
involved in pathway relevant to radiation.  
The first criterion of selection is based on the assumption that tumour cells 
reasonably downregulate molecules endowed with an oncosuppressive 
function, in order to promote and sustain tumour progression. In line with this 
scenario, a miRNA able to confer resistance to conventional treatments, 
including radiotherapy, is expected to be down-modulated in tumour tissues 
compared to normal ones, thus prompting to consider the downregulation as a 
reliable selection criterion. However, this feature is not enough to conclude that 
the downregulated miRNA is actually involved in mechanisms relevant to 
radiation response. To ascertain this link, among downregulated miRNAs we 
focused on those targeting genes belonging to pathways linked to radiation 
response, as a proof of their engagement in such processes.   By combining 
these two criteria, we were able to pick-up two miRNAs: miR-875-5p and miR-
205.  
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7.2.1. miR-875-5p 
 
No information was available on miR-875-5p function in cancer when we 
pursued the present study. However, the potential relevance of this miRNA was 
supported, first of all, by the evidence that miR-875-5p was found to be 
downregulated in PCa cell lines (Fig. 5.1) and tissues (Table 5.1) compared to 
non-neoplastic tissues, thus accomplishing the first criterion of selection. 
Moreover, as obtained by correlation analysis carried out in a previous study, 
miR-875-5p was the first miRNA in the list of 18 miRNAs directly correlated with 
E-Cadherin, an epithelial biomarker of the mesenchymal-to-epithelial transition 
(Table 5.1). Such correlation was instrumental for taking into consideration miR-
875-5p as a potential radiosensitizer in PCa, since it was reported that EMT is 
associated with radioresistance [176]. Moreover, we were encouraged to 
consider the correlation with E-Cadherin as a suggestion of a possible 
involvement in radiation response also based on our previous observation of a 
direct correlation between E-Cadherin mRNA levels and miR-205, a miRNA that 
we demonstrated to exert a prominent role in repressing EMT in PCa cells [81] 
and that was successively found to act as a tumour radiosensitizer in other 
tumour types [113].  
On this basis, we investigated the biological impact of miR-875-5p reconstitution 
in PCa cell lines by transfecting cells with miR-875-5p mimic. miR-875-5p was 
able to revert EMT in DU145 cells, promoting a more epithelial-like phenotpye 
(Fig. 5.2).  Moreover, an increased E-cadherin and β-catenin expression, at 
both mRNA and protein levels (Fig. 5.3), was observed in miR-875-5p-
reconstituted cells, which were also characterized by intense immunoreactivity 
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for both markers and enhanced co-localization at cell-cell adhesions compared 
to control cells (Fig.5.4). Altogether, these changes are compatible with a shift 
from a mesenchymal to a more epithelial and less motile phenotype, consistent 
with the results of wound healing assay (Fig. 5.5), indicating the capability of 
miR-875-5p to revert EMT of PCa cells. 
Once the ability of miR-875-5p to counteract EMT was ascertained, we tested 
miRNA impact on PCa cell sensitivity profile. In line with the solid premises that 
led us to focus on miR-875-5p, miRNA reconstitution resulted in an enhanced 
radiation response in both in vitro and in vivo PCa models (Figg. 5.6 and 5.10), 
thus supporting the role of miR-875-5p as a radiosensitizer molecule in PCa.  
miRNAs are able to impact on cell mechanisms by post-transcriptionally 
regulating the expression of specific genes that, in turn, are involved in such 
mechanisms. To explore the molecular mechanism underlying miR-875-5p 
radiosensitization, we tried to figure out its relevant targets, by intersecting i) 
genes found to be downregulated in miR-875-5p-reconstitute PCa cells and ii) 
genes predicted to be targeted by the miRNA. As a result, we obtained a list of 
19 genes, among which was EGFR (Table 5.2). Luciferase assay (Fig. 5.13) 
and expression analysis (Fig. 5.14) confirmed EGFR as a direct target of miR-
875-5p. Strikingly, a very recent publication by Zhang and collaborators [176] 
reported that miR-875-5p is remarkably decreased in human colorectal cancers 
and that its ectopic expression inhibits growth and promotes apoptosis in 
colorectal cancer cell lines via downregulation of EGFR, which, in line with our 
observation, was also validated as a direct target of the miRNA. Conversely to 
what observed in colorectal cancer cells, we found that miR-875-5p per se 
failed to affect PCa cell growth as a consequence of EGFR downregulation, 
thus corroborating the notion that the receptor tyrosine kinase is not a central 
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player in the onset of PCa and that the specific function of a given miRNA 
needs to be contextualized with respect to the disease. 
EGFR is one of the major players in determining radiation response in different 
tumour types [177,178], although the precise underlying mechanisms are still 
not fully understood. Most of the earlier studies linking EGFR and 
radioresistance focused on the prosurvival signaling induced by EGFR after 
ligand-independent activation in response to irradiation [179]. However, recent 
literature suggests that, following irradiation, EGFR translocates to the nucleus, 
where it directly contributes to the development of radioresistance by increasing 
DNA repair through the activation of DNA-PK, which is a regulator of NHEJ 
[160,170,180].  
Given such established role of EGFR in inducing radioresistance by activating 
DNA-PK-mediated DNA repair, we investigated whether miR-875-5p was able 
to interfere with such cascade via EGFR downregulation. Indeed, once 
validated EGFR as a direct target of miR-875-5p, we demonstrated that 
protecting EGFR from miRNA binding, and therefore from the consequent 
downregulation, the radiosensitizing effect associated with miR-875-5p was 
almost completely voided, thus ultimately providing a convincing evidence of 
EGFR relevance in mediating miR-875-5p radiosensitizing effect in PCa. 
However, investigating the most common mechanism underlying EGFR 
involvement in radiation response, we found out that DNA-PK activation upon 
miR-875-5p-induced EGFR downregulation was walmost neglectible, thus 
prompting us to suppose that other downstream molecules were presumably 
involved. In keeping with this, a possible role of EGFR in homologous 
recombination (HR) repair can be also hypothesized, based on the evidence 
that the EGFR inhibitor gefitinib was able to radiosensitize non small cell lung 
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cancer cells through inhibition of radiation-induced ATM activation, although the 
possibility that such an effect relies on gefitinib targets other than EGFR cannot 
be excluded [160]. In this study, we found that, in spite of the marked reduction 
of nuclear EGFR levels following irradiation in miR-875-5p reconstituted PCa 
cells, a very modest inhibitory effect on ATM activation, as determined by the 
expression of active, phosphorylated forms of the proteins, was observed. 
EMT was reported to be related to radioresistance in many cancers [159] and 
wealth of literature suggests a role of EGFR in this process [177,180]. As a 
consequence, the ability of miR-875-5p-mediated EGFR down-regulation to 
counteract EMT in PCa cells appears to significantly contribute to the observed 
radiosensitizing effect. In addition, inhibition of the EMT inducer ZEB1 may be a 
primary underlying mechanism for miR-875-5p-induced radio- sensitization, as 
demonstrated by the phenocopy experiment where siRNA-mediated ZEB1 
silencing recapitulated the miRNA effect on radiation response (Fig. 5.23). 
Indeed, it has been previously shown that ZEB1 promotes HR repair and 
tumour radioresistance [166]. Specifically, it was found that, following 
irradiation, ATM phosphorylates and stabilizes ZEB1. ZEB1, in turn, directly 
interacts with the deubiquitinase USP7 and enhances its ability to 
deubiquitinate and stabilize CHK1, thereby promoting HR-dependent DNA 
repair [166]. Consistent with this pathway, we found that miR-875-5p-induced 
radiosensitization was paralleled by a decreased CHK1 expression (Fig. 5.21). 
However, the small impact of miRNA reconstitution on ATM activation we 
observed in PCa cells (Fig 5.20) would suggest that such ZEB1 down-regulation 
does not rely on ATM but is, at least in part, dependent on EGFR knock-down, 
as indicated by the recovery of ZEB1 expression observed when cells where 
transfected with a miRNA mask specifically blocking the interaction between 
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miR-875-5p and EGFR mRNA (Fig. 5.18). In keeping with this are previous data 
indicating the ability of EGFR inhibitors to suppress ZEB1 expression [164,165]. 
Interestingly, it has recently been reported that other miRNAs able to counteract 
EMT, such as miR-200c [111], miR-204 [112] and miR-205 [113], act as 
radiosensitizers by directly targeting ZEB1. In addition, miR-205 inhibits DNA 
damage repair by directly targeting the ubiquitin-conjugating enzyme Ubc13 
that also promotes HR-mediated repair of DNA double strand breaks [113]. 
Altogether these findings pose ZEB1 at the crossroad of EMT and radiation 
resistance and suggest that its activity can be mediated by different targets and 
different interacting proteins. 
The relevance of EMT-related miRNAs in radiation response has been also 
corroborated by a recent study that analysed global miRNA expression profile in 
a large panel of head and neck squamous cell carcinoma cell lines showing that 
low expression of miRNAs involved in EMT inhibition was an important 
radioresistance determinant [181]. Moreover, low expression of miR-203, which 
emerged as the most important miRNA in cell lines, was shown to correlate with 
local disease recurrence after radiotherapy in laryngeal cancer patients [181]. 
Overall, the study on miR-875-5p role in PCa response to radiation, provided 
evidence that miR-875-5p acts as a promising radiosensitizer in PCa cell and 
animal models, by inhibiting EGFR-ZEB1 axis (Fig. 7.1). 
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Figure 7.1 Schematic representation of miR-875-5p mechanism of radiosensitization in 
PCa 
 
 
 
 
 
 
 
 
DNA-PK/ATM 
ZEB1 
EGFR 
miR-875-5p 
DNA repair DNA repair 
CHK1 
IR IR 
SENSITIVITY TO RADIATION 
 	
	
CONCLUSIONS AND DISCUSSION 
	
	 	
236	
 	
	
CONCLUSIONS AND DISCUSSION 
	
	 	
237	
7.2.2. miR-205 
 
In the framework of miRNAs sorted by following the second approach, along 
with miR-875-5p we singled out miR-205. 
Previous studies undertaken by our group reported that miR-205 is a tumour-
suppressor miRNA, the expression of which is reduced or lost in prostate 
tumours compared to normal tissues, with a particularly pronounced reduction 
in carcinomas from patients with disseminated disease. In this contest, 
Gandellini and collaborators demonstrated that miR-205 restoration in prostate 
cancer cells resulted in cell rearrangements consistent with a reversion of 
mesenchymal-to-epithelial transition, such as up-regulation of E-cadherin and 
reduction of cell locomotion and invasion [80]. Interestingly, results from this 
study suggested that these events were driven by the concurrent repression of 
specific predicted miR-205 targets, including protein kinase Cepsilon (PKC-ε). 
Strikingly, the latter seemed to play a direct role in regulating epithelial-to-
mesenchymal transition. In fact, its down-regulation led to a cell phenotype 
largely reminiscent of that of cells ectopically expressing miR-205. These 
findings provided the first evidence supporting a role of miR-205 in 
counteracting PCa EMT. A role of miR-205 in regulating EMT was unravelled 
for the very first time by Gregory and collaborators [167]. In this study, they 
found that miR-205 was markedly downregulated in cells that had undergone 
EMT in response to transforming growth factor (TGF)-beta. Together with miR-
200 family, miR-205 cooperatively regulated expression of the E-cadherin 
transcriptional repressors ZEB1 (also known as deltaEF1) and SIP1 (also 
known as ZEB2), factors previously implicated in EMT and tumour metastasis. 
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Inhibition of the microRNAs was sufficient to induce EMT in a process requiring 
upregulation of ZEB1 and/or SIP1. Conversely, ectopic expression of these 
microRNAs in mesenchymal cells initiated mesenchymal to epithelial transition 
(MET). Consistent with their role in regulating EMT, expression of these 
microRNAs was found to be lost in invasive breast cancer cell lines with 
mesenchymal phenotype.  
EMT phenotypic switch is known to enhance resistance to conventional 
therapies, including chemo- and radiotherapy [159]. However, besides such 
well-known role of EMT in radioresistance, the relevance of PKC-ε in 
determining cell response to radiation-induced injury is also supported by the 
study of Wanner et al [168]. The authors demonstrated that the activation of 
PKC-ε stimulates DNA-repair by promoting the nuclear accumulation of EGFR. 
It is known that irradiation causes EGFR translocation into the nucleus, where it 
is involved in the activation of DNA-PK, a protein kinase essential for DNA-
repair [170]. Specifically, they demonstrated that EGFR nuclear translocation is 
consequent to a phosphorylation in the tyrosine residue T654, which is 
operated by PKC-ε [168].  
Moreover, as for miR-875-5p, the direct correlation of miR-205 with E-cadherin 
is another evidence supporting a potential role of miR-205 in radiation response 
via EMT-counteracting.  
Furthermore, miR-205 was successively found to act as a tumour 
radiosensitizer in breast cancer [113]. Here the authors found that miR-205 
promotes radiosensitivity and is downregulated in radioresistant subpopulations 
of breast cancer cells, and that loss of miR-205 is highly associated with poor 
distant relapse-free survival in breast cancer patients. Mechanistically, radiation 
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suppresses miR-205 expression through ATM and ZEB1. Moreover, miR-205 
inhibits DNA damage repair by targeting ZEB1 and the ubiquitin-conjugating 
enzyme Ubc13. Altogether these findings demonstrate that miR-205 acts as a 
tumour radiosensitizer by targeting ZEB1.  
Finally, the possible relevance of miR-205 in radiation response is also 
suggested by its role in autophagy [153]. In these regards, miR-205 was 
observed to induce downregulation of RAB27A, a member of RAS oncogene 
family, and LAMP3, the lysosomal-associated membrane protein 3. miR-205-
dependent down-regulation of these lysosome-associated proteins leaded to an 
impairment of autophagy. Such constraints on the autophagic flux, in turn, 
resulted in an enhancement of cisplatin cytotoxic activity, thus ultimately 
indicating that miR-205 replacement sensitizes PCa cells to cisplatin treatment 
[153].  
On this promising basis, we were strongly encouraged to pursue the 
investigation of miR-205 as a radiosensitizer in prostate cancer. In keeping with 
our hypothesis, we found that miR-205 reconstitution was actually able to 
significantly enhance PCa sensitivity to radiation, in both cell (Fig. 6.2) and 
animal models (Fig. 6.6). Compatible with its radiosensitizing ability, we 
observed that miR-205 was able to interfere with cell repair mechanisms aimed 
at resolving the injury caused by radiation exposure. Specifically, miR-205 
reconstitution was found to delay  -H2AX foci resolution, indicating an 
impairment of cell proficiency in repairing radiation-induced DSBs (Fig. 6.3). 
Accordingly, extended comet tail moments were observed in miR-205 cells 
compared to controls upon exposure to -irradiation (Fig. 6.4), thus confirming 
that the extent of DNA damage is increased in presence of the miRNA.  
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Considering that the implication of miRNAs in specific pathways relies on their 
capacity to regulate target genes belonging to those pathways, we sought to 
identify miR-205 relevant targets with the final aim to dissect the molecular 
mechanism underlying its radiosensitizing potential. In particular, taking into 
account the targets that we found in literature to be potentially relevant in 
supporting a postulated role of miR-205 in radiation response [81,113,153], we 
investigated LAMP3, RAB27A, ZEB1 and PKC-ε. After an exploratory 
investigation, we concluded that PKC-ε could be the target mainly responsible 
of miR-205 radiosensitizing effect, as its silencing via an alternative strategy 
(siRNA molecule) was able to successfully resemble the radiosensitizing effect 
associated with miR-205, supporting the hypothesis that the miRNA exerts its 
effect via PKC-ε downregulation.  This assumption was actually substantiated 
and definitely corroborated when the use of a miR-Mask molecule able to 
specifically interfere with the interaction between miR-205 and PKC-ε resulted 
in a strong abrogation of miRNA radiosensitizing effect, thus demonstrating that 
miR-205 effect relies on its capacity to target PKC-ε.  
This finding is in line with the well-established role of PKC-ε in cell mechanisms 
of DNA damage repair [168]. Consistent with this, we found that pEGFR, and 
consequently pDNA-PK, levels were significantly reduced by miR-205 
reconstitution (Fig. 6.15).  
miR-205 is an emblematic example of how intricate is the network of targets 
modulated by a single miRNA. miR-205 involvement in radiation response 
process was postulated starting from the evidence of miRNA engagement in a 
variety of related pathways, centred on diverse genes and mechanisms, 
including PKC-ε, autophagy, EMT and ZEB1. In this study we demonstrated that 
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miR-205 radiosensitized PCa via PKC-ε downregulation (Fig. 7.2), However, it 
cannot be excluded that other targets can contribute to the final outcome. In 
keeping with this, ongoing experiments are focused on investigating whether 
the downregulation of ZEB1, which is the target demonstrated to mediate miR-
205 radiozensitization in Breast [113], is also implicated in PCa miRNA 
sensitization.   Preliminary results (data not shown) support this hypothesis, 
indicating that ZEB1 is downregulated upon miR-205 transfection and that 
ZEB1 silencing is able to partially recapitulate miR-205-sensitized phenotype, 
as well as observed for PKC-ε silencing (Fig. 6.8).  
Conversely, it is also conceivable that other miR-205 targets act, directly or 
indirectly, counteracting this radiosensitizing effect, thus counterbalancing the 
overall outcome. This consideration can be inferred from the effect of PKC-
ε silencing compared to that of the miRNA (Fig. 6.11). siPKC-ε induced a more 
enhanced radiosensitization than that of miR-205, suggesting that silencing only 
this specific target could lead to a greater sensitization than acting 
concomitantly on multiple targets as the miRNA does. At a first-sight 
consideration, this would prompt to prefer the exploitation of siRNA molecules 
rather that miRNA-based approaches in order to reach a higher sensitizing 
effect. However, it is worth noting that the greatest and most peculiar feature of 
miRNAs is precisely their ability to endogenously orchestrate the regulation of 
multiple target mechanisms, in an extraordinary balanced fashion, which is an 
exclusive property of physiological settings.   On one hand, the study of the 
effect of a specific miRNA could help uncovering the underlying mechanisms in 
order to exploit such information for the design of diverse intervention 
strategies: for instance, the evidence that miR-205 acts as a radiosensitizer in 
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PCa via PKC-ε downregulation, would support the use of PKC-ε small inhibitors 
to reach the same, and even more enhanced, effect. 
On the other hand, considering the importance of not exceeding in inducing a 
supra-physiological effect, it should be more appropriate to go for a more 
physiologic solution, by preferring the use of endogenous strategies, like 
miRNAs, also taking into account that these small molecules display the 
particular feature of simultaneously regulating multiple processes. In keeping 
with this is our finding that miR-205, likely due to its prominent role in EMT, was 
able to exert per se an oncosuppressive role in vivo, thus further impacting on 
the overall shrinkage of treated tumours. This toxic effect of the miRNA was not 
expected according to in vitro data, where the miRNA did not show any effect 
on cell viability and clonogenicity (as indicated by plating efficiency values in 
section 6.1.2). However, the ability of a miRNA to intervene in a multiplicity of 
mechanisms, including those that are not appreciable in cell model settings 
(e.g.: interaction with tumour microenvironment), could reasonably justify this 
result, further sustaining the choice of a miRNA-based multi-target strategy 
rather then one-target approaches.  
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Figure 7.2 Schematic representation of miR-205 mechanism of radiosensitization in 
PCa 
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Overall, the results of this project support the clinical interest in developing 
novel therapeutic approaches for PCa based on miRNA reconstitution (miR-
23a-3p, miR-875-5p and miR-205) to increase response to radiotherapy, based 
on their ability to concomitantly inhibit multiple processes, such as EMT and 
DNA damage repair, involved in radioresistance. Despite the indisputable 
advantage of using miRNAs to achieve a specific biological goal, including 
radiosensitization, it is worth mentioning that miRNA delivery represents a 
demanding challenge that still need to be addressed. In these regards, the 
applicability of strategies aimed at increasing specific miRNA expression in the 
clinical setting have been already investigated as the first liposomal 
nanoparticle-formulated mimic of the tumour suppressor miR-34a (MRX34) 
recently concluded the phase I clinical study for patients with different tumour 
types (https://clinicaltrials.gov/ct2/show/NCT01829971). Unfortunately, the trial 
terminated due to the onset of severe immune related adverse events in five 
patients. 
 
 
 
 
Table 7.1. Table reporting the list of miRNAs identified throughout this study as 
candidate radiosensitizers in PCa and their respective targets demonstrated to 
mediate, at least in part, miRNA-induced radiosensitization.   
miRNA 
Identification 
Strategy 
Modulation 
Relevant 
Target 
miR-23a-3p  1st  Downregulated (after IR) IL-6 
miR-24-3p 1st  Downregulated (after IR) - 
miR-875-5p 
 
2nd Downregulated (in PCa Vs normal) EGFR 
miR-205 2nd  Downregulated (in PCa Vs normal) PKC-ε 
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7.3 Future perspectives 
7.3.1 Fractionated radiotherapy 
 
External beam radiation therapy is the most diffused radiotherapy treatment 
modality for patients with prostate cancer. A conformal delivery of treatment is 
ideally adopted in order to spare as much as possible the amount of radiation 
received by the surrounding normal tissues [182]. To address this challenging 
issue, fractionated radiotherapy is used. Fractionation consists of dividing the 
total dose of radiation into several, smaller doses over a period of several days, 
thus reducing the toxic effects on healthy cells. Nowadays, conventionally 
fractionated radiation therapy (CFRT, a single 1.8–2.0 Gy fraction lasting one 
hour per day, five days per week, for about eight weeks) to a total dose of 76–
80 Gy represents the most adopted treatment modality [183]. Such CFRT 
schemes are based upon the premise that tumours typically are less responsive 
to fraction size than are late-responding normal tissues. Few years ago, John-
Aryankalayil and collaborators investigated the alteration of miRNA profile upon 
fractionated radiation in prostate cancer [100]. Interestingly, they found that 
fractionated radiation significantly altered more miRNAs as compared to single-
dose radiation. Encourage by these data and considering the increasing interest 
in fractionated radiotherapy in clinics, we propose to evaluate the impact of 
fractionated radiotherapy on PCa miRNome. Results will be compared with 
miRNA modulation profiles deriving from single-dose irradiation (results from 
section 4) in order to find out commonalities and differences between the two 
modalities of irradiation. For the sake of completeness, results deriving from our 
analysis will be also compared with data reported in literature so far.  
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7.3.2 Circulating miRNAs 
 
The documented possibility to detect miRNAs in peripheral blood has raised the 
interest in defining their potential as novel biomarkers for treatment monitoring. 
Both cell-free miRNAs, that are released in the blood circulation from necrotic 
and apoptotic cells of different origin – and exosome/oncosomes-associated 
miRNAs [184] have been reported to be secreted from prostate cells. 
Specifically, functional miRNAs, which are different depending on the cells of 
origin (tumorigenic vs non-tumorigenic), were found to be released [184]. As far 
as radiation treatment is concerned, the only information currently available 
indicates that radiation increases the abundance of exosomes released by 
glioblastoma cells and normal astrocytes, and specifically alters their molecular 
composition [185], and that radiochemotherapy induces changes in circulating 
miRNAs in head and neck cancer patiens [186]. 
Based on these findings and taking advance of the availability of longitudinal 
plasma samples, collected before, during (after 8 Gy and 50 Gy) and at the end 
of treatment, from 20 PCa patients who underwent radical radiotherapy (78 Gy 
IMRT) at our Institute, we propose to identify miRNAs (cell-free or vescicle-
associated) sensitive to radiation-induced modulation. Results should allow i) to 
determine the extent of overlap between the information generated with the 2 
types of circulating miRNAs (cell-free vs vescicle-associated) and provide new 
insight into their role in the biology of PCa; ii) to define miRNAs significantly 
modulated by radiotherapy, which could be exploited as novel biomarkers for 
treatment monitoring. Radiation-modulated miRNAs in patient plasma will be 
compared with those identified in cell models (Results from section 4) to see 
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whether (and to what extent) in vitro findings can be predictive of the clinical 
situation. 
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